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Abstract 
 
Synthetic chemists are always looking for challenging problems to solve. Design and synthesis 
of novel molecules that can act as agents of chemical and biological modification are one of the 
foremost goals of a synthetic chemist. This dissertation describes advances and efforts made in 
this area.  
Obesity is one of the critical problems of the modern age. Molecules that can remediate this 
condition are highly sought after.  The first chapter of this dissertation describes synthetic 
strategies explored to prepare these valuable natural products along with their structural and 
stereochemical analogues to study structure and activity relationships (SAR). This method gives 
easy access to the preparation of several complex natural products. This could eventually result 
in discovery of potent medicines for different diseases.  
Similarly, development of novel synthetic strategies was carried out in order to understand the 
role of autoinducer 2 (AI-2) in quorum sensing and is described in chapter 2. Quorum sensing is 
the way bacteria communicate with each other using small signaling molecules. AI-2 is a small 
molecule produced by a variety of bacteria and is proposed to be a universal quorum sensing 
signal. 4,5-dihydroxy-2,3-pentadione (DPD), which is a precursor to AI-2, and analogues were 
synthesized and utilized in studies designed to probe their role in quorum sensing. In addition, 
the effect of AI-2 on dual species mutualistic biofilm formation in a model dental plaque system 
is also discussed. 
The facile detection and efficient quantification of DPD has been a great challenge to 
researchers due to its chemical and physical properties. Chapter 3 of this dissertation discusses 
the development of optical sensors for the selective detection of DPD. 
Chapter 4 lists the experiments carried out to shed light on the role and mechanism of AI-2 in 
other biological systems such as the immune system and oxidative stress along with quorum 
sensing. It was deduced that autoinducer-2 suppresses the immune system by the interruption 
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of cytokine signaling, implying that the autoinducer plays a protective role during host 
colonization.  
vi 
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1. A biomimetic synthesis and biological 
studies of (-)-ascorbyl phloroglucinol and 
analogues 
 
The data presented below has been adapted from the following published article: 
 “A biomimetic synthesis and biological studies toward the construction of ascorbyl 
modified catechin natural products and analogues.”  Sneha A. Belapure, Zachary G. 
Beamer, John E. Bartmess, and Shawn R. Campagna; Tetrahedron 67 (2011) 9265-
9272. 
 
1.1. Introduction to obesity 
Worldwide there are more than one billion overweight adults, out of which at least 300 
million are clinically obese according to the World Health Organization.2 Approximately 
two thirds of adults are overweight or obese in the US alone. Obesity is a complex 
condition responsible for numerous diseases, including type-2 diabetes, hypertension, 
cardiovascular disease, respiratory problems, gall bladder disease, osteoarthritis, sleep 
apnea, and certain cancers.3,4 Obesity also has serious social and psychological 
consequences, such as low self-esteem and clinical depression, and affects all ages 
and socioeconomic groups. Historically this problem has been significant only in high-
income countries, but now it is a major concern in low and middle-income countries as 
well. 
Despite obesity reaching epidemic proportions, it remains largely an unsolved medical 
problem. The key causes of this epidemic are the increased consumption of energy-
2 
 
dense, nutrient-poor foods that are high in saturated fats and sugars coupled with 
reduced physical activity.5 Unfortunately, only a few medications are available, and 
most have unacceptable efficacy and side effects.6 Figure 1.1 depicts the distribution of 
obese adults across the world. 
 
Figure 1.1. Worldwide distributions of obese people.2 (World Health organization, 
http://www.who.int/en/) 
 
Obesity is a chronic metabolic disorder that results from an imbalance between energy 
intake and energy expenditure.7 This can be thought of as abnormal or excessive fat 
accumulation that presents a risk to health. Obesity is defined as a body mass index 
(BMI) of 30 kg/m2 or more, where a person‟s BMI is defined as their weight in kilograms 
divided by the square of their height in meters.2 A person with a BMI equal to or more 
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than 25 is considered overweight.2 Analysis of the relationship between BMI and 
mortality suggests that the theoretical optimum mean population BMI is around 21 
kg/m2.8 There are different therapies for obesity starting from lifestyle changes in diet 
and physical activity to pharmacological interventions and gastrointestinal surgery in 
extreme cases.6 Healthy diet and regular exercise help in weight maintenance and 
weight loss to some extent; however, these avenues are not sufficient to treat obesity, 
thus necessitating other medical options.2  
1.2. Current anti-obesity drugs 
There are several drugs known to be effective in obesity treatment. The past few 
decades have seen the introduction of anti-obesity drugs such as sibutramine, 
lorcaserin, rimonabant, and orlistat.6  
Anti-obesity drugs operate through one or more of the following mechanisms: 
 Suppression of appetite- Certain chemicals such as anorexiants (e.g., 
sibutramine) act on the central nervous system (specifically on the hypothalamus) to 
control the appetite.6 
 Increase in body metabolism- Metformin limits the amount of glucose that is 
produced by the liver as well as increases muscle consumption of glucose.6 
 Interference in fat absorption- Lipases break down triglycerides to 
monoglycerides, which are further absorbed by the body and lead to obesity. The 
lipase inhibition reduces this fat absorption by the body e.g., orlistat.6 
Many drugs that control appetite by acting on the central nervous system, specifically 
on the hypothalamus, have been withdrawn due to their side effects. These side 
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effects are often associated with their mechanism of action.6 In general, stimulants 
carry a risk of high blood pressure, faster heart rate, heart palpitation, closed-angle 
glaucoma, drug addiction, restlessness, agitation, and insomnia. Currently, the only 
USFDA-approved obesity drug on the market is orlistat (brand name Xenical or Alli).9 
It acts on the gastro-intestinal system by controlling fat absorption through pancreatic  
 
Figure 1.2. Mechanism of action of orlistat. (Coutinho, W. Obesity: knowledge, care, and 
commitment, but not yet cure. Arquivos Brasileiros de Endocrinologia & Metabologia 2009, 53, 262) 
 
and gastric lipase inhibition as shown in the Figure 1.2. The proposed mechanism of 
action of orlistat is that, it forms a complex with lipase, which in turn blocks the 
breakdown of fat and thereby prevents fat absorption.9 Although this medicine is 
commonly used, it is unpopular due to its gastrointestinal side effect profile that includes 
faecal urgency, incontinence and nausea.6,10 Many more drugs are still in clinical trials, 
but none of those have been proven effective or safe. Thus, new drugs without side 
effects and higher efficacy are warranted. Taking cues from nature, tea polyphenols 
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could provide an answer to this problem. 
1.3. Significance of polyphenols 
Polyphenols belong to a structural class of natural products characterized by the 
presence of a large number of phenol structural units. The chemical and biological 
significance of these natural products is dependent on the size and properties of 
polyphenols.11 A number of medical conditions can be prevented or improved with the 
use of polyphenols. These include circulatory disorders such as hypertension and 
coronary artery disease, lung disorders such as asthma, cancers of various types,12 
inflammatory conditions,13 certain liver conditions,14 diabetes, mood disorders, eye 
disorders15 such as cataracts, weak eyesight due to aging, and macular degeneration.16 
Polyphenols are compounds necessary for various organs and tissues, and compose 
part of several substances necessary for the human body to function properly.17 
 
Figure 1.3. Structures of common polyphenols 
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Polyphenols can be classified into hydrolyzable tannins (gallic acid esters of sugars) 
and phenylpropanoids, such as lignins, flavonoids, and condensed tannins (Figure 
1.3).18 This division is derived from the variety of simple polyphenolic units derived from 
secondary plant metabolism as well as classical divisions based upon the relative 
importance of each base component to different fields of study. Many polyphenols such 
as flavanols, catechins, and gallocatechins are isolated from tea leaf extract, and these 
compounds have been reported to have various biological and pharmacological 
functions.19,20,17,20b Biologically important polyphenols are abundantly found in several 
fruits like grapes, vegetables and particularly in tea plants.21 As mentioned previously, 
detailed examination of polyphenol activity might lead to the discovery of a potent anti-
obesity drug. 
1.4. General tea polyphenols 
Tea polyphenols have been reported to have an anti-HIV effect as well as antioxidative, 
antimutagenic, anticarcinogenic, antitopoisomerase, antiobesity, and 
hypocholesterolemic activities.22,23,24 There are three types of tea: green tea, oolong 
tea, and black tea, which have beneficial effects on health. Their types of tea are 
prepared or isolated from the same plant species, Camellia sinensis, but the preparation 
process for each one is different: oolong tea is semi-fermented, green tea is 
unfermented, and black tea is well fermented.22 Tea has one of the highest contents of 
flavonoids among common food and beverage products. Depending on how the tea is 
harvested, handled, processed, and brewed; the polyphenol level in the tea can vary.20a  
A recent publication details the chemical structures of over 60 polyphenols from green 
tea, oolong tea, and black tea, and the relationship between the chemical structure and 
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activity was evaluated for the antioxidative effect against lipid peroxidation by the ferric 
thiocyanate method in vitro.23 As with many natural compounds, which appear to be 
beneficial to human health, it is difficult to isolate and study tea polyphenols on their 
own, and some researchers have suggested that their actions in the human body may 
actually be the result of several compounds working together.17 The green tea catechins 
in particular, epigallocatechin 3-gallate (EGCG) are studied in great detail in relation to 
their health contributing potential. Figure 1.4 consists of structures of general tea 
polyphenols.2, 5,25,26, 26b 
 
Figure 1.4. Tea polyphenols 
 
Tea polyphenols are antioxidants, which can reduce the risk of developing coronary 
artery disease and a number of other health problems.20a The polyphenols found in tea 
have also been linked with cancer inhibition, as they appear to block the action of some 
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enzymes linked with cancer.27,28,29  Cancer rates seem to be lower in tea drinkers after 
controls for other obvious factors like diet are used to evaluate the data.29 The 
polyphenols found in tea also appear to suppress the growth of harmful bacteria, while 
promoting beneficial bacteria in the gut.25 The flavor of tea is also influenced by tea 
polyphenols.20a Tannins, found in high concentrations in black tea and lower 
concentrations in green and white tea, are responsible for its distinctive dark color and 
bitter, sharp flavor.20a The subtle and distinctive flavors of well-processed teas are due 
in part to polyphenols. 
1.5. Tea polyphenols in lipase inhibition 
 
Oolong tea is reported to prevent obesity by improving lipid metabolism.20a It is also 
effective for enhancing the metabolic rates of fat oxidation. Lipid homeostasis is 
maintained by the fine-tuning of lipogenesis and lipolysis, which are regulated by the 
cooperative action of various enzymes in tissues such as adipose, pancreas, and liver.30 
Dietary fats, which are in the form of triglycerides, are broken down to monoglycerides 
and fatty acids mostly by pancreatic lipase along with gastric and lingual lipase.31 These 
monoglycerides are then further absorbed by cells and stored as energy in adipose 
tissues. Approximately 60 to 85% of the weight of white adipose tissue is lipid, with 90-
99% being triglyceride.31 The excessive accumulation of these adipose tissues leads to 
obesity (Figure 1.5). 
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Figure 1.5. Pancreatic lipase mechanism of action. (Birari, R. B.; Bhutani, K. K. Drug Discovery 
Today 2007, 12, 879, reproduced with permission from Elsevier) 
 
The anti-obesity action of oolong tea is believed to be due to the enhancing effect of 
caffeine.32 Polyphenols lead to nonadrenaline-induced lipolysis in adipose tissues and 
pancreatic lipase inhibition.33 Tea polyphenols, in particular flavonoids and catechins, 
are well-known lipase inhibitors, and their activity ranges from an IC50 of 0.098 μM to 
more than 20 μM.33 Many of these activities have been ascribed to catechin-derived 
molecules, and a series of ascorbyl-modified catechins have been reported. The most 
common flavan-3-nols like (+)-catechin, (-)-epicatechin, (+)-gallocatechin, and (-)-
epigallocatechin (Figure 1.4) show minimum to no activity against pancreatic lipase.34 
On the other hand, 8-C-ascorbyl (-)-epigallocatechin and its esterified analogue showed 
activity with IC50 values of 0.646 μM and 0.791 μM, respectively (Table 1.1).
33 These 
data suggest that the presence of the ascorbyl moiety within the structure might be 
essential for the observed pancreatic lipase inhibition. Also, previously synthesized 
flavan-3-ol gallate ester and digallate esters such as (-)-epigallocatechin-3-gallate, and 
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(-)-epigallocatechin 3,5-digallate showed higher lipase inhibition activity.33  Moreover, 8-
C-ascorbyl-(-)-epigallocatechin (2a) demonstrated relatively potent anti HIV activity with 
an EC50 value of 4 μg/mL and a therapeutic index of 9.5 in H9 human lymphocyte 
cells.35 
 
Figure 1.6. Structures of ascorbyl polyphenols 
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Table 1.1. Reported inhibitory effects of polyphenols on pancreatic lipase33 
 
These natural products display a range of complexity from the simple ascorbylated 
phloroglucinol, (-)-ascorbyl phloroglucinol (1a), to more complex ascorbylated catechins 
(Figure 1.6). While the full spectrum of biological activities displayed by molecules of 
this class have not been fully explored, 8-C-ascorbyl-(-)-epigallocatechin (2a) has been 
shown to be effective in stopping the replication of HIV in vivo with an EC50 of 8.33 µM 
and for inhibiting pancreatic lipases in vitro with an IC50 of 0.646 µM.
36 This significant 
biological activity of these ascorbylated compounds make them potential drug targets, 
and their structures provide an interesting target for synthetic chemists.  
Entry Polyphenol IC50 (µM) 
1 Catechin >20 
2 Epicatechin >20 
3 Gallocatechin >20 
4 Epigallocatechin >20 
5 8-C-ascorbyl-(-)-epigallocatechin 0.646 
6 
8-C-ascorbyl-(-)-epigallocatechin 3-O 
gallate 
0.791 
7 Gallic acid >50 
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(-)-Ascorbyl phloroglucinol (1a) has previously only been isolated from ethanolic extract 
of Sargassum spinuligerum as its acetyl derivative and identified by means of spectral 
analysis as the corresponding acetate derivative 3.37 Prior work has also not been able 
to unambiguously assign the stereochemical configuration at the tertiary and hemiacetal 
carbons (C2‟and C3‟) for any ascorbylated phenols, although modeling has suggested 
that the SSRS configuration for C2′–5′, respectively, is the most stable for 3. This 
intriguing biological data coupled with the interesting structures and open questions 
concerning the stability and stereochemistry of these molecules led us to pursue the 
development of a synthetic strategy to construct the tricyclic core of this set of related 
compounds.33, 37 
1.6. Retrosynthetic analysis and design rationale 
 
Scheme 1.1. Retrosynthetic analysis1 
 
The first disconnection of ascorbyl compounds will lead to two segments; arenes and 
the ascorbyl moiety. These multifunctional arenes can be prepared first, and then the 
ascorbyl group will be incorporated. We reasoned that a late-stage introduction of the 
ascorbyl moiety onto the trioxyarene would be desirable for the construction of these 
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natural products and analogous structures. After observing the structural similarity for 
the ascorbylated natural products, it became obvious that all of these compounds could 
be constructed by a similar route in which the C-C bond between the ascorbyl group 
and the arene were formed if a suitable electrophilic version of ascorbic acid was used 
(Scheme 1.1). The inherent nucleophilicity of the trioxyarene would then provide the 
other counterpart of the reaction. The biosynthesis of these molecules has been 
proposed to proceed via a similar strategy.38 This convergent approach allows preparing 
a library of ascorbylated compounds with several arenes. 
 
Scheme 1.2. Preparation of dehydroascorbic acid (4)1 
 
Dehydroascorbic acid (DHAA) 4 can be easily generated by the oxidation of ascorbic 
acid, and this molecule has the desired electrophilic character.39 This is evidenced by 
the fact that the carbonyl groups at both C2 and C3 are almost exclusively found to be 
the hemiacetal or hydrate, respectively (Scheme 1.2). The observation that the bicyclic 
hemiacetal predominates also led to the hypothesis that the C-C bond would be formed 
preferentially from the opposite side of the dihydroxyethyl group of 4 yielding products 
with the relative stereochemistry shown in Scheme 1.2. Similar stereoselection has 
been observed in the reduction of L-ascorbic acid to the corresponding L-gulonic acid 
lactone (Scheme 1.3).40 
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Scheme 1.3. Hydrogenation of L-ascorbic acid 
 
 
 
1.7. Reaction of hydroxyarenes with indane 1,2,3-trione hydrate 
The base-catalyzed addition of phloroglucinol 6a to 4 has been reported, although the 
stereochemistry of the product remained ambiguous.38 In our hands, we were unable to 
obtain good results for the reaction of 6a with 4 under basic conditions using NaHCO3, 
NEt3, or K2CO3. It can be said that, in the base catalyzed reaction, C-alkylation of the 
aromatic carbon of the phenol takes precedence over O-alkylation of phenol. Due to 
this, we chose to investigate the use of acid catalysis for the addition of hydroxyarenes 
to 4. The first step in this process was to determine the relative reactivity of mono-, 1,3-
di-, and 1,3,5-trihydroxyarenes [phenol (6d), resorcinol (6c), and phloroglucinol (6a)] 
with a model 1,2,3-triketone (indane 1,2,3-trione hydrate 5). 5, which is commonly 
known as ninhydrin, was chosen as a model compound because of its structural 
features as well as its stability. These reactions have been reported using acetic acid 
(AcOH) as a catalyst, although a consistent set of conditions had not been evaluated for 
each molecule (Scheme 1.4).41,42 We explored the reactivity of several hydroxyarenes 
with 5 using AcOH as both the solvent and the catalyst at 60 ºC (Table 1.2). As 
expected, it was observed that as the electron density of the arene increased, the rate 
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of the reaction also increased. Nucleophiles containing methyl ethers could also be 
successfully used in this reaction. Further, a high yield of product was obtained even 
when a 1:1 ratio of electrophile and nucleophile was used. 
 
Scheme 1.4. Reactions of 5 with hydroxyarenes (6a-d)1  
 
Table 1.2. Reactions of 5 with arenes (6a-d)1 
 
 
 
Entry Arene Conditions Temp (ºC) t (h) Yield (%) 
1 6a AcOH (neat) 60 2 85 
2 6b AcOH (neat) 60 1.5 86 
3 6c AcOH (neat) 60 2 80 
4 6d AcOH (neat) 60 3 68 
a The product structures denote relative, not absolute, stereochemistry. 
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1.8. Optimization of conditions for the addition of 6a to 4 
 
 
 
 
 
 
Table 1.3. Optimization of conditions1 
Entry 
Equiv 
Arene  
Equiv 4 Conditions 
Temp 
(ºC) 
t 
(h)  
Yield 
(%) 
1 1 1 
AlCl3 (0.1 equiv), 
THF 
reflux 6 NR 
2 1 1 
BF3OEt2 (0.1 
equiv), THF 
reflux 6 NR 
3 1 1 AcOH:THF (2:5 v/v) reflux 6 42a 
4 1 1 AcOH:THF (2:5 v/v) r. t. 12 40 
5 1 1.5 AcOH:THF (2:5 v/v) r. t. 12 26b 
6 1.5 1 AcOH:THF (2:5 v/v) r. t. 12 69b 
a Decomposition was observed. b Yield based on 4. The arene was recoverable in all 
cases. 
Scheme 1.5. Reaction of DHAA (4) with phloroglucinol1  
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The next step was the optimization of conditions for the reaction of trione 4 and arene 
6a, phloroglucinol. The goal was to find out the optimal acid catalyst for the reaction of 1 
equivalent phloroglucinol with 1 equivalent of dehydroascorbic acid, 4, to give (-)-
ascorbyl phloroglucinol 1a. Initial attempts to perform this transformation in neat AcOH 
at elevated temperature led to less than desirable yields, and decomposition products 
were observed. Therefore, this reaction was then attempted using 0.1 equivalent of a 
Lewis acid, either AlCl3 or BF3
.OEt2, as the catalyst in THF. Even at elevated 
temperature, there was no conversion (Table 1.3 entries 1 and 2). Fortunately, 1a could 
be obtained in moderate yield when AcOH was used as a co-solvent in THF at either 65 
ºC for 6 h or at room temperature (r.t.) for 12 h, although decomposition was still 
observed at elevated temperature (Table 1.3 entries 3 and 4). We then found that using 
0.5 equiv excess of dehydroascorbic acid lowered the yield; however, use of a 0.5 equiv 
excess of arene gave the desired product in 69% yield based on 4 (Table 1.3 entries 5 
and 6). Further, the arene was recoverable in these reactions. In conclusion, the 
optimum reaction conditions identified were as follows: 
 Temperature- 25 ºC 
 Time- 12h 
 Reactant ratio- 1:1.5 (4: arene)  
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1.9. Probing the arene substrate scope  
 
Scheme 1.6. Synthesis of ascorbyl compounds (1b-i)1 
 
 
Table 1.4. Substrate scope of hydroxyarenes1 
Entry Arene X  Y Yield (%) 
1 6b OMe OMe 72a 
2 6c H OH NR 
3 6d H H NR 
4 6e H OBn NR 
5 6f H OAc NR 
6 6g H OMe NR 
7 6h OBn OBn 0b 
8 6i OH OAc NR 
a Yield based on 4. The arene was recoverable. 
b The benzylated arene decomposed. 
19 
 
With optimized conditions for the synthesis of naturally occurring 1a in hand, we set out 
to probe the range of hydroxyarenes that could be employed to synthesize other 
ascorbylated natural products and analogues as shown in Scheme 1.6. On one hand, a 
high reactivity of dehydroascorbic acid with hydroxyarenes is desirable for the 
construction of analogues; however, a lack of reactivity toward the pyrogallyl (1,2,3-
trihydroxybenzyl) and gallyl (3,4,5-trihydroxybenzoyl) moieties is desirable for the 
chemoselective synthesis of natural products, such as 2a-b, if strategies employing 
protecting groups are to be avoided. To begin this investigation, a series of phenol, 
resorcinol, phloroglucinol, and their derivatives were reacted with dehydroascorbic acid 
4 under the optimized conditions with AcOH as the catalyst (Table 1.4). Although 
arenes with a range of electron donating and withdrawing groups were studied, it was 
found that three electron donating groups were necessary for reaction to proceed with 
this substrate series (Table 1.4 entry 1). This is in contrast to the reactions with 5 where 
even phenol was capable of acting as a suitable nucleophile (Table 1.2). It was also 
noted that arenes containing benzyl ethers decomposed under the reaction conditions, 
and this has implications for further syntheses as discussed below in Section 1.5. 
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Scheme 1.7. Reaction of 4 with phenolic derivatives1 
 
Once it was determined that the arene substrate scope was limited for the series of 
phenol, resorcinol, and phloroglucinol derived molecules, the reactivity of 1,3,5-
trimethoxybenzene (8), pyrogallol (9), and methyl gallate (10) with 4 were explored. 
None of these arenes displayed any reactivity toward AcOH catalyzed addition to 
dehydroascorbic acid 4 (Scheme 1.7). The data obtained from the reactions using 9 and 
10 further indicate that the electronic properties of the arene are critical for successful 
reaction. It is likely that three electron donating groups which all direct addition to the 
same position on the arene ring are needed and that the presence of any electron 
withdrawing group hinders reaction. These conclusions are further supported by the 
data obtained using the bicyclic analogues discussed in the later section. The lack of 
reactivity between 4 and 8 is also suggestive that hemiacetal formation is necessary to 
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bring the reactants into close proximity before C-C bond formation can occur. 
1.10. Structural characterization of L-ascorbyl phloroglucinol 1a 
 
The reported method isolated 1a after peracetylation of the ethanolic extract to get 3 in 
order to facilitate efficient purification of 3. In our hands, 1a was found to be amenable 
to standard purification techniques, including flash chromatography on silica, as long as 
alcohols were not used as the solvent in the presence of an acid source. If MeOH was 
used to elute the column, the presence of an extra methoxy group could be observed in 
the 1H NMR spectrum, presumably arising from the formation of an acetal at C30. To 
confirm that the material obtained from the reaction of 4 with phloroglucinol was 
structurally identical to naturally occurring (-)-ascorbyl phloroglucinol, product 1a was 
peracetylated. Both the 1H and 13C NMR spectra were compared to those reported for 
the derivatized natural product, and it was found that all resonances matched the 
reported values. The reactions leading to both (-)-ascorbyl phloroglucinol 1a and the 
methylated analogue 1b proceeded to yield a single product, although the exact 
stereochemical configurations at C2‟ and 3‟ were still ambiguous. The stereochemistry 
for carbons 2‟, 3‟, 4‟, and 5‟ had previously been hypothesized to be SSRS based on 
NOE data and structural modeling of 3 using the SYBYL software package. To obtain 
more robust evidence for the stereochemistry, the crystallization of both 1a and 1b was 
attempted. These efforts were unsuccessful for 1a; however, upon standing in 
hexanes/ethyl acetate, colorless needle-shaped crystals of 1b were obtained. The 
configuration of 1b was determined to be SSRS from crystallographic data (Figure 1.7). 
Based on these data and precedent from the reduction of L-ascorbic acid to gulonic acid 
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lactone, we hypothesize that the addition of the arene to the side of 4 opposite the 
dihydroxyethyl side chain will be a general feature of these reactions. 
 
 
 
` 
1.11. Synthesis of the ascorbylcatechin tetracyclic core 
 
The driving force for the development of a synthetic strategy was to form the core 
structure of the natural products 2a and 2b. Once the substrate scope and 
stereochemical outcome had been determined for the reactions leading to tricyclic 
products, such as phloroglucinol 1a, the reactions using bicyclic arenes were 
investigated to determine the constraints on the construction of the tetracyclic core of 
the ascorbylated catechins (Scheme 1.8). A set of four hydroxylated chroman and 
chroman-4-ones was used, and only one of these molecules, chroman-5,7-diol (11c), 
was able to successfully react with 4 (Table 1.5). These bicyclic substrates fit the 
constraints observed for reactions with the substituted arenes discussed previously in 
that three activating groups that all direct to the same position are needed for reaction 
and no deactivating groups can be tolerated. Regioisomers can be generated upon 
reaction of 4 with 11c. One of these isomers, 12c, corresponds to the desired tetracylic 
core of the natural products 2a and 2b, while the other ring system, as in 13c, has not 
Figure 1.7. Crystal structure of ascorbyl compound 1b1 
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been shown to be a naturally occurring compound. (Note, if Y is a hydroxyl, e.g., as in 
13c and 13c’ in Table 1.7, two possible hemiacetals could be generated and may 
interconvert after rotation around the C-C bond formed during the reaction of the arene 
with 4.) We obtained mixture of two molecules when 11c was reacted with 4 using the 
conditions optimized for the reaction of 1a. These molecules were separable by flash 
chromatography on silica gel, and a battery of 1D and 2D NMR experiments allowed the 
structure of both to be elucidated (see supplementary data). 
 
Scheme 1.8. Preparation of 12c and 131 
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Table 1.5. Reactions of 4 with chromanes1 
 
1.12. Structural characterization of 12c and 13c 
 
Several NMR experiments were carried out such as 1H NMR, 13C NMR, 1H-1H 
correlation spectroscopy (COSY) and 1H-13C heteronuclear multiple-bond correlation 
spectroscopy (HMBC), of these experiments the most useful was HMBC, and it was 
concluded that 12c and 13c were the major and minor component, respectively (Tables 
1.6 and 1.7 and associated Figures). The 1H peak shifts and correlations in the COSY 
experiment allowed H7, H8, and H9 to be identified for each molecule. With these data 
in hand, the peak for C5 could be assigned from the HMBC experiment based on 
chemical shift and coupling with H7 and H9. The connectivity of 12c and 13c (or 13c’) 
could then be determined from the HMBC data, and the molecules could be readily 
differentiated. For the skeleton of 12c, only a pair of two or three bond 1H-13C couplings 
involving C5 is possible between this atom and both  H7 or H9. In contrast, a trio of two 
or three 1H-13C couplings should be observed for C5 of either 13c or the isomer 13c‟ 
Entry Arene X Y Product Ratio Yield (%) 
1 11a CH2 H NA NR
 
2 11b C=O H NA NR 
3 11c CH2 OH 1.88:1 (12c:13c) 72 
4 11d C=O OH NA NR 
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since the aromatic proton H6 is also able to couple with this key carbon atom along with 
both H7 and H9. Indeed, the HMBC data were consistent with the expected proton-C5 
coupling patterns for both 12c and 13c, although 13c and 13c’ could not be 
distinguished via NMR spectroscopy. 
 
 
 
 
 
Table 1.6. 2D data for 12c1 
 
Atom 1H, mult, J = Hz 13C COSY HMBC  
H7 4.20, m - H8 C8, C9, C5 
H8 1.98, m - H7, H9 C7, C9, C4 
H9 2.54, m - H8 C7, C8, C3, C4, 
C5 
H2 6.13, s - - C1, C3, C4, C6 
H6 - - - - 
C5 - 153.7 - H7, H9 
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Table 1.7. 2D data for 13c1 
 
Both molecular mechanics (MMX) and density functional theory (DFT) calculations were 
performed to determine the relative conformational stabilities of 12c, 13c, and 13c’ 
(Table 1.8).43 Solvation was not considered in either case. PC Model v. 4.0 (Serena 
Software) was used for the MMX calculations, and intramolecular hydrogen bonding 
Atom 
1H, mult, J = Hz 13C COSY HMBC  
H7 4.17, t, J = 5.2  - H8 C8, C9, C5 
H8 1.94, m - H7, H9 C7, C9, C4 
H9 
2.54, t, J = 6.3 - H8 C7, C8, C3, C4, C5 
H2 - - - - 
H6 6.03, s - - C1, C2, C4, C5 
C5 - 158.2 - H7, H9, H6 
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was maximized among all hydroxyl groups. MMX predicted 13c to be 1.1 kcal/mol more 
stable than either 12c or 13c’, which were within 0.2 kcal/mol of each other. The DFT 
calculations were performed at the B3LYP/6-31.G* level of theory with Gaussian 03, 
and the structures determined by MMX were used as starting geometries.44  
Table 1.8. Molecular orbital package (MOPAC) calculations1 
Molecule 
Empirical 
formula 
Heat of 
formation 
(kcal/mol) 
Total 
energy 
(eV) 
Total energy kcal 
Total 
energy 
(kcal/mol) 
1a C12H12 O9 -358.28264 -4256.34683 -1.629e-19 -9.81513 e4 
1a 
no side 
chain 
C10 H8 O7 -266.45514 -3373.69551 -1.291e-19 -7.77974 e4 
1b C14H16 O9 -349.73517 -4555.22560 -1.743e-19 -10.50435 e4 
1b 
no side 
chain 
C12H12 O7 -257.52210 -3672.55755 -1.405e-19 -8.46891 e4 
12c C15H16 O9 -360.55711 -4678.30696 -1.790e-19 
-10.788175 
e4 
12c 
no side 
chain 
C13H12 O7 -268.07124 -3795.62709 -1.452e-19 -8.75271 e4 
13c C15H16 O9 -360.56178 -4678.30717 -1.790e-19 
-10.788176 
e4 
13c 
no side 
chain 
C13H12 O7 -268.06389 -3795.62677 -1.452e-19 -8.752716 e4 
13c’ C15 H16 O9 -361.95955 -4678.36778 -1.790e-19 
-10.788316 
e4 
13c’ 
no side 
chain 
C13H12 O7 -264.51030 -3795.47267 -1.452e-19 -8.752359 e4 
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Again, 13c was found to be lower in energy than 13c’ by 1.0 kcal/mol, and both were 
found to be lower in energy than 12c by 7.5 and 6.5 kcal/mol for 13c and 13c‟, 
respectively. These results suggest that the reaction may be under kinetic control and 
that 13c is the most likely structure for the minor isomer, although this has not been 
confirmed. However, it should be noted that the energies calculated for all molecules by 
MMX could be altered by up to 8 kcal/mol by breaking hydrogen bonding with negligible 
geometry changes. This highlights the fact that the cores of these structures are similar 
in energy. Further, intramolecular hydrogen bonding networks are typically disrupted in 
hydrogen bonding solvents, such as the 5:2 AcOH/THF (v/v) solution used for this 
reaction, and it is possible that solvation of either the C1 or C3 hydroxyl in the 
intermediate(s) increases steric interactions during the formation of either 12c or 13c, 
as exemplified for C1 in Scheme 2.8. Such solvation effects, which were ignored during 
the calculations described above, could explain the formation of the product with the 
lowest gas phase stability under the reaction conditions employed in this study. While 
the reaction of 11c with 4 yielded 12c with the naturally occurring tetracyclic core as the 
major product, the fact that this molecule was only 65% of the isolated material led us to 
investigate whether protection at the hydroxyl on the carbon that would become C3 
would shift the selectivity further toward 12c due to sterics (Figure. 1.8). Unfortunately, 
the construction of either C3 benzylated or silylated hydroxylated chromans proved 
difficult due to lability of the protecting group. These observations are consistent with 
the decomposition of dibenzylated arene 6b under the reaction conditions, and they 
highlight the good leaving group ability of trioxyarenes. 
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Figure 1.8. Effect of solvent on the regioselectivity1 
 
This developed synthetic strategy for the ascorbylation of arenes, was then applied to 
complex arenes. Thus the ascorbylation of (+)-catechin was carried out using similar 
reaction conditions (Scheme 1.9). It can be assumed that the reaction with catechin led 
to the desired product based on partial characterization. The corresponding product was 
mixture of isomers (14, 14’), which was partially characterized due to purification issues. 
Even after repetitive column chromatography, a single isomer could not be isolated.  
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Scheme 1.9. Reaction of 4 with (+)-catechin 
 
In summary, a method utilizing readily available 4 for the biomimetic ascorbylation of 
phenolic natural products has been reported herein. This reaction was found to be 
stereo-, chemo-, and regioselective, and a synthesis of the natural product, (-)-ascorbyl 
phloroglucinol (1a), was accomplished. Data obtained from the crystal structure of 1b 
corroborate previous theoretical assignment of the configuration for the stereocenters at 
the ascorbyl phenol junction in compounds of this type. Further, the tetracyclic core of 
ascorbylated catechins, such as 8-C-ascorbyl-(-)-epigallocatechin, was constructed. 
Efforts are underway to evaluate the bioactivity of the molecules reported herein and to 
expand the scope of this methodology to the construction of more complex ascorbylated 
natural products and analogues. 
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1.13. Bioassay data 
 
The successful syntheses of natural product 1a and analogues were followed by 
assessing their ability to modulate or inhibit certain biological responses. As 
mentioned previously, these molecules were hypothesized to be potential pancreatic 
lipase inhibitors due to structural resemblance with reported tea polyphenols. Since 
polyphenols are widely known for their diverse biological applications, these 
molecules were also tested for glucocorticoid receptor agonists (GR) as well as biofilm 
inhibition.  
1.14. Pancreatic Lipase Inhibition assay 
 
Pancreatic lipase is a key enzyme for lipid absorption.45  It is well known that dietary 
fat is not directly absorbed from the intestine unless it has been subjected to the 
action of pancreatic lipase. Therefore, to suppress weight gain, it would be effective to 
reduce fat absorption by lipase inhibition. The initial step was to identify the 
appropriate standard for the assay. Orlistat, a specific pancreatic lipase inhibitor, is 
clinically used for preventing obesity and hyperlipidemia.46 Endothelial lipase, a 
member of the triglyceride lipase gene family expressed in endothelial cells, prefers 
phospholipid-enriched high-density lipoprotein (HDL) over triglyceride as substrate. 
Orlistat is a potent inhibitor of endothelial lipase (IC50 = 16 nM). Levels of HDL 
cholesterol are inversely correlated with endothelial lipase protein activity. Therefore, 
inhibition of endothelial lipase by compounds like GSK264220A may be expected to 
increase HDL levels and potentially decrease the risk of cardiovascular disease.47 
Hormone sensitive lipase (HSL) catalyzes the hydrolysis of tri-, di-, and 
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monoacylglycerols, as well as cholesterol esters, thus mobilizing fatty acids as a 
primary source of energy in mammals.48 The enzyme is highly expressed in adipose 
tissue and steroidogenic tissues and is less abundant in skeletal muscle, heart, brain, 
pancreatic beta cells, adrenal gland, ovaries, testes, and macrophages.49 Its presence 
in various tissues indicates that the enzyme plays diverse roles including those in 
steroidogenesis and spermatogenesis, foam cell formation in atherosclerosis, and 
diabetes.49  CAY10499 is also a potent inhibitor of human hormone-sensitive lipase 
(HSL) exhibiting an IC50 of 90 nM for the recombinant enzyme. The in vivo 
pharmacological efficacy of CAY10499 has not been reported.50 These known 
inhibitors orlistat, GSK264220A and CAY10499 were used as standards (Figure 1.9).  
 
Figure 1.9. Reported lipase inhibitors 
 
The pancreatic lipase activity was measured using 4-methylumbelliferyl oleate (4-MU 
oleate) as a substrate. 4-MU oleate is a suitable fluorogenic substrate for lipases, which 
gets hydrolyzed by lipase enzyme and generates the fluorescent 4-methyl umbelliferone 
as described in Scheme 1.10. Hence the notion of the assay is if there is lipase activity 
in the solution, high fluorescence will be observed, and inhibition of this enzyme will 
decrease the fluorescence. The intensity of fluorescence was measured by fluorimeter 
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using wavelength filters 34/440 nm.  
 
Scheme 1.10. Hydrolysis of the substrate by lipase 
 
Initially, the assay was optimized for lipase VI from pigs using known inhibitors.51  
Orlistat and GSK264220A were used as standard inhibitors. The lipase hydrolysis was 
monitored by fluorometric analysis for 2 h, and measurements were taken every 30 min. 
Based on the above experiment, it can be said that time required for the reaction is 30 
min (Figure 1.9) since no significant change was noticed after 30 min. So it can be 
concluded that orlistat is the appropriate standard for this assay with IC50 around 1 μM 
for this particular lipase enzyme in vitro, which was used for all further experiments. It 
should be noted that the other negative control experiments such as only enzyme, 
target molecules as well as only substrate were carried out. 
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Figure 1.10. Lipase inhibition assay with reported inhibitors 
 
All synthesized molecules, including model compounds (7a-d), were tested for lipase 
inhibition using the fluorometric analysis. It was also confirmed that molecules do not 
react with the substrate causing its hydrolysis. The following graphs (Figure 1.10A) 
depict the lipase activity after 30 min for every molecule along with their respective 
A) B) 
C) D) 
E) 
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controls. All the experiments were carried out in duplicate. As can be seen in the graphs 
(Figure 1.11), molecule 1a, 1b, and 3 do not have any activity towards lipase inhibition 
since there was no decrease in the emission intensity. Compound 12c, 13c, and 14 
show very little activities. Similarly, compounds (7a-d) decreased the emissions; 
however they cannot be considered appreciable lipase inhibitiors as can been from 
Figure 1-12. 
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Figure 1.11. Lipase inhibition assay (fluorescence intensity) for ascorbyl compounds 
(1a, 1b, 3, 12c, 13c, 14) 
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Figure 1.12. Measured emission intensities for 7a-d 
 
In conclusion, it can be said that none of the molecules are found to be active against 
porcine lipase VI. Since no potent target molecule as a lipase inhibitor was found, we 
decided to test these molecules for other significant biological functions. 
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1.15. Glucocorticoid receptor (GR) agonists assay 
 
Glucocorticoids are steroid hormones that are essential for normal growth and 
development, for liver and immune functions, and for mediating the stress response.52, 
53,54 Synthetic steroids with selective glucocorticoid receptor agonist (SEGRA) like 
properties were discovered in the late 1990s. During the 2000s, many potential 
SEGRAs were synthesized and had non-steroidal structures. These compounds were 
investigated in cellular models, which established that these molecules bind to the 
glucocorticoid receptor with an affinity similar to dexamethasone, which is a potent 
glucocorticoid, and that they are able to repress the production of inflammatory 
mediators such as IL-6 and prostaglandin E2. Both non-selective glucocorticoids and 
selective glucocorticoid receptor agonists work by binding to and activating the GR.54 
Synthetic derivatives of glucocorticoids, such as dexamethasone, have 
immunosuppressive, anti-inflammatory, osteocatalytic, proteolytic, and hyperglycemic 
activities and are used to treat various pathological conditions.55 The GR is a ligand-
activated intracellular transcriptional regulator that is a member of the nuclear receptor 
super family. In the absence of a ligand, the GR is retained in the cytoplasm by 
association with chaperone proteins.52 The recently-introduced selective 
glucocorticoid receptor (GR) agonists (SEGRAs) offer anti-inflammatory action 
comparable to that of common GCs, but with a reduced side effect profile.56 In the 
absence of glucocorticoids, the GR resides in the cytosol in an inactive state 
complexed with heat shock proteins (HSPs).54 Binding of glucocorticoids to the GR 
activates the receptor by causing dissociation of the bound HSPs.54  
In chronic inflammatory diseases of the skin like atopic dermatitis, the side-effects of 
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corticoids are problematic because of the necessary long-term treatment. Therefore, 
SEGRAs are being investigated as an alternative topical treatment. Systemic long-
term treatment of inflammations with corticoids is particularly resposible to cause 
metabolic side-effects, which makes the development of oral SEGRAs an interesting 
goal. Eye inflammation is also a potential application because corticoids can promote 
eye infections, and cataracts. It remains to be seen whether selective receptor 
agonists cause significantly less side effects than classical corticoids in clinical 
application. Currently, glucocorticoids (GCs) are used as anti-inflammatory and 
immunosuppressive drugs. Their outstanding therapeutic effects, however, are often 
accompanied by severe and sometimes irreversible side effects. 
For this reason, one goal of research in the GC field is the development of new drugs, 
which show a reduced side-effect profile while maintaining the anti-inflammatory and 
immunosuppressive properties of classical GCs. In order to find a potent target 
molecule, synthesized molecules (1a, 1b, 12c, and 13c) were evaluated using a GR 
assay by Dr. Jason Collier and his lab members. In this assay luciferase activity was 
measures using 3XR as a promotor since binding activity of transcription factors 
results in the expression of luciferase, an enzyme capable of catalyzing 
bioluminescent reaction.57 Light emitted from the chemical reaction is directly 
proportional to the amount of expressed enzyme, and thus the binding activity of the 
targeted transciptor factor (TF). The luciferase activity was measured in the presence 
of the ascorbyl compounds at different concentrations (1 nM, 10 nM, 100 nM, 1000 
nM, and 10000 nM) as shown in Figure 1.13. The light intensity was measured using 
luminometer in the assy. The 10 nm solution of dexamethanose was used as a 
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standard for the assay, which exhibited around 18 fold luciferase activities. The 
luciferase activity was not detected in the significant amounts in the case of any test 
molecules. Hence, unfortunately, none of them had GR agonist activity over the nM 
and µM ranges. This assay only confirms that, these molecules do not bind to the 
receptor as glucocorticoid agonists. 
 
 
Figure 1.13. Glucocorticoid receptor (GR) agonists assay for ascorbyl compounds 
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1.16. Biofilm inhibition assay 
 
Recent studies have shown that black and green tea polyphenols exhibit both 
antimicrobial and strong cancer-preventive properties. Experiments were conducted to 
determine the effects of these polyphenols on Candida albicans.58 Standard growth 
curves demonstrated a 40% reduction in the growth rate constant (k), with a 2 mg/mL of 
concentration of Polyphenol 60, a green tea extract containing a mixture of polyphenolic 
compounds. Cultures treated with 1.0 μM (-)-epigallocatechin-3-gallate (EGCG), the 
most abundant polyphenol, displayed a 75% reduction of viable cells during biofilm 
formation.59,60 Established biofilms treated with EGCG were also reduced, by 80%, as 
determined through XTT colorimetric assays. Identical concentrations of 
epigallocatechin (EGC) and epicatechin-3-gallate (ECG) demonstrated similar biofilm 
inhibition. Many resistant interactions with fungi and bacteria involve the accumulation 
of toxic concentrations of phenolic compounds. Catechin and proanthocyanidins were 
found to complex with spores and hyphae of pathogenic fungi of fruit crops. Based on 
these literature reports, we decided to test our molecules for biofilm inhibitory activities.  
Bacterial strains E. coli 700728 and E. coli 25404 were chosen since they were readily 
available and easy to handle.61 The control experiment was carried out to optimize the 
conditions of biofilm generation for both strains, and the results are depicted in the 
Figure 1.14.  It was observed that E. coli 700728 strain forms biofilms in minimal media 
and that E. coli 25404 forms biofilm readily in LB media based on the measured 
absorbance values. E. coli 700728 does not grow in LB media, and E. coli 25404 have a 
lower growth rate in minimal media. The biofilm was stained using crystal violet solution, 
which can be then washed twice to remove excess dye.62 The excess washing might 
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affect the structural features of the biofilm. E.coli cultures were shaken at 37 ºC and 
dilutions (1:4) were carried out before measuring the absorbance. Biofilms were stained 
and extracted by ethanolic crystal violet solutions. Absornances of these biofilms were 
then measured at specific wavelength (570 nm). 
 
 
These synthetic ascorbylated polyphenols 1a, 1b, 12c, 13c, and 14 were tested on both 
strains of E. coli, and the results are shown below in Figure 1.15. It was observed that 
molecules 1a, 1b, and 14 do not inhibit biofilm formation of E. coli 25404 or E. coli 
700728. Since there was no decrease in the absorbance was noted, it can be 
determined that these molecules are not inhibiting biofilms in E.Coli. Molecule 12c 
showed an interesting moderate inhibition around 1-10 μM both in E. coli 25404 and E. 
Figure 1.14. Absorbance at 570 nm for media and bacteria 
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coli 700728. However, its isomer 13c did not show biofilm inhibition for either strain of E. 
coli. 
 
Figure 1.15. Absorbaces at 570 nm of E. coli 25404 and E. coli 700728 with test 
molecules 
 
Conclusions 
The novel method of stereoselective ascorbylation of different oxygenated arenes was 
developed.1 To the best of our knowledge, this is the only cost effective method of 
generating the tetracyclic core structure of 8-C-ascorbyl epigallocatechin and its 
analogues. This elegant reaction helps to selectively introduce many stereocenters in 
one step. Additionally, this convergent synthetic approach provide access to a library of 
compounds to study structure and activity relationship (SAR). 
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Unfortunately, these molecules showed very little activity against lipase VI assay or 
biofilm formation in E. coli. However polyphenols exhibit a wide spectrum of biological 
activities, thus it is plausible that the synthesized molecules will display biological 
activities which have not been found. 
1.17. Experimental section 
Materials and general methods 
All reagents and solvents were purchased from Fisher Scientific and used without 
further purification unless noted. Lipase inhibitors were purchased from CAYMAN 
chemicals and sigma-aldrich. Silica gel (60 A, 40-63 mm, 230-400 mesh) and polyester 
backed thin-layer chromatography (TLC) plates (Silica G w/UV, 200 mM) were 
purchased from Sorbent Technologies. All reactions were carried out under nitrogen 
unless otherwise stated. All 1D 1H and 13C spectra were recorded using 300 MHz 
Varian Mercury or 500 MHz Varian INOVA spectrometer. Deuterated solvents used for 
NMR analyses were purchased from Cambridge Isotope Laboratories. The NMR 
chemical shifts are reported in parts per million (ppm) and referenced to the solvent 
peak. All 2D NMR spectra were recorded on a 600 MHz Varian INOVA. IR spectra were 
obtained on a Varian 4000 FTIR instrument. High-resolution mass spectra (HRMS) 
were obtained with an Applied Biosystems MDS Sciex Qstar Elite time-of-flight mass 
spectrometer (MS), and optical rotations were recorded using a Perkine Elmer 241 
polarimeter. Data for the X-ray crystal structure of 1b were collected on a Bruker-AXS 
Smart APEX II diffractometer fitted with a Nicolet LT-2 low temperature device and a 
graphite-monochromated Mo Ka radiation at 0.71073 A. The detail analysis of the 
crystal structure is shown in supplemental information of this document. 
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Table 1.9. Crystal structure properties of 1b 
Identification code 1b 
Empirical formula C14H16O9 
Formula weight 328.27 
Temperature 296(2) K 
Wavelength 0.71073 Å 
Crystal system Orthorhombic 
Space group P2(1)2(1)2(1) 
Unit cell dimensions a = 6.743(5) Å α = 90° 
 b = 13.829(10) Å β = 90° 
 c = 14.625(11) Å γ = 90° 
Volume 1363.7(17) Å
3
 
Z 4 
Density (calculated) 1.584 mg/m
3
 
Absorption coefficient 0.135 mm
-1
 
F (000) 676 
Crystal size 0.05 x 0.05 x 0.4 mm
3
 
Theta range for data collection 2.03 to 28.46° 
Index ranges -8 ≤ h ≤ 8, -18 ≤ k ≤ 18, 
 -19 ≤  I ≤ 19 
Reflections collected 15452 
Independent reflections 3262 [R(int) = 0.0374] 
Completeness to theta = 28.46° 96.7% 
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Identification code 1b 
  
Refinement method Full-matrix least-squares on F
2
 
Data/ restraints/ parameters 3262 / 0 / 214 
Goodness-of-fit on F
2
 1.019 
Final R indices [I > 2sigma(I)] R1 = 0.0351, wR2 = 0.0780 
R indices (all data) R1 = 0.0492, wR2 = 0.0848 
Absolute structure parameter -0.1(9) 
Largest diff. peak and hole 0.188 and -0.185 eÅ
-3
 
 
General procedure for the reaction of hydroxyarenes with 5 
(7a-d) These reactions were carried out via slight modifications of previously reported 
procedures. Ninhydrin (1.00 mmol) and the appropriate hydroxyarene (1.00 mmol, 6a-d) 
were placed in a round-bottom flask and dissolved in 3 mL of AcOH. If the reagents 
were not completely soluble, THF was added dropwise until the mixture was 
homogeneous. The solution was then refluxed for 2-3 h. At this time, the reaction 
mixture was cooled to rt and diluted with 10 mL of H2O. The product was isolated after 
extractions of the aqueous layer with ethyl acetate (EtOAc, 3X15 mL). The combined 
organic layers were dried with MgSO4, filtered, and then concentrated in vacuo. The 
resulting crude product was purified by column chromatography on silica gel using 20% 
acetone in CH2Cl2 as the eluent. 
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4b,7,9,9b-Tetrahydroxy-4bH-indeno[1,2-b]benzofuran- 10(9bH)-one (7a) and 4b,9b-
dihydroxy-4bH-indeno[1,2-b]benzofuran-10(9bH)-one (7d).  
These molecules have been reported previously, and all analytical data collected for 
these studies matched those in the literature.42,41 
4b,7,9b-Trihydroxy-4bH-indeno[1,2-b]benzofuran-10(9bH)-one (7c). Rf (30% 
acetone/CH2Cl2) 0.68; mp = 226 
ºC; IR (KBr, thin film)  ‾ν  max (cm
-1): 1150, 1466, 1499, 
1626, 1731, 2957, 3280-3580 (br); 1H NMR (500 MHz, acetone-d6, δ): 8.62 (s, 1H), 7.98 
(d, J = 7.8 Hz, 1H), 7.88 (t, J = 7.5 Hz, 1H), 7.74 (d, J = 7.7 Hz, 1H), 7.69 – 7.58 (m, 
1H), 7.26 (d, J = 8.3 Hz, 1H), 6.55 (s, 1H), 6.44 (dd, J = 8.3, 2.2 Hz, 1H), 6.25 (d, J = 2.2 
Hz, 1H), 5.65 (s, 1H); 13C NMR (126 MHz, acetone-d6, δ): 161.0, 158.7, 148.9, 136.3, 
134.5, 130.7, 126.2, 124.9, 122.8, 116.3, 109.1, 97.3, 82.2; HRMS-ESI (m/z): [M-H]- 
calcd for C15H10O5, 269.0450; found, 269.0454.  
4b,9b-Dihydroxy-7,9-dimethoxy-4bH-indeno[1,2-b]benzofuran-10(9bH)-one (7b) Rf 
(30% acetone/CH2Cl2) 0.79; mp = 204 
ºC; IR (KBr, thin film) ‾ν   max (cm
-1): 1152, 1466, 
1497, 1623, 1734, 2956, 3419; 1H NMR (500 MHz, acetone-d6, δ): 7.93 (d, J = 7.2 Hz, 
1H), 7.84 (t, J = 7.0 Hz, 1H), 7.73 (d, J = 7.3 Hz, 1H), 7.63 (d, J = 7.0 Hz, 1H), 6.45 (s, 
1H), 6.06 (s, 1H), 6.00 (s, 1H), 5.52 (s, 1H), 3.77 (s, 3H), 3.72 (s, 3H); 13C NMR (126 
MHz, acetone-d6, δ): 196.9, 164.3, 159.8, 159.2, 148.1, 135.9, 131.0, 124.7, 122.8, 
110.5, 104.6, 93.9, 92.0, 88.2, 83.3, 55.0, 54.9; HRMS-ESI (m/z): [M-H]-  calcd for  
C17H13O6 , 313.0712; found, 313.072.  
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Preparation of L-dehydroascorbic acid (4). 
This material was prepared via a slight modification of a known procedure.39 Briefly, 
iodine (1.40 g, 5.68 mmol) was added in one portion to a stirring solution of L-ascorbic 
acid (1.00 g, 5.68 mmol) dissolved in methanol (10 mL), and the reaction mixture was 
allowed to stir for 10 min at rt. At this time, lead carbonate (3.40-3.65 g) was added 
slowly to the brown reaction mixture until it turned colorless. The resulting mixture was 
filtered through celite to remove the bulk of the Pb, and the filtrates were then treated 
with H2S to precipitate the remaining metal. The resulting solids were removed from the 
filtrate by a second filtration through Celite, and air was blown through the crude 
solution containing 4 to remove excess H2S. Concentration in vacuo gave the desired 
product as a white, sticky solid in w25% yield and sufficient purity to be used in further 
reactions. 
Partial characterization of this material has been reported previously. 
1H NMR (300 MHz, D2O, δ): 4.55 (ddd, J = 5.2, 2.7, 0.8 Hz, 1H), 4.24 (dd, J = 10.4, 2.6 
Hz, 1H), 4.12 (dd, J = 10.4, 2.6 Hz, 1H), 3.70–3.74 (m, 1H). 
Chroman-5,7-diol (11c).  
Phloroglucinol 6a (1.00 g, 7.93 mmol) was placed in a round bottom flask and dissolved 
in 10 mL of aqueous 2 N NaOH at rt An ethanolic solution of 1,3- dibromopropane 
(0.881 mL, 8.72 mmol dissolved in 10 mL) was then added slowly, and the reaction 
mixture was stirred for 10 h at rt. At this time, the reaction was cooled to 0 ºC with an ice 
bath and then acidified using 1 N HCl to pH 2.  The aqueous layer was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were then dried with MgSO4 and 
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filtered. The resultant supernatants were concentrated under vacuμM to give a crude 
liquid, which was then purified via flash silica chromatography using 20% acetone in 
CH2Cl2 as the eluent. This procedure yielded 0.450 g of 11c as a pure, amorphous 
white solid (34%).Rf (30% acetone/CH2Cl2) 0.75; mp = 176 
ºC; IR (KBr, thin film) ‾ν  max 
(cm-1): 949, 1189, 1278, 1475, 1521, 1621, 2975, 3100-3480 (br); 1H NMR (500 MHz, 
acetone-d6, δ): 8.02 (s, 1H, OH), 7.83 (s, 1H, OH), 5.96 (d, J = 2.3 Hz, 1H, Ar H), 5.79 
(d, J = 2.3 Hz, 1H, Ar H), 4.07 – 3.96 (m, 2H, -OCH2CH2CH2-), 2.52 (t, J = 6.6 Hz, 2H, -
OCH2CH2CH2-), 1.94 – 1.77 (m, 2H, -OCH2CH2CH2-); 
13C NMR (126 MHz, CD3OD, δ): 
156.2, 156.0, 155.9, 101.3, 94.5, 94.4, 94.4, 65.8, 22.0, 18.5; HRMS-ESI (m/z): [M-H]-  
calcd for  C9H9O3, 165.0552; found, 165.0557.  
5,7-Dihydroxychroman-4-one (11d).  
This preparation follows a known procedure that employed resorcinol 6c. 63 
Phloroglucinol 6a (0.88 g, 7.00 mmol) and 3-chloropropionic acid (0.83 g, 7.70 mmol) 
were dissolved in 2.7 mL of triflic acid. The reaction mixture was then heated at 80–90 
ºC for 1 h. At this time, the reaction was cooled to rt and diluted with EtOAc (20 mL). 
The resulting mixture was then poured onto ice (~60–70 g), and a precipitate formed. 
The resulting mixture was extracted EtOAc (3 x 20 mL). The organic layers were then 
combined, dried over MgSO4, filtered, and then concentrated in vacuo to give 3-chloro-
1-(2,4,6-trihydroxyphenyl)propan-1-one as a an orange oil that was of sufficient purity to 
be used directly in the next step. This intermediate was then placed in a round bottom 
flask and cooled to 0 ºC in an ice bath. 2 N NaOH (50 mL) was then added slowly to the 
reaction vessel, and the resulting mixture was stirred at rt for 2 h. At this time, the 
reaction was cooled to 0 ºC and acidified to pH 2 with 6 N H2SO4. The crude product 
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was first purified by extraction with EtOAc (3 x 25 mL); and the combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo to give a yellow oil. This 
material was purified by flash chromatography using silica gel eluted with 20% acetone 
in CH2Cl2 to give 146 mg 11d as an amorphous, pale-yellow solid (11 %). Partial 
characterization of this material has been reported previously. 64Rf (30% 
acetone/CH2Cl2) 0.76; 
1H NMR (300 MHz, DMSO-d6, δ): 9.67 (s, 1H), 9.39 (s, 1H), 6.11 
(d, J = 2.3 Hz, 1H), 5.90 (d, J = 2.3 Hz, 1H), 2.73 – 2.62 (m, 4H); 13C NMR (75 MHz, 
DMSO-d6, δ): 196.7, 166.9, 164.0, 163.5, 102.5, 96.1, 95.2, 66.7, 36.3; HRMS-ESI 
(m/z): [M-H]- calcd for C9H7O4, 179.0344; found, 179.0349. 
General procedure for the ascorbylation of hydroxyarenes (1a-i, 12a-d and 13a-d). 
Dehydroascorbic acid, 4, (0.250 g, 1.43 mmol) was placed in a round-bottom flask and 
dissolved in THF (5 mL). (5 mL). The phloroglucinol derivative (2.14 mmol, 6a-i) was 
then added to the reaction in one portion followed by glacial acetic acid (2 mL), and the 
resulting solution was stirred for 8–10 h. At this time, the reaction mixture was 
concentrated in vacuo, and the resulting material was purified via flash silica 
chromatography  using 70% EtOAc in hexanes as the eluent. 
(3R,3aR,8bS)-3-((S)-1,2-dihydroxyethyl)-3a,6,8,8b-tetrahydroxy-3,3a-
dihydrofuro[3,4-b]benzofuran-1(8bH)-one (1a).  
This material was obtained in 69% yield as a white, amorphous solid. Rf (50% 
EtOAc/hexanes) 0.56; [α]D 
25 -46 (c 0.01, H2O); IR (KBr, thin film) ‾ν   max  (cm
-1): 1150, 
1472, 1633, 1773, 2962, 3256–3430 (br); 1H NMR (600 MHz, D2O, δ): 6.08 (d, J = 1.1 
Hz, 1H, Ar H), 6.06 (d, J = 1.8 Hz, 1H, Ar H), 4.48 (d, J = 6.1 Hz, 1H, -
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OCHCHOHCH2OH), 4.21 (dd, J = 10.7, 5.3 Hz, 1H, -OCHCHOHCH2OH), 3.85 (dd, J = 
11.8, 4.0 Hz, 1H, -OCHCHOHCH2OH), 3.74 (dd, J = 11.7, 6.4 Hz, 1H, - 
OCHCHOHCH2OH); 
1H NMR (600 MHz, DMSO-d6, δ): 9.55 (s, 1H, OH), 9.46 (s, 1H, 
OH), 7.77 (s, 1H, OH), 6.03 (s, 1H, OH), 5.88 (s, 1H, Ar H), 5.72 (s, 1H, Ar H), 4.96 (s, 
1H, OH), 4.70 (s, 1H, OH), 4.12 (d, J = 4.7 Hz, 1H, -OCHCHOHCH2OH), 3.82 (m, 1H, -
OCHCHOHCH2OH), 3.52 (m, 1H, -OCHCHOHCH2OH), 3.39 (m, 1H, -
OCHCHOHCH2OH); 
13C NMR (151 MHz, D2O, δ): 174.4, 161.2, 159.1, 156.1, 110.9, 
101.4, 97.3, 90.9, 83.3, 78.7, 69.4, 62.1; HRMS-ESI (m/z): [M-H]-  calcd for  C12H11O9, 
299.0403; found, 299.0403. 
(3R,3aR,8bS)-3-((S)-1,2-dihydroxyethyl)-3a,8b-dihydroxy-6,8-dimethoxy-3,3a-
dihydrofuro[3,4-b]benzofuran-1(8bH)-one (1b).  
This material was generated in 72% yield as a white, crystalline solid. Rf (70% 
EtOAc/hexanes) 0.43; [α]D 
25 -82.6 (c 0.01, H2O); mp = 181 
ºC; IR (KBr, thin film) ‾ν  max 
(cm-1): 800, 1107, 1152, 1596, 1789, 2362, 2459, 2568, 2962, 3168, 3305, 3469; 1H 
NMR (300 MHz, D2O, δ): 6.20 (d, J = 1.9 Hz, 1H, Ar H), 6.18 (d, J = 1.2 Hz, 1H, Ar H), 
4.46 (d, J = 6.4 Hz, 1H, -OCHCHOHCH2OH), 4.19 (dd, J = 10.1, 5.7 Hz, 1H, -
OCHCHOHCH2OH), 3.88 – 3.82 (m, 1H, -OCHCHOHCH2OH), 3.81 (s, 3H, -OCH3), 
3.78 (s, 3H, -OCH3), 3.72 (m, 1H, -OCHCHOHCH2OH); 
1H NMR (500 MHz, DMSO-d6, 
δ): 8.00 (s, 1H, OH), 6.15 (s, 1H, Ar H), 6.14 (s, 1H, Ar H), 5.09 (s, 1H, OH), 4.74 (s, 1H, 
-OCHCHOHCH2OH), 4.17 (s, 1H, -OCHCHOHCH2OH ), 4.02 (s, 1H, OH), 3.86 (s, 1H, 
OH), 3.74 (s, 6H, -OCH3), 3.53 (s, 1H, -OCHCHOHCH2OH), 3.37 (s, 1H, -
OCHCHOHCH2OH); 
13C NMR (151 MHz, D2O, δ): 174.4, 164.8, 159.0, 158.7, 110.9, 
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102.3, 93.5, 89.4, 83.4, 78.9, 69.4, 62.0, 55.9, 55.8; HRMS-ESI (m/z): [M-H]-  calcd for  
C14H16O9, 327.0713; found, 327.0713.   
Procedure for X-ray analysis of 1b.  
To obtain crystallographic data (Table 7), a suitable crystal was selected and mounted 
using glue, and the data were collected at 28 ºC.  Hydrogens were refined isotropically 
in idealized positions via the riding model approximation. Empirical absorption correction 
was performed with SADABS software package from Bruker. In addition, the global 
refinements for the unit cell and data reduction of the structure were performed using 
the Saint version 6.02 (Bruker), and all calculations were performed using SHELXTL 
version 5.1 proprietary software package from Bruker. Crystallographic data for 1b have 
been deposited in the Cambridge Crystallographic Data Centre (CCDC) as 
supplementary publication numbers CCDC 827129. These data can be freely obtained 
from the CCDC by sending an application by email to deposit@ccdc.cam.ac.uk. 
(7aR,8R,10aS)-8-((S)-1,2-dihydroxyethyl)-5,7a,10a-trihydroxy-3,4,7a,8-tetrahydro-
2H-furo[3',4':4,5]furo[2,3-h]chromen-10(10aH)-one (12c).  
This material was the major product from reaction of 4 with 11c and was generated in 
47% yield as a white, amorphous solid. Rf (60% acetone/CH2Cl2) 0.76;[α]D
25 - 14 (c 0.01, 
acetone); IR (KBr, thin film) ‾ν max (cm
-1): 1155, 1455, 1511, 1638, 1775, 2959, 3000-3620 
(br); 1H NMR (500 MHz, D2O, δ): 6.13 (s, 1H, Ar H), 4.46 (d, J = 5.7 Hz, 1H, -
OCHCHOHCH2OH), 4.20 (m, 3H, -OCH2CH2CH2- and -OCHCHOHCH2OH), 3.87 (dd, J 
= 11.9, 4.3 Hz, 1H, -OCHCHOHCH2OH), 3.75 (dd, J = 11.8, 6.5 Hz, 1H, -
OCHCHOHCH2OH), 2.61 – 2.47 (m, 2H, -OCH2CH2CH2- ), 2.03 – 1.92 (m, 2H, -
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OCH2CH2CH2-); 
13C NMR (126 MHz, D2O, δ): 174.3, 158.3, 156.1, 153.7, 110.5, 105.3, 
101.0, 90.4, 87.3, 82.9, 78.8, 76.0, 72.5, 69.2, 66.8, 61.9, 20.8, 18.4; HRMS-ESI (m/z): 
[M-H]-  calcd for  C9H9O3, 339.0733; found, 339.0732.  
(6bS,9R,9aR)-9-((S)-1,2-dihydroxyethyl)-6,6b,9a-trihydroxy-2,3,9,9a-tetrahydro-1H-
furo[3',4':4,5]furo[2,3-f]chromen-7(6bH)-one (13c).  
This material was the minor product from reaction of 4 with 11c and was obtained in 
25% yield as a white, amorphous solid. Rf (70% acetone/CH2Cl2) 0.75; [α]D
25 +10.8 (c 
0.01, acetone); IR (KBr, thin film) ‾ν   max (cm
-1): 1155.16, 1239.66, 1455, 1511, 1 638, 
1775, 2959, 2990-3620 (br); 1H NMR (500 MHz, D2O, δ): 6.03 (s, 1H, Ar H), 4.46 (d, J = 
5.4 Hz, 1H, -OCHCHOHCH2OH), 4.24 (dd, J = 9.8, 6.7 Hz, 1H, -OCHCHOHCH2OH ), 
4.17 (t, J = 5.2 Hz, 2H, -OCH2CH2CH2-), 3.87 (dd, J = 11.8, 4.4 Hz, 1H, -
OCHCHOHCH2OH), 3.74 (dd, J = 11.8, 6.8 Hz, 1H, -OCHCHOHCH2OH), 2.54 (t, J = 
6.3 Hz, 2H, -OCH2CH2CH2-), 1.94 (m, 2H, -OCH2CH2CH2- ); 
13C NMR (126 MHz, D2O, 
δ): 174.1, 158.3, 156.2, 153.0, 110.6, 101.2, 99.6, 97.3, 83.2, 78.8, 69.1, 67.1, 61.8, 
20.7, 17.7; HRMS-ESI (m/z): [M-H]-  calcd for  C15H16O9, 339.0733; found, 339.0731. 
Preparation of (3R,3aS,8bS)-3-((S)-1,2-Diacetoxyethyl)-1-oxo-1,3,3a,8b-
tetrahydrofuro[3,4-b]benzofuran-3a,6,8,8b-tetrayl tetraacetate (3).  
(-)-Ascorbyl phloroglucinol 1a (100 mg, 0.33 mmol) was placed in a round-bottom flask 
contained distilled pyridine (215 mL), and acetic anhydride (215 mL) was then added. 
The reaction mixture was stirred for 14 h at rt. At this time, the contents of the reaction 
vessel were poured into ice water (50 mL), and the resulting solution was extracted with 
EtOAc (3 x 10 mL).  The organic layers were collected, combined, dried with MgSO4, 
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and concentrated in vacuo to give an oil, which was purified via flash silica 
chromatography using 10% acetone in CH2Cl2 as the solvent yielding 3 white, 
amorphous solid in 10% yield. Characterization of this material has been reported 
previously.37 1H NMR (600 MHz, CDCl3, δ): 6.71 (d, J = 1.6 Hz, 1H, Ar H), 6.67 (d, J = 
1.5 Hz, 1H, Ar H), 5.78 – 5.59 (m, 1H, - OCHCHOHCH2OH), 4.97 (d, J = 4.5 Hz, 1H, 
OCHCHOHCH2OH), 4.41 (dd, J = 11.8, 4.5 Hz, 1H, OCHCHOHCH2OH), 4.26 (dd, J = 
11.8, 6.3 Hz, 1H, OCHCHOHCH2OH), 2.33 (s, 3H, -OAc), 2.28 (s, 3H, -OAc), 2.16 (s, 
6H, -OAc), 2.11 (s, 3H, -OAc), 2.09 (s, 3H, -OAc); 13C NMR (151 MHz, CDCl3, δ): 170.5, 
169.9, 168.2, 166.5, 166.1, 154.7, 148.4, 168.4, 158.2, 110.2, 109.6, 112.1, 83.9, 82.1, 
68.0, 62.7, 21.3, 21.0, 21.1, 21.0, 20.1, 20.0. 
Partial characterization of 14. 
This material was obtained in 35% yield as a white, amorphous solid after column 
chromatography using 10% acetone in CH2Cl2 as the eluent. The reaction was carried 
out using previously mentioned protocols. The separation of stereoisomers could not be 
achieved by repetitive column chromatography using combinations of several organic 
solvents; hence 1H NMR and 13C NMR chemical shifts are not assigned however listed 
below. [α]D 
25 0.002 (c 0.01, H2O); IR (KBr, thin film) ‾ν   max  (cm
-1): 1155, 1472, 1633, 
1773, 2962, 3250–3430 (br); 1H NMR (300 MHz, DMSO-d6, δ): 9.17 (s), 8.91 (s), 8.84 
(s), 6.70 (m), 6.56 (m), 5.92 (m), 5.87 (m), 5.75 (m), 5.04(m), 4.86 (m), 4.65 (m), 4.56 
(m), 4.46 (m), 4.13 (m), 4.01(m) , 3.84 (m), 3.54(m) ); 13C NMR (126 MHz, DMSO-d6, δ): 
172.65, 172.43, 159.17, 157.71, 157.27, 157.11, 155.03, 153.53, 145.44, 145.34, 
145.09, 145.07, 130.72, 130.43, 118.83, 118.18, 115.59, 115.31, 114.84, 111.63, 
111.44, 103.23, 102.03, 101.79, 96.61, 95.97, 90.19, 82.73, 82.20, 81.99, 81.20, 78.71, 
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78.69, 69.95, 66.53, 65.95, 62.04, 40.54, 40.45, 40.37, 40.28, 40.20, 40.11, 40.04, 
39.95, 39.87, 39.78, 39.70, 39.61, 39.52, 39.45, 27.91, 27.66; HRMS-ESI (m/z): [M-H]-  
calcd for  C12H11O9, 463.087; found, 463.0877. 
Lipase assay method 
25 μL of a sample solution (1a, 1b, 3, 12c, 13c, 14, 7a-d) dissolved in water and 50 μL 
of a 0.1 mM 4-MU oleate solution dissolved in a buffer consisting of 13 mM Tris-HCl, 
150 mM NaCl, and 1.3 mM CaCl2 (pH 8.0) were mixed in the well of a microtiter plate, 
and 25 μL of the lipase solution (50 U/mL) in the above buffer was then added to start 
the enzyme reaction. Initially, reaction was continued for 2 h, and readings were taken 
every 30 min. The reaction can be quenched by, adding 0.1 mL of 0.1 M sodium citrate 
(pH 4.2). The amount of 4-methylumbelliferone released by lipase hydrolysis was 
measured with a fluorometrical microplate reader (Fluoroskan Ascent C Lab- Systems, 
Inc.) at an excitation wavelength of 355 nm and an emission wavelength of 460 nm. 
GR agonists assay /Transient transfection and luciferase assay 
832/13 Cells were grown to 60% confluency in 24-well dishes and transfected with 50 
ng GAS-luciferase construct using TransIT LT-1 transfection reagent (Mirus Bio; 
Madison, WI) using a 3:1 ratio of TransIT LT-1: DNA according to the manufacturer‟s 
instructions. Cells were lysed in passive lysis buffer (Promega; Madison, WI), and 
luciferase assays were performed with cellular lysates using the luciferase reporter 
system (Promega) in a GloMax plate reading luminometer (Promega). Relative light 
units were normalized to protein content using a BCA protein assay (Pierce; Rockford, 
IL). 
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Biofilm inhibition assay 
Biofilm formation in polystyrene microtiter dishes was assayed as described previously 
with a few modifications. An overnight culture of E. coli in LB or LM medium was diluted 
1:100 in fresh medium and grown for another hour. After the addition of different 
concentrations of the compounds (1a, 1b, 3, 12c, 13c, 14), 100 μL aliquots of culture 
were pipetted into the wells of the microtitre dishes and incubated for 48 h at 30 ºC. 
Thereafter, the medium was removed, and 100 μL of a 1% (w/v) aqueous solution of 
crystal violet (CV) was added. Following staining at room temperature for 20 min, the 
dye was removed and the wells were washed thoroughly twice. For quantification of 
attached cells the CV was solubilized in 95% ethanol, and the absorbance was 
determined at 570 nm. Inhibitor-mediated reduction of biofilm formation was correlated 
to the value obtained without addition of the compounds. 
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2. Role of AI-2 in mutualistic dual biofilm growth 
and synthesis of AI-2 analogues 
 
The data presented below has been adapted from the following published article:  
“Autoinducer-2 influences interactions amongst pioneer colonizing streptococci in oral 
biofilms.” Giancarlo Cuadra-Saenz, Dhana L. Rao, Adam J. Underwood, Sneha A. 
Belapure, Shawn R. Campagna, Zhichao Sun, Steven Tammariello, and Alexander H. 
Rickard Microbiology (2012), 158, 1783–1795. 
2.1. Quorum sensing 
 
Quorum sensing has been described as the process that allows bacteria to count their 
numbers, determine when they have reached a critical mass, and then change their 
behavior in unison to carry out processes that require many cells acting together to be 
effective.65,66,67 The most widespread quorum sensing system in Gram-negative 
bacteria was first discovered in the marine symbiont Vibrio fischeri, where it controls 
bioluminescence. Quorum sensing plays critical roles in regulating diverse cellular 
functions in bacteria, including bioluminescence, virulence, biofilm formation, and 
antibiotic resistance.68,69,70 The following picture (Figure 2.1) shows the biofilm formation 
due to quorum sensing in hot water springs.71 
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Similar example was first discovered in 1970 in the bioluminescent Gram-negative 
bacterium, Vibrio fischeri. V. fischeri is a symbiont of the Hawaiian bobtail squid 
Euprymna scolopes (Figure 2.2) and lives in its light organ, whose rich nutrients allow 
fast proliferation of the bacteria.72 When the bacteria density is sufficiently high, genes 
involved in bioluminescence are expressed, and light is produced to provide an 
antipredatory response by preventing the squid from casting a shadow under 
moonlight.72 
Figure 2.1. Biofilm formation in a hot spring. (Koerdt, A.; Gödeke, J.; Berger, J.; Thormann, K. 
M.; Albers, S.-V. Crenarchaeal Biofilm Formation under Extreme Conditions PLoS ONE 2010, 5, 
e14104, reproduced as per PLoS Creative Commons Attribution License guidelines) 
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Figure 2.2. Hawaiian squid Euprymna scolopes. (http://www.kahikai.org, Image credit: Eric 
Roettinger) 
 
Bacteria release a large variety of small molecules, including siderophores, secondary 
metabolites, and metabolic end products.73 They also produce and respond to diffusible 
compounds known as signal molecules or autoinducers, which are known to play a 
crucial role in bacterial cell-to-cell communication.65 It is believed that these molecules 
are used to determine the density of bacterial population.74 The signal molecule is 
released during growth and accumulates in the local environment of the population. 
2.2. Signaling molecules in bacteria 
 
Both Gram-negative pathogens and Gram-positive pathogens utilize quorum-sensing 
system to alter the synthesis of virulence factors and to adapt themselves to the 
metabolic requirements of their communities.75 As a microbial community grows, 
individual organisms synthesize and secrete quorum-sensing molecules into the 
extracellular environment. Thus, the extracellular concentration of signaling molecules is 
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directly proportional to the microbial population. A few examples of such quorum 
sensing molecules are depicted below in Figure 2.3.  
 
Figure 2.3. Quorum sensing signaling molecules 
 
There are several types of quorum sensing molecules used by bacteria.76 The 
classification is based on the chemical structure of the signal molecule. There are three 
major classes of quorum sensing signal molecules: peptide autoinducers (AIPs), acyl-
homoserine lactones (AHLs), and derivatives of 4,5-dihydroxy-2,3-pentanedione (DPD) 
collectively called autoinducer 2 (AI-2).77,78,79,80 
Peptide Signals of Gram-Positive Bacteria 
Most Gram-positive bacteria utilize amino acid peptides as signal molecules.65 
Precursor signal proteins are synthesized within the cell by ribosomes.65  Active signal 
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molecules are formed by short peptide chains, which are generated by cleaving 
translated proteins.65 The cell senses the threshold concentration of these peptide 
signal molecules and responds to it.81 However, unlike most Gram-negative AHL 
signals, the peptide signal does not freely diffuse across the cell membrane.81 Export of 
signal peptides from the cell requires energy in the form of ATP to power an ABC 
transporter. Gram-positive bacterial peptide signals can be modified in multiple ways 
before they are fully active. The signal peptides tend to be small, very stable, and 
subject to post-translational modifications. The primary roles of these modifications are 
thought to affect activation and stability of the signaling molecule.82 The peptide signals 
can be linear or cyclic and typically range in size from 5 to 26 amino acid residues.65 
Depending upon the bacterium, the signal peptide is processed before, during, and/or 
after transport. The peptide signal required for development of the competent state in S. 
pneumoniae is called CSP (competence stimulating peptide). CSP is a 17–amino acid 
peptide that is produced from a 41–amino acid precursor peptide called ComC.82 
Another example of peptide quorum sensing is the agr system of Staphylococcus 
aureus.  The agr system controls the expression of K-, L- and N-toxins, serine protease, 
DNAase, fibrinolysin, enterotoxin B and toxic shock syndrome toxin-1 virulence 
factors.83 
Acyl-Homoserine Lactone Signals of Gram-Negative Bacteria 
The similar cell-cell communication system was discovered in 1970 by Nealson et al. in 
Gram-negative species of marine bacteria, V. fisheri.84 The predominant Gram-negative 
bacterial signaling pathways utilize acyl-homoserine lactone (AHL) signal molecules. 
The AHL structure consists of a cyclic ester with a fatty acid chain linked by an amide 
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bond. AHLs are amphipathic molecules (which have both a polar (hydrophilic) end and 
a nonpolar (hydrophobic) end) that are freely diffusible through cell membranes and are 
stable for long periods in aqueous solution.78 AHLs contain fatty acid chains of varying 
length but most often contain an even number of carbons.82  Although there are different 
AHLs for different bacteria, the core structure of the homoserine lactone is the same.  
The variation in side chain length, the presence of the functional group at C3 (hydroxyl 
or ketone group), and the degree of saturation gives specificity to these signals.81   
Autoinducer-2 (AI-2) 
AI-2 is a third category of autoinducer mediated quorum sensing. AI-2 is the first known 
molecule that facilitates communication between different bacterial species. AI-2 is a 
family of molecules derived from a single precursor (S)-4,5-dihydroxy-2,3-pentanedione 
(DPD).85,81 This direct precursor of AI-2 exists in several borated and unborated forms. 
DPD is present in ~35% bacteria but the active signaling molecules vary in different 
species.65 It suggests that this highly reactive and unstable molecule, DPD, undergoes 
other rearrangements to form a variety of cyclic compounds that react with borate and 
other available reactive moieties to form different signaling molecules in different 
species of bacteria.81 Additionally, the presence of a boron atom as an essential 
element in several organisms can be justified based on its critical role in quorum 
sensing processes. In V. harveyi, the addition of borate to DPD drives the partial 
conversion of DPD to the stable borate-containing active AI-2 molecule. Figure 2.4 
depicts the different forms of DPD in the equilibrium.86,65 
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This direct precursor of AI-2, DPD, exists in several forms such as cyclic, hydrated form 
and corresponding borate adducts in equilibrium. DPD is present many bacteria, but the 
active signaling molecules vary in different species.85,87  
 
 
 
 
 
 
Figure 2.4. DPD in dynamic equilibria 
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AI-2 facilitates interspecies communication, which is believed to enhance the 
cooperation and therefore the survival of bacterial species in a mixed community. DPD 
is produced from S-adenosyl-L-methionine (SAM) in three enzymatic steps (Figure 
2.5).88,89,90,91 
1. SAM acts as a methyl donor in SAM-dependent methyltransferase reactions, which 
leads to the formation of S-adenosyl-L-homocysteine (SAH).92  
2. The hydrolytic cleavage of the glycosidic bond in both 5-methylthioadenosine (MTA) 
and SAH is catalyzed by S-adenosyl homocysteine nucleosidase. When SAH serves as 
Figure 2.5. Activated methyl cycle. (Winzer, K.; Hardie, K. R.; Burgess, N.; 
Doherty, N.; Kirke, D.; Holden, M. T. G.; Linforth, R.; Cornell, K. A.; Taylor, 
A. J.; Hill, P. J.; Williams, P., LuxS: its role in central metabolism and the in 
vitro synthesis of 4-hydroxy-5-methyl-3(2H)-furanone. Microbiology 2002, 
148 (4), 909-922) 
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a substrate, adenine and S-ribosyl-L-homocysteine (SRH) are formed.92  
3. Finally, LuxS converts SRH into homocysteine and DPD.92  
Even though AI-2 is widely thought to be a signaling molecule, the possibility of it being 
a by-product of the activated methyl cycle cannot be discluded. Also, the detailed 
mechanism of the AI-2 signaling process is not completely understood as of yet.  A 
detailed knowledge of AI-2 could help identify potent inhibitors of pathogenic processes.  
2.3. Synthesis of DPD 
 
The AI-2 precursor DPD, was chemically synthesized using the approach reported by 
Semmelhack et al. (2005).93 The process is described briefly as follows (Scheme 2.1). 
The synthesis started with the hydrogenation of commercially available L-ascorbic acid 
using palladium on carbon as a catalyst to obtain L-gulono lactone 16.40 This lactone 
was then protected as its cyclohexylidene acetal using 1,1-dimethoxycyclohexane 17. 
The next step was oxidative cleavage of molecule 17 using potassium periodate (KIO4) 
and potassium bicarbonate (KHCO3) to generate an aldehyde 18. The conversion of the 
aldehyde to molecule 20 was carried out using the Corey-Fuchs homologation 
procedures. The methylation of terminal alkyne 20 was achieved by reaction with methyl 
iodide to yield molecule 21. The introduction of an isotopic carbon was achieved at this 
step using 13C methyliodide. The last step was the Seebach oxidation reaction in the 
presence of sodium meta-periodate and catalytic ruthenium oxide dihydrate to yield 
protected DPD 22. This molecule was stored in protected form at -80 ºC until needed 
and then deprotected with 10% aqueous sulfuric acid as described previously. 93 Once 
deprotected, DPD spontaneously exists in multiple inter-convertible forms.93 Collectively 
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this is known, as chemically synthesized AI-2 (csAI-2), and 100 µL stocks at 1 mM were 
stored at -80 ºC for no more than 2 months due to the possibility of degradation. 
 
Scheme 2.1. Synthesis of DPD 
 
Synthesized DPD then can be used for several biological experiments in order to study 
its effect on the biological systems such as V. harveyi, E. coli, Steptococci etc. 
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2.4. Introduction to dental plaque  
 
Dental plaque is a biofilm that develops naturally on the teeth.94 Dental plaque is formed 
by colonizing bacteria that attach themselves to a smooth surface of a tooth like any 
other biofilm.95 Dental plaque can be defined as the diverse community of micro-
organisms found on the tooth surface as a biofilm, embedded in an extracellular matrix 
of polymers of host and microbial origin.94 It is important to have knowledge of the 
properties of biofilms and microbial communities across all sectors of industrial, 
environmental and medical microbiology because biofilms express properties not 
exhibited by the same organisms growing in liquid culture.94  Bacteria are abundantly 
found in nature as part of a consortium, the properties of which are more than the sum 
of the component species.95 It has been speculated that plaque forms part of the 
defense systems of the host by helping to prevent colonization by microorganisms, 
which may be pathogenic.95 Oral bacteria in plaque do not exist as independent entities, 
but function as a co-ordinated, spatially organized and fully metabolically integrated 
microbial community.96 Dental plaque accumulates preferentially at stagnant sites that 
afford protection from the vigorous removal forces that apply in the mouth.97 
The phases of biofilm development can be described as; 
(a) Adsorption of host and bacterial molecules to the tooth surface 
(b) Passive transport of oral bacteria to the tooth surface 
(c) Co-adhesion of later colonizers to already attached early colonizers  
(d) Multiplication of the attached microorganisms  
(e) Active detachment 
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 It is reported that based on live/dead stain the bacterial vitality may vary throughout the 
biofilm, with the most viable bacteria present in the central part of plaque and the lining 
of the voids and channels.94 Uneven patterns of penetration of radiolabelled fluoride, 
sucrose and phosphate were found in plaque generated naturally on an in situ biofilm 
model. Parameters such as nutrients, pH, and oxygen are critical for microbial growth.94 
The gradients in pH are also responsible for enamel demineralization.98 Oral 
actinomyces and streptococci coaggregate and are among the first bacteria to colonize 
a freshly cleaned enamel surface and act as a foundation for other bacterial species to 
grow.99 The study of the significance of dental plaque as a mixed species biofilm will 
have the potential to impact significantly on the development of inhibitors and antiplaque 
agents. These inhibitors with higher effective delivery systems can be selective for the 
particular bacteria and specific against surface-associated microorganisms in the 
mouth.98 This development process requires generation of biofilm models, mechanistic 
studies of the biofilm formation and then screening of novel compounds not only for 
their ability to kill or inhibit biofilm, but also to promote biofilm detachment through 
interference with communication networks that coordinate or regulate microbial activities 
within biofilms.99-100 
2.5. Effect of AI-2 on oral biofilms of streptococci  
 
Streptococcus gordonii and Streptococcus oralis belong to a genus that has been 
referred to as containing „pioneering colonizers‟ and these species are consistently 
isolated from dental-plaque biofilm communities.101 The two species coaggregate with 
each other and numerous other oral species through complex adhesin–receptor 
mechanisms.102 Streptococcus oralis 34 and Actinomyces Naeslundii T14V generate a 
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mutualistic interaction on saliva as the sole nutrient source.102 A crucial role for AI-2 as 
a concentration-dependent, interspecies signal has been identified in a naturally 
occurring bacterial partnership.102 It is reported that a genetically complemented luxS 
mutant of Streptococcus does participate in mutualistic growth, and, significantly, that 
synthetic DPD added at the appropriate concentration restores the mutualistic growth in 
the luxS mutant/actinomyces biofilm.  Recent studies have indicated that inactivation of 
the luxS gene in S. gordonii DL1 altered very early biofilm development.103 However, it 
was not clear whether AI-2 and/or metabolic defects due to the inactivation of the luxS 
gene were responsible for the altered architecture because chemically synthesized AI-2 
(csAI-2) was not available at that time. Later it was found that AI-2 could be the 
interspecies signal required for mutualism between the coaggregating oral bacteria.102  
Also, AI-2 levels are critical to the dual-species phenotype of mutualistic interdigitated 
biofilm growth.102 The optimal concentration of AI-2 for mutualism to occur was between 
0.08 and 8 nM, above and below which mutualism was retarded. Collectively these 
research findings indicate that intra-generic (inter-species) interactions between 
pioneer-colonizing streptococci may be facilitated by the production and detection of low 
(pM to nM) concentrations of AI-2.  
The synthesis of AI-2 was carried out in order to get more knowledge of the role of AI-2 
in single and dual species biofilms. The synthesized DPD was then used to determine 
whether AI-2 influences the development of S. gordonii DL1 and S. oralis 34 single- and 
dual-species biofilms when human saliva was used as the sole nutrient source. In order 
to achieve this and help in the interpretation of our findings from dual-species studies, 
properties of each wild-type and luxS mutant species were studied, including their 
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relative ability to grow in batch cultures, produce AI-2 and remove AI-2 from their 
surroundings. It is also determined that AI-2 is able to influence the biofilm thickness, 
biovolume and architecture in these cases. AI-2 activity was monitored during batch-
culture growth for both the wild type and luxS mutant of S. gordonii DL1 (Figure. 2.6a) 
and S. oralis 34 and were compared for their relative amounts of AI-2 genererated by 
respective species (Figure.2.6b). S. gordonii DL1 and S. gordonii DL1 luxS were grown 
with 1 mM boric acid and reached stationary phase by 6 h (Figure 2.6a). S. oralis 34 
and S. oralis 34 luxS grew at comparable rates and reached stationary phase within 8 h 
(Figure 2.6b). AI-2 activities cultures of S. gordonii DL1, S. oralis 34 and their isogenic 
luxS mutants were measured by the V. harveyi AI-2 bioluminescence induction assay, 
which gives an indication of AI-2 concentration (Figure 2.6a, b).  
 
Figure 2.6. Growth kinetics and concurrent amount of AI-2 (expressed as fold induction 
of bioluminescence over unused broth) during batch-culture growth of wild-type and 
luxS mutants of S. gordonii DL1 and S. oralis 34. (a) Solid lines show the growth 
kinetics of S. gordonii DL1 in Schaedler broth () or Schaedler broth plus 1 mM boric 
acid ( ) and growth kinetics of S. gordonii DL1 luxS in Schaedler broth () or Schaedler 
broth plus 1 mM boric acid (). Dotted lines show AI-2 activity in cellfree supernatant 
from cultures of S. gordonii DL1 in Schaedler broth () or Schaedler broth plus 1 mM 
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boric acid ( ) and AI-2 activity in cell-free supernatant from cultures of S. gordonii DL1 
luxS during growth in Schaedler broth () or Schaedler broth plus 1 mM boric acid (). 
(b) Solid lines show the growth kinetics of S. oralis 34 in Schaedler broth () or 
Schaedler broth plus 1 mM boric acid ( ) and growth kinetics of S. oralis 34 luxS in 
Schaedler broth () or Schaedler broth plus 1 mM boric acid (). Dotted lines show AI-2 
activity in cell-free supernatant from cultures of S. oralis 34 during growth in Schaedler 
broth () or Schaedler broth plus 1 mM boric acid ( ) and AI-2 activity in cell-free 
supernatant from cultures of S. oralis 34 luxS during growth in Schaedler broth () or 
Schaedler broth plus 1 mM boric acid ().(Cuadra-Saenz, G.; Rao, D. L.; Underwood, A. J.; 
Belapure, S. A.; Campagna, S. R.; Sun, Z.; Tammariello, S.; Rickard, A. H. Autoinducer-2 influences 
interactions amongst pioneer colonizing streptococci in oral biofilms. Microbiology 2012, 158, 1783.) 
 
AI-2 activity was only detected in wild-type S. gordonii DL1 and S. oralis 34 cell-free 
supernatants after growth in Schaedler broth supplemented with 1 mM boric acid. 100 
μM csAI-2 was introduced to the culture of S. gordonii DL1 and S. oralis 34 cells, and 
the importation by bacteria was observed by the V. harveyi BB170 bioluminescence 
assay (Figure 2.7a, and b). The corresponding control experiment showed that AI-2 was 
not changed in the media alone. However, when csAI-2 was added to S. gordonii DL1 
luxS or S. oralis 34 luxS cell suspensions, AI-2 activity was rapidly reduced over time. 
Both S. gordonii DL1 luxS (Figure 2.7a) and S. oralis 34 luxS (Figure 2.7b) reduced 
csAI-2 activity by 50% within 20 min of exposure. After 60 min, AI-2 was imported by 
approximately 80% by S. gordonii DL1 luxS while S. oralis 34 luxS  reduced the activity 
95% (Fig. 2.7a vs. 2.7b). 
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Figure 2.7. Removal of AI-2 activity by exponential-phase S. gordonii DL1 luxS cells and 
S. oralis 34 luxS cells. Removal was characterized by a percentage decrease in 
bioluminescence in the V. harveyi BB170 assay. (a) S. gordonii DL1 luxS cells 
suspended in PBS supplemented with 100 mM csAI-2 (+), cell-free PBS supplemented 
with 100 mM csAI-2 (x) and S. gordonii DL1 luxS in PBS (-). (b) S. oralis 34 luxS cells 
suspended in PBS supplemented with 100 mM csAI-2 (boxed x), cellfree PBS 
supplemented with 100 mM csAI-2 (encircled +) and S. oralis 34 luxS in PBS (-). 
(Cuadra-Saenz, G.; Rao, D. L.; Underwood, A. J.; Belapure, S. A.; Campagna, S. R.; Sun, Z.; 
Tammariello, S.; Rickard, A. H. Autoinducer-2 influences interactions amongst pioneer colonizing 
streptococci in oral biofilms. Microbiology 2012, 158, 1783.) 
 
2.6. Effect of luxS disruption on single-species streptococcal biofilm 
development  
 
Confocal laser scanning microscopy and computer-based image analysis determined 
the structural development of single-species biofilms of S. gordonii DL1, S. oralis 34 and 
their isogenic luxS mutants. By 6 h, the S. gordonii DL1 WT biofilm cells were more 
scattered than the LuxS, and by 22 h the architectural differences were even more 
pronounced (Figure. 2.8a vs. 2.8b). At 22 h, S. gordonii DL1 formed homogeneous 
biofilms covering most of the surface. However, S. gordonii DL1 luxS formed biofilms 
that, through visual inspection of confocal stacks in the x- and y-dimensions, appeared 
to cover less of the surface (Figure. 2.8). The COMSTAT analysis, however, showed 
that S. gordonii DL1 biofilms occupied a significantly smaller biovolume (P, 0.001) and 
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were significantly thinner (P, 0.001, expressed in computer statistics (COMSTAT) as the 
average thickness) as compared with the isogenic luxS mutant (Table 2.1). In summary, 
although S. gordonii DL1 luxS biofilms visually appeared to possess less biovolume at 
22 h than the wild-type (Figure. 2.8b vs. 2.8a), the measured biovolume of S. gordonii 
DL1 luxS was actually two times greater than wild-type. COMSTAT analyses showed no 
significant difference in the roughness of biofilms between wild type and mutant. It was 
also noticed that, S. oralis 34 and S. oralis 34 luxS (Figure. 2.8c, d) did not form 
substantial biofilms over a 22 h time period as well as no difference with respect to 
biovolume, roughness and thickness was observed (Table 2.1).  
 
Figure 2.8. Representative confocal micrographs from an experiment showing the 
spatiotemporal development of single-species biofilms of (a) S. gordonii DL1, (b) S. 
gordonii DL1 luxS, (c) S. oralis 34 and (d) S. oralis 34 luxS. Biofilms were labelled with 
Alex Fluor 488 anti-S. gordonii DL1 antibody (red) and Alexa Fluor 555 anti-S. oralis 34 
WGA lectin (yellow). Images were collected at 2, 6 and 22 h after inoculation of 
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flowcells. Bars, 50 mm. Dimensions of the regions shown are 387-387 mm (x-y 
perspective). Side-views of each biofilm (x-z perspective) are under each corresponding 
22 h x-y biofilm. (Cuadra-Saenz, G.; Rao, D. L.; Underwood, A. J.; Belapure, S. A.; Campagna, S. R.; 
Sun, Z.; Tammariello, S.; Rickard, A. H Autoinducer-2 influences interactions amongst pioneer colonizing 
streptococci in oral biofilms. Microbiology 2012, 158, 1783.) 
 
2.7. Effect of exogenous AI-2 on single-species streptococcal biofilm 
development  
 
Figure 2.9. Representative 2D and 3D confocal micrographs from an experiment 
showing the effect of csAI-2 on the spatiotemporal development of single-species 
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biofilms of S. gordonii DL1 luxS biofilms. Images taken after 2, 6 and 22 h of growth in 
flowing 25% saliva and showing biofilm development of (a) S. gordonii DL1, (b) S. 
gordonii DL1 luxS and (c–g) S. gordonii DL1 luxS in 25% saliva supplemented with 
0.01, 0.1, 1, 10 and 100 nM csAI-2. Twenty-two hour biofilms are also shown in 3D to 
exemplify changes in structure. Biofilms were labelled with Alex Fluor 488 anti-S. 
gordonii DL1 antibody. Bars, 50 mm. Dimensions of the regions shown are 387-387 mm 
(x-y perspective). (Cuadra-Saenz, G.; Rao, D. L.; Underwood, A. J.; Belapure, S. A.; Campagna, S. 
R.; Sun, Z.; Tammariello, S.; Rickard, A. H. Autoinducer-2 influences interactions amongst pioneer 
colonizing streptococci in oral biofilms. Microbiology 2012, 158, 1783.) 
 
Biofilms were visualized and computationally rendered in 2D and 3D to examine the 
change in architecture (Figure. 2.9) after addition of csAI-2 in the S. gordonii DL1 
culture of the LuxS mutant. 3D analysis yielded a noticeable pattern of AI-2 
concentration-dependent changes in biofilm architecture (Figure. 2.9). As compared 
with the S. gordonii DL1 biofilms, the S. gordonii DL1 luxS biofilms were relatively 
concentrated at a region after 22 h (Figure. 2.9a vs. 2.9b) and possessed cellular 
masses that projected into the lumen of the flowcells. Biofilms developed in saliva 
containing the lowest or highest concentrations of csAI-2 (0.01 or 100 nM) resulted in 
the development of S.  gordonii DL1  luxS biofilms that resembled  S. gordonii DL1  luxS 
biofilms grown in the absence of csAI-2 (Figure. 2.9c, g vs. b). COMSTAT analysis 
confirmed the visual observations from the 2D projections and 3D renderings. S. 
gordonii DL1 luxS mutant biofilms grown in the presence of varying concentrations of 
csAI-2 possessed a biovolume and average thickness that was not significantly different 
to that of the wild-type grown in nonsupplemented saliva (Table 2.1). When csAI-2 was 
added to S. gordonii DL1 luxS biofilms, these possessed biovolumes and average 
thicknesses that were statistically different from those formed by the wild-type (P, 0.05) 
but similar to the  S. gordonii DL1  luxS biofilms in saliva-lacking exogenously supplied 
csAI-2 (Table 2.1). 
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Table 2.1. Data for S. oralis 34, S. gordonii DL1. (Cuadra-Saenz, G.; Rao, D. L.; Underwood, A. 
J.; Belapure, S. A.; Campagna, S. R.; Sun, Z.; Tammariello, S.; Rickard, A. H. Autoinducer-2 influences 
interactions amongst pioneer colonizing streptococci in oral biofilms. Microbiology 2012, 158, 1783.) 
 
 
S. oralis 
34 
S. oralis 34 
luxS 
S. gordonii DL1 
S. gordonii DL1 
luxS 
Biovolume 0.18 (0.15) 0.12 (0.10) 1.71(0.56) 3.69(0.53) 
Average 
thickness 
0.52(0.26) 0.37(0.24) 4.08(1.15) 9.18 (4.55) 
Roughness 
coefficient 
1.90(0.10) 1.93(0.07) 0.49(0.21) 0.41(0.14) 
 S. gordonii DL1 luxS plus csAI-2 (nM) 
 0.01 0.1 1 10 100 
Biovolume 3.23 (1.02) 1.38 (0.36) 
1.47 
(0.50) 
1.56 
(0.45) 
3.53 (0.46) 
Average 
thickness 
7.73 (2.61) 4.12 (2.36) 
3.53 
(2.47) 
3.04 
(2.30) 
8.12 (1.37) 
Roughness 
coefficient 
0.69 (0.36) 0.74 (0.26) 
0.53 
(0.30) 
0.44 
(0.25) 
0.64 (0.25) 
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2.8. Effect of disruption of luxS on dual-species streptococcal biofilm 
interactions  
 
The wild-type and luxS mutant strains of both species were grown in saliva-fed biofilms 
in all four possible dual-species combinations in order to determine the role of LuxS in 
the survival of the individual species within dual species biofilms. S. gordonii DL1 was 
more abundant than S. oralis 34 by 22 h (Figure. 2.10). After 22 h, when one or both of 
the two partners produced AI-2 (wild-type), the biofilms developed to give specific 
architecture with island-like topographies and mosaics of S. oralis 34 cell clusters 
(yellow) surrounded by S. gordonii DL1 cells (red) (Figure. 2.10a–c). Dual-species 
biofilms of S. gordonii DL1 luxS and S. oralis 34 luxS  were more architecturally 
homogeneous, containing relatively thin and small clusters of S. oralis 34 luxS  (Figure. 
2.10d). COMSTAT analysis confirmed that the biovolume occupied by S. gordonii DL1 
was greater than that of S. oralis 34.  The similarity between dual-species, wild type–
luxS mutant biofilms where only one of the species produced AI-2 (Figure. 2.10b, c), 
and dual-species, wild-type biofilms is higher than the similarity between biofilms dual-
species, wild-type biofilms luxS mutant biofilms (Figure. 2.10b, c vs. a or d). However, 
dual species biofilms containing S. gordonii DL1 luxS exhibited significantly increased 
biovolumes. When both species were luxS mutants, S. oralis 34 luxS was in much lower 
quantities compared with all other combinations (81:1, Figure. 2.10d). Taken together, 
the biovolume data and ratio calculations determine that the biofilm properties of S. 
oralis luxS can be biologically complemented by S. gordonii DL1 in dual species, wild-
type–luxS mutant biofilms but not the vice-versa. 
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Figure 2.10. Effect of disruption of luxS and addition of csAI-2 on the spatiotemporal 
development of dual-species biofilms of S. gordonii DL1 and S. oralis 34. 
Representative confocal micrographs from an experiment show typical biofilms 
developed after 2, 6 and 22 h post-inoculation. Development of biofilms: (a) S. gordonii 
DL1 and S. oralis 34, (b) S. gordonii DL1 and S. oralis 34 luxS, (c) S. gordonii DL1 luxS 
and S. oralis 34, (d) S. gordonii DL1 luxS and S. oralis 34 luxS, and (e–g) S. gordonii 
DL1 luxS and S. oralis 34 luxS biofilms developed in 25% saliva supplemented with 
0.01, 1 and 100 nM csAI-2. Streptococcal communities were labelled with Alex Fluor 
488 anti-S. gordonii DL1 antibody (red) and Alexa Fluor 555 anti-S. oralis 34 WGA lectin 
(yellow). Side-views of each biofilm (x-z perspective) are under each corresponding 22 
h x-y biofilm. Bars, 50 mm. (Cuadra-Saenz, G.; Rao, D. L.; Underwood, A. J.; Belapure, S. A.; 
Campagna, S. R.; Sun, Z.; Tammariello, S.; Rickard, A. H Autoinducer-2 influences interactions amongst 
pioneer colonizing streptococci in oral biofilms. Microbiology 2012, 158, 1783.) 
 
 
2.9. Effect of exogenous AI-2 on dual-species streptococcal biofilm 
interactions  
 
The data from luxS disruption in both Streptococcus species altered the dual-species 
biofilm architecture and the relative abundance of each species suggested that either 
LuxS plays a role in metabolic functions of the biofilms or that AI-2 is responsible for 
biofilm development. CsAI-2 was added to saliva, with final concentrations of 0.01, 1 
and 100 nM to determine the mechanism of dual species biofilm interactions. Confocal 
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images of the 2 and 6 h biofilms showed microcolonies with both species coaggregated 
regardless of addition or concentration of csAI-2 (Figure. 2.10e–g). After 22 h of 
development, biofilms that were fed csAI-2 concentrations of 0.01 and 100 nM in saliva 
were more architecturally similar to each other (Figure. 2.10e, g) than to the dual-
species luxS mutant biofilm (Figure 2.10d). The large changes in biovolume ratios were 
solely due to differences in the amount of S. oralis 34 luxS in the biofilms. The 
biovolume ratio for dual-species luxS mutant biofilms that were supplemented with 1 nM 
csAI-2 was not significantly different from that of the dual-species, wild-type biofilms. 
Dual-species, luxS mutant biofilms added with either 0.01 or 100 nM csAI-2 yielded S. 
oralis 34 luxS biovolumes that were significantly different from those of wild-type 
biofilms. The data also suggest that in the dual species S. oralis 34 biofilm development 
is dependent on the AI-2 concentration because of the observation of reduced thickness 
of the biofilm at lower concentrations of AI-2. Collectively these results suggest a role 
for AI-2 in mediating changes in dual-species biofilm properties including relative 
species abundance. 
2.10. Data Interpretation 
 
It can be concluded based on these experiments that AI-2 influences intra-species 
interactions between S. gordonii DL1 biofilm cells and inter-species interactions 
between S. oralis 34 and S. gordonii DL1. Additionally, both can import AI-2 in solution 
(expressed as AI-2 activity, Figure. 2.10). This biofilm study indicates the change in 
single-species biofilms of S. gordonii DL1. Furthermore, AI-2 concentration influences 
the relative amount of S. oralis 34 in dual-species biofilms, but did not affect the amount 
S. gordonii DL1. Thus, an effect of AI-2 may not be observed for a particular species in 
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single-species biofilms, but may be observed in dual-species biofilms (in the case S. 
oralis 34) or vice versa (In the case of S. gordonii DL1). 
The bioluminescence assay also showed that both wild-type species produce AI-2, 
while the isogenic luxS mutant of each did not produce AI-2. A requirement for boron 
was evident to detect AI-2 produced by the wild-type species, as AI-2 could not be 
detected in non-supplemented media. The addition of 1 mM boric acid will favor the 
boronated AI-2 only, which can be detected by the bioluminescence assay. Thus, both 
S. gordonii DL1 and S. oralis 34 produce AI-2, albeit at low concentrations, and 
comparisons of fold-induction findings indicate that S. gordonii DL1 produces relatively 
more (Figure. 2.9a, and 2.9b). It is not known whether oral streptococci recognize a 
borated or non-borated form of AI-2, although boron is present in the oral cavity at 
concentrations >400 nM.104 
To determine whether AI-2 is not only produced but also recognized and potentially 
removed by one or both species further studies are required. In order to achieve this, 
csAI-2 was added to single-species cell suspensions of S. gordonii DL1 luxS and S. 
oralis 34 luxS (Figure. 2.9a and b). The luxS mutants were studied because neither 
produced AI-2. Both luxS mutant species imported AI-2 activity from solution. The 
bioluminescence detection system determined, that S. oralis 34 luxS removed all 
detectable AI-2 from the suspension within 60 min while S. gordonii DL1 luxS reduced 
the AI-2 activity by >80%.  (Figure.2.10a vs. 2.9b).  The ability of Salmonella 
typhimurium and Actinobacillus actinomycetemcomitans to remove AI-2 from solution 
has received much attention, and specific ABC-type transporters have been 
demonstrated to be involved in AI-2 uptake,105 which might be present in Steptococcus 
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species. Oral streptococci may use a similar specific recognition and removal process. 
The rates of imporation might be specific to the species; in particular, S. oralis 34 
produces relatively less AI-2 than S. gordonii DL1 but is capable of removing (or 
scavenging) it at a greater rate. 
As expected, S. gordonii DL1 forms more substantial single-species biofilms in saliva 
than does S. oralis 34. Detailed imaging of the biofilm, clarified that S. oralis 34 wild 
type and luxS mutant single-species biofilms after 2 h, 6 h and 22 h exhibit limited 
growth/biofilm development. This is likely because only S. gordonii can bind strongly to 
salivary alpha-amylase,106 and S. gordonii DL1 is able to more efficiently use saliva for 
growth.107 
In single-species biofilms, inactivation of the luxS gene in S. gordonii DL1 alters biofilm 
architecture, while the S. oralis 34 biofilm is not dependent on luxS. This dependence 
on luxS is not conclusive since an absence of change in architecture does not 
necessarily mean that S. oralis 34 does not respond to AI-2, simply that it does not 
affect the ability of this species to form single-species biofilms. Previous studies have 
shown that the availability of AI-2 influences mutualism between S. oralis 34 and 
Actinomyces  oris T14V.108 Conversely, inactivation of luxS in S. gordonii DL1 results in 
an alteration of biofilm structure (Figure. 2.9 and Figure. 2.10). This can be attributed to 
the change in metabolic pathways due to alteration of the luxS, and not AI-2-based 
communication. The results also described that addition of AI-2 at a concentration range 
of 0.1-10 nM to saliva restored the architecture of S. gordonii DL1 luxS to that which 
was visually similar to the wild type argues against this; however, this particular 
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requirement for a narrow range of AI-2 concentrations may allow S. gordonii DL1 to 
differentiate between planktonic and biofilm life-styles.   
In dual species biofilms, biofilm cells of S. gordonii DL1 numerically dominate over S. 
oralis 34. Depending upon the availability/concentration of AI-2, a doubling effect on S. 
gordonii DL1 biovolume was observed as well as changes in architecture specifically, 
changes in biovolume and changes in mosaic–like patterning were observed for S. 
oralis 34 cells. This interaction is surprisingly different to the inter-digitated mutualistic 
biofilms that forms between S. oralis 34 and A. oris T14V.107-109 Based on these results, 
we can assume that either both species are propagating independently or actually 
competing against one another by detecting the amount of AI-2. Our initial experiments 
with single-species biofilms indicated a potential for the independent growth as 
disruption of luxS did not affect S. oralis 34 biofilm development while disruption of luxS 
in S. gordonii DL1 resulted in a more substantial and architecturally irregular biofilm that 
would respond to changes in csAI-2 concentration. The dual-species experiments 
displayed more complex interactions, which could be construed as competition. S. 
gordonii DL1 seemingly possesses a threshold requirement for AI-2 but in S. oralis 34, 
AI-2 cannot be biologically complemented and if this occurs, S. gordonii DL1 grows 
better in a biofilm to effectively out-compete S. oralis 34. This work demonstrated that a 
similar range of AI-2 concentration was required for mutualism between S. oralis 34 and 
A. oris T14V. Interestingly, in that study,102, 110 mutualism was abolished when luxS in S. 
oralis 34 was disrupted, but A. oris T14V could still produce AI-2 (genetic manipulation 
A. oris T14V is extremely difficult). Similar to our finding of the interaction between wild-
type S. oralis 34 and S. gordonii DL1 luxS, it is possible that AI-2 produced by A. oris 
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T14V in saliva was not sufficient to biologically complement S. oralis 34. Thus, AI-2 
concentration is critical for mediating interactions. A key consideration to AI-2 mediated 
biological complementation is not only production, but also recognition and or removal. 
It has been shown that both S. gordonii DL1 and S. oralis 34 can remove AI-2 activity. 
Thus, as observed in our dual-species biofilms, it is possible that the amount of AI-2 
produced by S. oralis 34 may be enough to complement S. gordonii DL1 luxS, but this 
concentration is never reached because of synchronous AI-2 removal by S.oralis 34.  
Another consideration is that there is a role for coaggregation in these interactions. S. 
oralis 34 and S. gordonii DL1 coaggregate. Coaggregation can improve attachment; S. 
gordonii DL1 acts as a microbial anchor to allow S. oralis 34 to remain in biofilms,  and it 
will also allow two species to be in close proximity.111 Thus there might be a 
requirement for only low concentrations of AI-2. Finally, coaggregation could allow for 
contact-dependent expression, which alters how cells respond to AI-2 in dual-species 
biofilms. The potential for contact-dependent expression has been studied previously by 
Inagaki and co-workers who indicated that contact-dependent expression may occur in 
the oral pathogen Tannerella forsythia as a consequence of coaggregation with other 
oral species.112 An important study could be the construction and testing of mutant 
strains of S. gordonii DL1 and S. oralis 34 that do not coaggregate and do not produce 
or respond/import AI-2. AI-2 influences inter-generic mutualistic interactions, that is 
displayed as luxuriant interdigitated biofilm growth, between coaggregating S. oralis 34 
and A. oris T14V,108 and also AI-2 may be involved in enhancing biofilm formation 
between coaggregating S. gordonii DL1 and P. gingivalis ATCC 33277.113 This study 
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reports the concentration-dependent role for AI-2 in influencing relative proportions in 
dual-species containing coaggregating bacteria for the first time.  
AI-2 moderates interactions between pioneer colonizers in biofilms that are grown under 
environmental conditions representative of the healthy oral cavity: at 37 oC in flowing 
human saliva. Both S. oralis and S. gordonii can be isolated from immature dental 
plaque biofilms and can colonize clean surfaces within 4 h of exposure to the human 
oral cavity.114 Recently, Periasamy and Kolenbrander115 demonstrated that the 
periodontal pathogen Porphyromonas gingivalis ATCC 33277 does not form dual-
species biofilms with S. oralis 34 and instead forms dense dual-species biofilms when 
paired with S. gordonii DL1. Thus, biofilms containing S. gordonii DL1 may be more 
susceptible to the integration of periodontal pathogens than S. oralis 34. This is 
significant because future approaches to control periodontal disease could therefore 
incorporate AI-2 analogs or inhibitors to manipulate early dental plaque communities to 
favor species that do not support the coaggregation/integration of pathogens. The 
potential for a community of streptococci to act as a catalyst or inhibitor to changes in 
oral health has also received attention in a review by Whitmore and Lamont.116 In 
summary, this work reported, that AI-2 influences intra-species interactions between S. 
gordonii DL1 cells and also changes inter-species interactions between S. oralis 34 and 
S. gordonii DL1 cells. These interactions are dependent upon AI-2 concentration and 
are evident by changes in biofilm architecture, biovolume. The manipulation of AI-2 
quorum sensing in oral biofilms could lead to a solution to periodontal disease.117 
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For this study, the synthesis of DPD was carried out in our lab and biological 
experiments were carried out in Dr. Alexander H. Rickard‟s lab. All methods and a list of 
materials used are published in the given article.118 
2.11. Introduction to DPD analogues 
 
AI-2 analogues can play a critical role in furthering our understanding of the detailed 
mechanism of AI-2 based quorum sensing process.  This in turn can lead to discovery 
of potent inhibitors of pathogenic biofilms. It is also possible to effectively modulate 
quorum sensing (QS) processing in a variety of bacteria that have different QS 
receptors or processing enzymes using small molecules.119,120 The endogenous AI-2 
controls virulence in various pathogens such as Vibrio. cholerae and E. coli O157 which 
leads to the increased understanding of the AI-2 receptors, which can be applied to 
modulate pathogenicity. There have been several experiments carried out to shed light 
on the structure and activity relationship of AI-2 analogues.121 Earlier reports explained 
the interaction between the heterocyclic oxygen atom and receptor proteins as well as 
the importance of the linear form and dynamic equilibrium of DPD as crucial 
requirements for activation of AI-2 based QS circuits.122 Some of the alkyl–DPDs 
showed potent inhibitory activity against the QS of S. typhimurium and synergistic 
effects on the QS of V. harveyi.119 These results indicate that minor alterations at the C1 
position of DPD can have a profound impact upon the function of AI-2 molecules. The 
effect of the analogues on bioluminescence was first examined in V. harveyi strain 
BB170; the strain capable of producing bioluminescence through the AI-2 pathway but 
not through AHL pathway due to the absence of the AHL receptor, LuxN.123 Thus, the 
use of this strain excludes the possibility of the analogues being recognized by the AHL 
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receptor and exerting agonist or antagonist effects via this pathway. The periplasmic 
receptor proteins of both bacterial species recognize a closed form of DPD in which the 
ketone at C3 is hydrated. The previous literature suggests stereochemistry at C2 
distinguishes the signals employed by each species: V. harveyi responds to the S 
isomer whereas S. typhimurium responds to the R isomer.119 In S. typhimurium, the 
carbocyclic analogues, are locked into a cyclic conformation, and do not possess a 
primary alcohol for phosphorylation, nor can they achieve the linear conformation 
required for quorum sensing activity.119 Based on the data collected by these reports, it 
is evident that the linear form of DPD and analogues is necessary for biological activity 
in S. typhimurium. The presence of the acyclic form and the dynamic equilibrium was 
considered as an important requirement for intraspecies signaling. In this case, it is the 
cyclic isomer that is recognized by the cell, but the linear isomer is the agent directly 
responsible for regulating gene expression.124 It is believed that hydrogen bonding at C3 
play an important role in gene expression. The restoration of this hydrogen bonding 
interaction may account for the difference in activity between the dihydroxy methyl 
pentadione (DHMP) analogues (Figure 2.11). 
 
Figure 2.11. DPD and its reported analogues 
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The data demonstrate that these C4-alkoxy-5-hydroxy-2,3-pentadiones (C4-alkoxy-
HPDs) are capable of more potent  quorum sensing (QS) agonism than the natural 
signal used in V. harveyi.125 The examination of the length of the C4-hydroxy alkylation 
was also done. Thus, while C4-MeO-HPD presented modest QS activity, remarkably, 
C4-EtO-HPD and C4-PrO-HPD appeared to be better ligands than DPD. Notably, 
analogue C4-PrO-HPD, a racemate, was almost 10-fold more potent than the natural 
ligand DPD with a submicromolar EC50 value of 0.15 ± 0.03 μM, whereas the EC50 
value of DPD was 1.07 ± 0.06 μM in V. harveyi assay. It was speculated that a single 
enantiomer of analogue C4-PrO-HPD may provide even greater enhanced activity.  
These AI-2 analogues were designed to establish the quorum sensing mechanism and 
eventually modulate it specifically, and their effects were found to be helpful to achieve 
the goal.  
These previous findings with C1-alkyl-DPD analogues,126 highlights how manipulation of 
the DPD scaffold can provide valuable tools for in-depth studies of the ligand−receptor 
interactions used for AI-2 mediated QS.  DPD analogs with a new stereocenter at C-5 
4,5-dihydroxyhexanediones (DHDs) have been synthesized and their biological activity 
tested in two bacteria.125 (4S,5R)-DHD is a synergistic agonist in Escherichia coli (which 
contains the LsrB receptor), while it is an agonist in Vibrio harveyi (LuxP), displaying the 
strongest agonistic activity reported so far (EC50 = 0.65 μM) in this organism.
127 Thus, 
modification at C-5 leads to novel methods to manipulate quorum sensing as a method 
for controlling bacteria. Among C-1 alkyl-DPD analogs, CF3-DPD proved to be a weak 
agonist, and hexyl-DPD was the only inhibitor reported in V. harveyi, with an IC50 of 
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approximately 10 μM. All C-1 alkyl-DPD analogs assayed in V. harveyi proved to be 
synergistic agonists in the presence of a physiological concentration of DPD, enhancing 
bioluminescence induced by the natural autoinducer. Thus, these synthetic structural 
analogs of DPD reveal that minor alterations can have profound impact on their 
biological effects, and that these effects differ depending on the class of AI-2 receptor 
tested. Knowledge of the biological activity of C-5 substituted DPD analogues 
complements that of the known C-1 alkyl analogs and should be useful for the design of 
novel quorum sensing modulators. The addition of a single carbon to the C1-alkyl chain 
of the analogues plays a crucial role in determining the effect of the analog on the QS 
response. While an ethyl modified analogues is an agonist, propyl becomes an 
antagonist of the QS circuit.126  Antagonistic activity of C1-alkyl analogs of AI-2 is likely 
due to competitive binding to the LsrR transcriptional regulator. It has been 
demonstrated that, unlike other bacterial kinases, LsrK from E. coli has broad substrate 
specificity and phosphorylates C1-alkyl AI-2 analogs of different shapes and sizes.126  
The lower alkyl chain AI-2 analogues (C1 and C2) destabilize the LsrR-DNA complex 
and promote lsr transcription whereas higher alkyl chain AI-2 analogs (C3-C7) stabilize 
the Lsr-DNA complex and inhibit lsr transcription.126 Hence it can be concluded that 
depending on the nature of the C1-alkyl chain, phosphorylated AI-2-like molecules can 
either stabilize or destabilize LsrR-DNA complex. Therefore, small molecules that 
possess phosphate-like moieties as well as C1-alkyl chains of appropriate length and 
shape could become potential QS modulators in bacteria that utilize LsrR-like 
transcriptional factors to regulate QS circuits.126,127 
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2.12. Synthesis of DPD analogues 
 
Based on the previous literature,126,127 we decided to synthesize structural as well as 
stereochemical AI-2 analogues. The synthesis of the stereochemical analogue with 
inverted stereochemistry was first carried out to study importance of the AI-2 
stereochemistry127 (Figure 2.12). Further, the substitution at the C1 position was thought 
to be important in order to examine the effect of the conformational change on signaling 
process. In particular, the introduction of the oxygen at C1 was achieved. Lastly, the 
specific analogue where dihydroxyl group is protected as a formyl acetal was designed 
in order to preserve the linear geometry of the DPD and avoid cyclic forms. 
Unfortunately, this analogue could not be synthesized due to practical difficulties. The 
introduction of formyl group was attempted using paraformaldehyde. The complete 
conversion of starting material was observed, but the desired product could not be 
isolated. Similarly, the introduction of methylene group by the reaction with 
diazomethane could not be achieved.  
 
Figure 2.12. DPD and its target analogues 
 
The synthesis of the stereochemical analogue (D-DPD) of AI-2 was achieved using the 
same synthetic sequence as DPD with D-gulono lactone as a starting material.93, 128 The 
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synthesis of the structural analogues started from the previously known intermediate of 
AI-2 synthetic Scheme. This intermediate 20 was alkylated in presence of base at low 
temperature, and addition of methoxymethylene chloride was done. The next few steps 
were identical to Scheme 2.1 in which Seebach oxidation followed by acid catalysed 
acetal deprotection were performed to yield the novel structural analogue 26 as 
described in Scheme 2.2. 
 
Scheme 2.2. Synthesis of DPD analogue 26 
 
The next analogue, which incorporates a hydroxyl group at the C1 position, was 
synthesized using similar protocols as described in Scheme 3.3. The alkylation of 20 
using paraformadlehyde followed by protection of the hydroxyl group as a 
tetrahydropyran was performed to obtain 28 as a mixture of diastereomers. Finally, 
ruthenium-catalyzed oxidation followed by a deprotection reaction yielded 30. 
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Scheme 2.3. Preparation of DPD analogue 30. 
 
All the synthesized analogues were characterized by 1H and 13C NMR spectroscopy. 
The derivatization of analogues 25 and 29 with phenylene diamine was achieved to 
obtain the respective quinoxalines 32 and 33, in order to confirm the presence of 
diketone. The newly formed corresponding quinoxalines 32 and 33 were characterized 
by NMR to confirm the presence of diketone moiety (Scheme 2.4). 
 
Scheme 2.4. Reactions with phenylene diamine 31. 
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These analogues, 26 and 30, were later used in experiments to study their effect on 
quorum sensing. Molecule 26 was further derivatized as a quinoxaline 35 after the 
reaction with diamine molecule 34 as depicted in the Scheme 2.5. This diamine tag 34 
was developed in our lab to form a stable quinoxaline derivative of DPD, which can then 
be readily characterized by liquid chromatography tandem-mass spectrometry (LC-
MS/MS).128 
 
Scheme 2.5. Quinoxaline formation of the analogue 26. 
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The formation of the quinoxaline (35) was monitored by 1H NMR spectroscopy without 
isolating the product (Figure 2.13).  
 
 
 
Figure 2.13. 1H NMR of A) 26 at t = 0 min, B) quinoxaline 35 at t = 40 min. 
 
2.13. Bioluminescence assay 
 
The first obvious biological experiment was to study the bioluminescence studies of V. 
harveyi MM32129 using known protocols. This assay measures the emission intensity 
generated by glowing bacteria. The intensity of the bioluminescence is directly 
proportional to the amount of bacteria. Analogue test solutions alone did not display any 
bioluminiscence. The bioluminescence data suggest that the analogues are less active 
A) 
B) 
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than DPD. The stereochemical analogue D-DPD is 100 times less potent compared to 
DPD. Also, both structural analogues 26 and 30 showed an insignificant activity around 
100 nM. It was confirmed again that the stereochemistry of DPD is important for the 
signaling process. Additionally, the substitution at the C1 carbon, especially, 
introduction of heteroatom, in this case oxygen, decreases the potency of the AI-2 in 
quorum sensing as can be seen in Figure 2.14. This can be attributed to the change in 
the size of the molecule or change in the binding ability to boron or its binding ability to 
the receptor. This result might be helpful in synthesizing other C1 analogues and to 
eventually discover the biofilm inhibitor. 
 
Figure 2.14. Bioluminescence assay (fluoroscence intensity) of V. harveyi MM32. 
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Section 3.13. E. coli importation studies 
The analogues were also tested on E. coli BW25113 (wild type, WT) and E. coli 
JW2662-1 (luxS- strain). As mentioned in previous work,130 Escherichia coli may import 
and degrade AI-2 as a mechanism to interfere with signaling in competitive species. 
After the DPD concentration/cell density ratio had been calculated for the E. coli 
cultures, it was apparent that AI-2 was not simply a quorum-sensing signal in this 
bacterium. It is known that E. coli imports AI-2 at early to mid-stationary phase.  
However, previous work did not eliminate the possibility that AI-2 is a quorum sensing 
signal during the exponential phase for this species. Initially, the [DPD] was measured 
in cell free supernatants for both WT and luxS- strains of E. coli. The known 
concentration of DPD was introduced in E. coli luxS and measured as control 
experiments. The sample preparation and detection methods were followed using our 
protocols including derivatization of the diketone and analysis by LC-MS/MS method.128 
These species were chosen as the relative levels of DPD produced during growth have 
been studied for both via several methods.128 The isotopic DPD was also synthesized in 
the lab, which was used as internal standard for the detection.  E. coli BW25113 (wild 
type, WT) and E. coli JW2662-1 (luxS- strain) cultures grown to stationary phase were 
diluted 50 fold in fresh LB, and samples of the cultures were collected at regular 
intervals until the cells entered late exponential/early stationary phase. A final 
concentration of 10 μM 13C-DPD was used as an internal standard for quantification 
purposes, and was added to each aliquot. After centrifugation to remove cells and other 
particulates that had formed, diamine tag 34 was also added to the samples at a final 
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concentration of 1.3 mM. After 1h reaction time, the samples were subjected to LC-
MS/MS analysis.  
 
Figure 2.15. 12C-DPD and 13C-DPD analysis by LC-MS/MS 
 
Figure 2.16. 12C-D-DPD analysis by LC-MS/MS 
 
In the first experiment, samples in media with known concentrations (series 3) of 12C-
DPD, 13C-DPD, D-DPD were run on MS to check the viability of internal standard 
sample solutions as well as other possible instrumental and manual errors (Figure 2.14, 
2.15). The experiments were carried out in duplicate. Cell number was observed by 
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optical density readings, which measures absorbance at 570 nm. The first analogue 
tested was the enantiomer of DPD for the E. coli importation studies. The importation 
studies of D-DPD were partially conclusive.  At lower concentrations, the data shows 
(Figure 2.16) that D-DPD affects the importation of DPD. The data for higher 
concentrations was not reproducible. As it can be seen from the graph that as the 
concentration of D-DPD increases, the importation of DPD rapidly increases as well. 
Usually, in E. coli WT after 4 h there is ~40 μM of DPD observed. When D-DPD is 
introduced, a signal for DPD and D-DPD of ~20 μM was observed.  Figure 3.15 depicts 
the graphs of both strains of E. coli that measure AI-2 concentration by LC-MS/MS over 
the time. 
 
Figure 2.17. Effect of D-DPD on E. coli importation of DPD 
 
The effect of the next analogue 26 on E. coli importation studies was also evaluated by 
LC-MS/MS using single reaction monitoring (SRM) for 411 m/z – 333 m/z.  It was 
observed that E. coli did not import the analogue 26 rapidly; however, it cannot be 
conclusive because the degradation studies for the analogue have not been done yet.  
Since the internal standard of this analogue was not available, the quantification of the 
analogue was not carried out. However, the MS signal for the analogue did not change 
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significantly over time indicating that bacteria are not importing the analogue (Figure 
2.17). It was also noted that analogue 26 did not affect the DPD importation in E. coli 
(Figure 2.18). 
 
Figure 2.18. Effect on 35 on E. coli importation 
 
Conclusions 
In summary, it can be said that AI-2 plays an important role in the moderation of 
interactions between pioneer colonizers in biofilms that are grown under environmental 
conditions representative of the healthy oral cavity in flowing human saliva. This 
document also describes the synthesis of stereochemical and structural analogues for 
SAR studies. These analogues were tested to compare their activity with DPD in 
quorum sensing. Also, their effect on the importation of DPD in E. coli was detailed. 
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2.14. Synthetic methods for analogue preparation 
The synthesis and characterization of AI-2 was carried out based on reported protocols 
by Semmelhack.93 
Preparation of (R)-2-(3-methoxyprop-1-yn-1-yl)-1,4-dioxaspiro[4.5]decane (24) 
500 mg (3.01 mmol) of molecule 20 was dissolved in 5 ml dry THF in a round bottom 
flask.  The solution was cooled to -78 ºC, and to this solution 2 mL of 2 M n-butyl lithium 
solution in hexanes was added dropwise. The resultant reaction mixture was allowed to 
stir for 30 min at -78 ºC followed by addition 1 g (12 mmol) of methoxymethyl chloride to 
the reaction mixture. The reaction was stirred at room temperature for 6-8 h. At this 
time, the reaction was quenched by adding 100 μL of water. The solution was dried 
using MgSO4, filtered and concentrated under vacuo. The crude product was purified by 
column chromatography using 10% diethyl ether in hexanes as eluent to obtain bright 
yellow viscous liquid. Rf (10% Et2O/hexanes) 0.78; 
1H NMR (300 MHz, CDCl3) δ 4.73 
(td, J = 6.3, 1.6 Hz, 1H), 4.20 – 4.03 (m, 3H), 3.96 – 3.77 (m, 1H), 3.41 – 3.23 (m, 3H), 
1.68 (m, 2H), 1.59 – 1.48 (m, 6H), 1.37 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 110.86, 
84.00, 81.49, 69.49, 65.09, 59.78, 57.50, 37.38, 35.66, 35.64, 35.36, 25.86, 25.05, 
25.01, 24.99, 23.80, 23.29, 22.22, 14.06. HRMS-ESI (m/z): [M-H]+  calcd for  C12H19O3, 
211.1334; found, 211.1337. 
(S)-3-methoxy-1-(1, 4-dioxaspiro[4.5]decan-2-yl)propane-1,2-dione (25) 
This compound was prepared by using reported protocols for the Seebach oxidation 
reaction93 to obtain bright yellow liquid as a product. The crude product obtained after 
the oxidation reaction was purified by column chromatography using 10% Et2O/hexanes 
as eluents to obtain 320 mg of pure product in 20% yield. Rf (10% Et2O/hexanes) 0.67, 
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1H NMR (300 MHz, CDCl3) δ 5.13 – 4.98 (m, 1H), 4.65 – 4.54 (m, 1H), 4.51 (dd, J = 4.3, 
0.6 Hz, 1H), 4.38 – 4.23 (m, 2H), 4.19 (d, J = 4.5 Hz, 1H), 3.50 – 3.37 (m, 3H), 1.77 – 
1.50 (m, 8H), 1.42 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 197.18, 196.75, 112.19, 
77.26, 77.00, 76.83, 76.75, 74.39, 65.53, 59.74, 37.41, 35.55, 35.40, 34.65, 25.86, 
25.09, 24.97, 24.87, 23.91, 23.87, 23.78, 23.63, 23.33, 22.28; HRMS-ESI (m/z): [M-H]+  
calcd  for  C12H19O5, 243.1232; found, 243.123 
(S)-4,5-dihydroxy-1-methoxypentane-2,3-dione (26) 
The deprotection reaction of 25 to yield 26 was achieved in acidic water.93 2 mg of 25 
was first dissolved in 1 mL water and then 100 μL 10% aqueous H2SO4 was added. The 
solution was allowed to react for 2 h at rt. The molecule was characterized without 
isolation. 1H NMR (500 MHz, D2O) δ 4.29 – 4.24 (m, 1H), 4.23 – 4.15 (m, 1H), 4.10 (dd, 
J = 6.1, 4.4 Hz, 1H), 3.93 (d, J = 4.1 Hz, 1H), 3.90 – 3.86 (m, 1H), 3.85 – 3.80 (m, 1H), 
3.63 (dd, J = 5.9, 0.8 Hz, 1H), 3.60 (dd, J = 3.4, 0.8 Hz, 1H), 3.45 – 3.41 (m, 1H), 3.39 – 
3.36 (m, 3H), 2.40 (m, 3H), 1.88 (m, 3H), 1.73 (m, 2H); 13C NMR (126 MHz, D2O) δ 
220.56, 210.53, 102.07, 101.99, 75.93, 75.13, 74.08, 73.68, 72.82, 72.60, 71.32, 70.49, 
69.74, 63.19, 62.78, 59.06, 59.01, 58.75, 58.65, 48.85, 41.35, 38.71, 26.81, 24.10. This 
compound is not detectable by mass spectrometry as it exist in a dynamic equilibrium 
and ionizes poorly. 
Synthesis of (R)-3-(1,4-dioxaspiro[4.5]decan-2-yl)prop-2-yn-1-ol (27) 
500 mg (3.01 mmol) of compound 20 was placed in a round bottom flask and was 
dissolved in 5 mL of dry THF at -78 ºC. To this solution 2 mL of n-butyl lithium was 
added slowly. The reaction mixture was allowed to stir for 30 min, and then a 
suspension of paraformaldehyde (15-20 mmol) in THF was added to the reaction 
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mixture. The reaction was stirred overnight at room temperature. At this time, the 
reaction was quenched by 100 μL water. The reaction mixture was dried using MgSO4, 
filtered, and concentrated under vacuo. The crude product was purified by column 
chromatography using 20% diethyl ether in hexanes as eluent to yield a light yellow 
liquid. Rf (20% Et2O/hexanes) 0.45; 
1H NMR (300 MHz, CDCl3) δ 4.75 (ddt, J = 4.7, 3.1, 
1.7 Hz, 1H), 4.15 (ddd, J = 7.9, 6.2, 3.3 Hz, 1H), 3.89 (ddd, J = 7.9, 6.4, 3.3 Hz, 1H), 
1.78 – 1.67 (m, 4H), 1.59 (m, 8H), 1.39 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 130.34, 
110.52, 82.31, 76.39, 73.72, 69.71, 69.53, 68.44, 65.50, 64.89, 36.29, 35.84, 35.64, 
35.46, 35.38, 25.07, 25.02, 23.89, 23.85; . HRMS-ESI (m/z): [M-H]-  calcd for  C11H15O3, 
195.1021; found, 195.102. 
Synthesis of (2R)-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-yn-1-yl) -1,4-
dioxaspiro[4.5] decane (28) 
100 mg (0.50 mmol) of 27 was taken in a round bottom flask and was dissolved in 5 mL 
of dry DCM. To this solution, dihydropyran (1 mmol) and 10 mol% catalyst pyridinium p-
toluene sulfonic acid (PPTS) was added in one portion. The reaction mixture was stirred 
at room temperature overnight. After completion of reaction mixture, it was washed with 
water. The solution was dried using MgSO4, filtered, and concentrated in vacuo to yield 
a mixture of diastereomers 28. The catalyst, PPTS, was prepared in the lab using 
known protocols. Rf (10% Et2O/hexanes) 0.75; 
1H NMR (300 MHz, CDCl3) δ 4.90 (m, 
2H), 4.76 (m, 4H), 4.25 (s, 4H), 4.10 (s, 4H), 3.83 (m, 1H), 3.50 (s, 2H), 1.71 (bs, 18H), 
1.37 (bs, 10H);
 
13C NMR (126 MHz, CDCl3) δ 110.92, 96.86, 96.81, 94.65, 83.36, 81.84, 
65.23, 62.93, 62.00, 61.96, 54.25, 35.70, 35.42, 30.70, 30.23, 30.20, 25.45, 25.33, 
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25.04, 23.86, 19.76, 19.04, 19.00; HRMS-ESI (m/z): [M-H]+  calcd  for  C16H25O4, 
281.1753; found, 281.1750. 
1-((S)-1,4-dioxaspiro[4.5]decan-2-yl)-3-((tetrahydro-2H-pyran-2-yl)oxy)propane-1,2-
dione (29) 
This compound was prepared by using reported protocols for the Seebach oxidation 
reaction93 to obtain bright yellow liquid as a product. The crude product obtained after 
the oxidation reaction was purified by column chromatography using 10% Et2O/hexanes 
as eluents to obtain 104 mg of pure product in 13% yield. Rf (10 % Et2O/hexanes) 0.69; 
1H NMR (500 MHz, CDCl3) δ 5.06 (q, J = 6.6, 5.7 Hz, 1H), 4.97 – 4.90 (m, 1H), 4.82 (dt, 
J = 5.3, 2.7 Hz, 1H), 4.67 (dt, J = 6.0, 3.0 Hz, 2H), 4.64 (t, J = 3.2 Hz, 1H), 4.60 (p, J = 
4.1, 3.5 Hz, 2H), 4.35 – 4.31 (m, 1H), 4.28 (td, J = 7.2, 5.7, 2.3 Hz, 2H), 4.19 – 4.15 (m, 
1H), 4.07 (ddd, J = 8.1, 5.4, 2.4 Hz, 1H), 4.05 – 4.00 (m, 1H), 3.93 – 3.78 (m, 2H), 3.59 
– 3.44 (m, 4H), 1.52-1.8 (m, 28H); 13C NMR (126 MHz, CDCl3) δ 197, 196.2, 131.21, 
129.75, 115.42, 115.11, 98.02, 77.81, 77.54, 77.29, 73.79, 67.48, 66.08, 63.82, 63.44, 
60.58, 35.90, 35.20, 31.20, 30.55, 25.97, 25.47, 24.33, 20.26, 19.46; HRMS-ESI (m/z): 
[M-H]+  calcd  for  C16H25O6, 313.1651; found, 313.164. 
(S)-1,4,5-trihydroxypentane-2,3-dione (30) 
The deprotection reaction of 29 to yield 30 was achieved in acidic water.93 2 mg of 29 
was first dissolved in 1 mL water and then 100 μL 10% aqueous H2SO4 was added. The 
solution was allowed to react for 2 h at rt. The molecule was characterized without 
isolation. 1H NMR (500 MHz, D2O) δ 4.75 (bs, 1H), 4.10 (m, 1H), 3.85 (m, 1H), 3.76 (bs, 
1H), 3.53 (m, 1H), 2.27 (bs, 4H), 1.72 (m, 10H), 1.59 (m, 6H); 13C NMR (126 MHz, D2O) 
δ 94.55, 64.82, 62.50, 41.35, 38.70, 31.63, 26.81, 24.45, 24.10, 20.23. This compound 
103 
 
is not detectable by mass spectrometry as it exist in a dynamic equilibrium and ionizes 
poorly. 
General procedure for quinoxaline formation 
The protected 1 mM DPD or its analogues were deprotected using 10% aqueous H2SO4 
for 3 h at room temperature. To this solution, 1.2 equivalents of the diamine tag were 
added, and reactions were monitored by NMR until completion. 
(R)-2-(methoxymethyl)-3-(1,4-dioxaspiro[4.5]decan-2-yl)quinoxaline (32) 
1H NMR (300 MHz, CDCl3) δ 8.15 – 8.04 (m, 2H), 7.81 – 7.66 (m, 2H), 5.64 – 5.50 (m, 
1H), 5.13 (dt, J = 12.5, 1.3 Hz, 1H), 4.81 (dt, J = 12.4, 1.3 Hz, 1H), 4.66 (ddd, J = 8.3, 
6.6, 0.9 Hz, 1H), 4.50 – 4.37 (m, 1H), 1.84 – 1.51 (m, 8H), 1.44 (q, J = 5.7, 5.2 Hz, 2H); 
13C NMR (126 MHz, CDCl3) δ 152.99, 152.48, 141.61, 130.60, 130.44, 129.87, 129.56, 
111.73, 75.86, 74.52, 68.05, 59.59, 36.46, 35.90, 30.24, 25.75, 24.63, 24.57; HRMS-
ESI (m/z): [M-H]+  calcd  for  C18H23N2O3, 315.1709; found, 315.1701. 
2-((R)-1,4-dioxaspiro[4.5]decan-2-yl)-3-(((tetrahydro-2H-pyran-2-
yl)oxy)methyl)quinoxaline (33) 
1H NMR (300 MHz, CDCl3) δ 8.1 (bs, 2H), 7.75 (bs, 2H), 5.75 (dt, J = 12.2, 1.32 Hz, 
1H), 5.61 (dt, J = 12.2, 1.32 Hz, 1H), 5.45 (dd, 2H), 4.90 (s, 1H), 4.76 (s, 5H), 4.64, 4.45 
(s, 6H), 4.10 (s, 4H), 3.83 (m, 14H), 3.50 (s, 4H), 1.71 (s, 4H), 1.37 (s, 30H); 13C NMR 
(126 MHz, CDCl3) δ 152.79, 141.30, 141.17, 141.08, 129.96, 129.91, 129.85, 129.80, 
129.35, 129.29, 129.02, 111.19, 111.09, 98.98, 98.84, 77.26, 77.21, 77.00, 76.75, 
75.29, 74.98, 69.41, 68.87, 67.70, 67.69, 62.53, 62.05, 38.74, 35.89, 35.52, 35.44, 
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30.48, 30.45, 30.37, 25.37, 25.34, 25.20, 24.07, 24.05, 24.00, 23.76, 19.46, 19.09; 
HRMS-ESI (m/z): [M-H]+  calcd  for  C22H29N2O4, 385.2127; found, 385.212. 
(S)-dimethyl 2,2'-((2-(1,2-dihydroxyethyl)-3-(methoxymethyl)quinoxaline-6,7-
diyl)bis(oxy))diacetate (35) 
The quinoxaline 35 was prepared in water and reaction was monitored by NMR without 
isolation. 1H NMR (500 MHz, D2O) δ 7.1 (s, 1H), 7.05 (s, 1H), 5.19 – 5.04 (m, 2H), 3.85 
(m, 4H), 3.75 (s, 1H), 3.52 (s, 2H), 3.44 – 3.31 (m, 1H), 2.38 (t, J = 7.2 Hz, 2H), 1.85 (m, 
4H), 1.72 (m, 2H).  E. coli importation studies by LC-MS/MS were carried out using 
method described by Campagna et al.130 
The method for bioluminescence assay is described in the previous chapter 1.  
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3. Development of optical sensors to detect and 
quantify DPD 
 
The author is thankful to Stephen Dearth for his assistance in synthesizing 
intermediates and acquiring UV-Vis and fluorescence data. 
3.1. Introduction to AI-2 detection methods 
 
Autoinducers are signaling molecules responsible for quorum sensing.65 The structural 
and mechanistic studies of these molecules are necessary in order to discover 
treatments on bacterial infections propagated by biofilm formation.36  The detection and 
quantification of these signaling molecules is the first step towards the evaluation of the 
role of autoinducers in the quorum sensing.128  This part of my research is focused on 
the development of optical sensors to detect DPD in biological samples. 
The detection of DPD has been a great challenge to biologists as well as chemists due 
to multitude of reasons; some of them are listed below. 
 AI-2 consists of highly unstable and reactive species, which exist, in a dynamic 
equilibrium as mixture of several forms.93, 131 
 DPD decomposes upon concentration.34 
 The structure of DPD has no chromophore, so detection by spectrophotometry is 
not possible. 
 The low ionization potential renders mass spectrometric (MS) based detection 
impossible. 
Currently, the detection of DPD is carried out using a bioluminiscence assay with a V. 
harveyi reporter strain, an AI-2 receptor protein based biosensor assay, or by 
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derivatization of DPD followed by mass spectrometric detection. These methods will be 
discussed below briefly. 
3.2. Current detection methods for DPD 
3.2.1. Bioluminescence assay 
 
Usually V. harveyi BB120 or V. harveyi MM32 are used to evaluate the role of AI-2 in 
quorum sensing.129 V. harveyi expresses density-controlled functions, such as 
bioluminescence, in response to the cell density.129 The assay measures light induction 
in a reporter strain with mutations in both the HAI-1 receptor LuxN and in the DPD 
synthase LuxS in the presence of candidate AI-2 containing cell-free supernatants.144 
The presence of molecules in the supernatants of biological samples, e.g. glucose and 
boric acid, collectively is known to affect the assay. While this assay is sensitive and 
has a low limit of detection, its small linear range (0.08-0.8 μM) limits quantitation.132,144 
Another drawback of this method is high culture to culture variability for bacteria, making 
it hard to reproduce the results.36,132,133 
3.2.2. Biosensors derived from AI-2 receptor proteins 
 
This type of AI-2 detection method is a sensor derived from the AI-2 receptor protein 
LuxP.133b The sensor is based on ligand binding-induced changes in Förster resonance 
energy transfer (FRET) between a cyan and yellow variant of green fluorescent protein 
(GFP) fused to the termini of the AI-2 receptor, LuxP.133b,134 Other sensors have 
modified AI-2 receptor proteins LuxP and LsrB with environmentally sensitive 
fluorescent dyes.133b The protein sensors bind specifically to AI-2 and produce dose 
dependent changes in their fluorescence yield. These methods are applied to monitor 
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the enzymatic synthesis of AI-2 in real time and determine the extracellular and 
intracellular AI-2 concentrations in several bacterial culture fluids.134  The disadvantage 
of these methods is their dependence on the concentrations of other molecules, in 
particular, borate which are essential to the assay.134 Additional drawbacks to this 
method include low sensitivity limited by the signal-receptor binding affinity (270 nM), 
the difficulty and expense of obtaining the sensor protein, and a limited dynamic range 
(0.1 - 30 μM).134 
3.2.3. GC/MS method  
 
The third method utilizes GC/MS to detect a DPD derivative. These methods require 
several reaction steps for the derivatisation of DPD using phenylene diamine as well as 
for the synthesis of the isotopic quinoxaline as an internal standard, followed by solid-
phase extraction and 50-fold concentration, which demands extra time and handling.135 
3.2.4. Liquid chromatography-tandem mass spectrometric technique  
 
Recently, our lab has developed an efficient method of DPD detection and quantification 
based on liquid chromatography-tandem mass spectrometry (LC-MS/MS).128 The 
method relies on reaction of DPD with a tag molecule to form a stable quinoxaline 
derivative. This derivative can be further analyzed by a selected reaction monitoring 
(SRM) based LC-MS/MS method (Figure 3.1). MS detection is comparatively sensitive 
and has a large linear dynamic range. Also, SRM technology affords specificity in 
retention time, parent ion m/z, and fragment ion m/z. The diamine tag was developed 
and synthesized in the lab. The previously known commercially available phenylene 
diamine was not used due to a small dynamic range and since it was not detectable in 
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supernatants. In order to quantitate the [DPD], isotope labeled DPD was synthesized 
and used as an internal standard. This technique is reproducible, quantitative, and 
sensitive for the measurement of the concentration of AI-2 from a variety of sources. 
This technique was applied to the detection of AI-2 from E. coli and V. harveyi. It was 
also used to directly measure the concentration of the signal in complex biological 
systems such as from oral bacteria in human saliva. 
 
Figure 3.1. Schematic representation of DPD analysis by LC-MS/MS 
 
Although our LC-MS/MS method for DPD detection is useful, in order to facilitate the 
rapid detection of AI-2 outside of the laboratory we decided to construct fluorescent 
based detection methods for this molecule. Solid-supported optical sensors for AI-2 may 
be more amenable to use in the clinic or in the field allowing the effective detection of 
this molecule.  The fluorophore in the sensors will either be environment-sensitive and 
turned on by the formation of the AI-2 derivative or will form a FRET pair with this 
moiety. This technology should allow non-fluorescent AI-2 to be selectively detected as 
a corresponding fluorescent derivative. Even though the LC-MS/MS method is selective 
and efficient, high costs necessitated by the mandatory use of LC-MS instrument pose a 
major disadvantage towards use of this method. In order to carry out AI-2 studies in 
absence of expensive instruments, another method of quantization is needed.  
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3.3. Development of optical sensors 
As mentioned previously, there is no chromophore present in DPD so its direct 
detection by spectrophotometric analysis is not possible. The detection of its 
quinoxaline derivatives described in previous sections can be carried out using 
fluorometic analysis. However, this method is not selective. The quinoxaline of DPD 
(DPD-Q) is fluorescent with absorption maximum and emission maxima at 345 and 395 
nm, respectively. The unreacted diamine tag does not absorb strongly at wavelengths 
above ~320 nm, which allows the monitoring of the reaction with DPD via fluorescence. 
Unfortunately, the quinoxaline emission wavelength overlaps strongly with that of other 
molecules in the medium, e.g. tryptophan, complicating direct fluorescent detection of 
DPD-Q. To circumvent this issue, we decided to develop optical sensors that will 
efficiently react with DPD and will exhibit selective spectrophotometric properties.  
3.4. Synthetic strategy 
 
The idea was to derivatize the DPD into a stable molecule with desirable optical 
properties. The ideal tag would be a compound that readily reacts with DPD, and forms 
the stable derivative which should be capable of fluorescence emission above 400 nm 
in order to avoid overlap with the emission of tryptophan.  Also, the unreacted tag 
should not be fluorescent at the selected absorption frequency. Literature reports 
suggest that DPD reacts with diamine aromatic moiety readily to form a stable 
quinoxaline derivative (Scheme 3.1).128 This reactivity coupled with spectrophotometric 
properties of the known quinoxaline derivatives was used to develop the new optical 
sensor. The new sensor was envisioned as diamino benzene coupled to another 
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aromatic system. Triazoles do not deactivate the diamine aromatic ring; hence the 
reactivity of the sensor towards DPD is preserved. Additionally, triazole group allows 
preparing several analogues with variable linker lengths. The triazole entity as an 
additional aromatic system was selected owing to their facile synthesis and stability of 
the products.136 Additionally, the presence of the triazole does not decrease the 
reactivity of amino groups on the benzene. These triazoles can be synthesized using 
catalytic Cu(I) from their corresponding azides and alkynes allowing preparation of 
several compounds to identify the optimal tag.136  
 
Scheme 3.1. General synthesis of quinoxaline 
 
3.5. Copper(I)-catalyzed Azide-Alkyne Cycloaddition 
 
The copper-catalyzed reaction of an azide and a terminal alkyne allows the specific 
synthesis of 1, 4-disubstituted regioisomers even at room temperature.137 These 
copper-catalyzed azide-alkyne cycloadditions enjoy an enormous rate acceleration of 
107 to 108 compared to the uncatalyzed 1,3-dipolar cycloaddition.137 These reactions 
take place over a broad temperature range, are insensitive to aqueous conditions as 
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well as to pH over a range of 4 to 12, and tolerate a broad range of functional groups.138 
In most of the reactions, purification is not required as pure products can be isolated by 
simple filtration or extraction.139 The active Cu(I) catalyst can be generated from Cu(I) 
salts or Cu (II) salts using sodium ascorbate as the reducing agent.139 Addition of a 
slight excess of sodium ascorbate prevents the formation of oxidative homocoupling 
products. The Cu species undergo metal insertion reaction into the terminal alkynes, 
and a  complex with the triple bond of a terminal alkyne is formed (Figure 3.2). These 
Cu-adducts coordinate with the azide followed by the cyclization and reductive 
elimination of copper.139 
 
 
 
3.6. Synthesis of the optical sensors 
The synthesis of the optical sensors can be divide into three parts; preparation of the 
azide, formation of the terminal alkyne, and copper(I)-catalyzed azide-alkyne 
Figure 3.2. Mechanism of CuAAC reaction 
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cycloaddition (CuAAC). The synthesis of the azides were carried out using well-known 
protocols.140 Alkyl bromides (36a-b) were treated with sodium azide using DMSO as a 
solvent.140 These azides (37a-b) were isolated and characterized before carrying out 
further procedures (Scheme 3.2). 
  
 
 
The synthesis of the terminal alkyne was carried out based on reported procedures as 
described in Scheme 3.3.141,142 The synthesis of the alkyne started with the iodination of 
commercially available nitoraniline 38 using monoiodochloride and acetic acid as a 
solvent to yield molecule 39. Compound 39 was then coupled with the azide via a 
Sonogashira coupling reaction.143 Palladium(II) was used as the catalyst to obtain 40. 
The removal of the trimethylsilyl group was achieved in the presence of base at room 
temperature. Molecule 41 was reduced with zinc and acetic acid to obtain diamine 
42.144,145 
Scheme 3.2. Synthesis of alkyl azides 
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Terminal alkyne 42 was coupled with azides to obtain 1,2,3-triazoles. This Cu(I) 
catalyzed 1,3-dipolar addition allows the expedient synthesis of several molecules for 
studies. Cu-catalyzed click reactions have been reported to be regiospecific resulting in 
exclusive formation of trans-1,2,3-triazoles (43a-b)138 as shown in the Scheme 3.4. 
 
 
Scheme 3.3. Synthesis of terminal alkyne 42 
Scheme 3.4. Synthesis of triazole 43a-b 
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Another approach for the synthesis of 43a-b, which proved to be more convenient and 
produced better yields, is also depicted below (Scheme 3.5). In this synthetic Scheme, 
the click reaction of the terminal alkyne 41 with the azide was carried out before the 
reduction of the nitro group to the amine. The hydrogenation of 44a was carried out with 
Pd/C and hydrogen to obtain 43a in good yields. This hydrogenation process did not 
work with 44b, possibly due to interference from the free carboxylic acid group. The 
reduction of 44b was achieved by zinc and acetic acid to obtain 43b.  
 
Scheme 3.5. .Alternative approach to prepare triazoles 43a-b 
 
3.7. Synthesis of quinoxalines and their spectrophotometric analysis 
 
These two synthesized triazole tags (43a-b) were completely characterized by NMR 
and also tested for their spectrophotometric properties. These tags were then allowed to 
react with a model diketone system to obtain the corresponding quinoxalines. Tag 43a 
was reacted with 2,3-butadione 45 in chloroform (Scheme 3.6), and NMR as well as 
UV-visible spectroscopy was used to monitor the formation of the quinoxaline. The 
resultant quinoxaline 46 displayed maximum absorption at 325 nm and emission at 
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~425 nm for the corresponding excitation wavelength. Formation of quinoxaline 46 was 
monitored by fluorescence and was observed to be complete in 120 min (Figure 3.3). 
 
Scheme 3.6. Reaction of tag 43a with 2,3-butadione 45 
 
Figure 3.3. Absorbance and emission data for 43a and 46 respectively 
 
 
Scheme 3.7. Reaction of tag 43a with DPD to get 47 and possible intermediate 48 
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Figure 3.4. 1H NMR and spectrophotometric data for tag 43a and 47 
 
The tag 43a was then reacted with DPD in a water-methanol mixture, and the reaction 
yielding 47 was monitored by 1H NMR and UV-Vis spectroscopy (Scheme 3.7). The 
maximum absorption of quinoxaline 47 is 337 nm. This maximum absorption frequency 
was used as an excitation wavelength for the fluorescence studies. The emission of the 
quinoxaline 47 was observed at ~421 nm (Figure 3.4). The unreacted tag did not show 
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any emission at this excitation frequency. The experimental conditions are shown below 
in table. 
Table 3.1. Experimental conditions 
 Solvent 
Excitation 
wavelength 
Emission 
wavelength 
Temperature 
Reactant 
ratio 
Concentration 
47 Methanol 337 nm 421 nm RT 1:1 100 μM 
49 Water 355 nm 430 nm RT 1:1 100 μM 
 
Similar experiments were performed on the second tag. 43b was reacted with DPD in 
water, and the quinoxaline 49 was formed and evaluated by 1H NMR and 
spectrophotometric techniques without isolation. The reaction is described in Scheme 
3.8. A selective peak in the absorption spectrum was observed for quinoxaline 49 at 355 
nm, which was used as an excitation wavelength for the fluorescence experiments. In 
the emission spectrum, a peak that was selective for the quinoxaline was observed at 
430 nm (Figure 3.5) 
 
 
Scheme 3.8. Reaction of DPD with 43b 
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Figure 3.5. 1H NMR and spectrophotometric data of tag 43b and 49 
 
3.8. Linear range and sensitivity of the method 
 
Kinetic experiments were also performed to determine the rate of the reaction. The time 
required for the reaction yielding 47 was found to be ~120 min for 80% formation of the 
product. The reaction was monitored by 1H NMR as well as UV-Vis experiments. The 
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long reaction time could be partially explained based on the presence of the DPD 
methyl acetals formed due to methanol in situ (Scheme 3.9). To circumvent this 
problem, we decided to make the water-soluble tag 43b that was prepared. As 
expected, due to the absence of complications from methyl acetal intermediates, the 
time required to form 49 was ~50 min for 90% product formation.  
 
Scheme 3.9. Formation of methyl acetals 48 
 
The rate of reaction can be further improved by using an excess of the tag. Next, 
emission of 47 and 49 at different concentrations were measured (Figure 3.6C). The 
increase in the concentration of quinoxalines (47 and 49) was plotted over the time and 
the curve obtained suggested that the order of the reaction might be pseudo-first order 
(Figure 3.6A and B). The sensitivity of the experiment was also determined which 
corresponds to the slope of the line (Figure 3.6D). It was also confirmed that optical 
sensors were able to detect DPD at concentrations as low as 50 nM (Figure 3.6D).  
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Figure 3.6. Linear range and sensitivity experiments of quinoxalines 47 and 49 
 
In order to determine the rate constants for reactions, decrease in the concentrations of 
DPD as percent were plotted over the time required for the reactions (Figure 3.7A and 
3.7B). The graph of logarithm of DPD percentage over time resulted in the straight line. 
The slope of the straight line corresponds to the rate constant as shown in Figure 3.7C 
and 3.7D. 
A) B) 
C) D) 
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Figure 3.7. Rate constant calculations for 47 and 49 
 
 
3.9. Development of FRET sensors 
 
We also decided to develop DPD sensors that tether the diamine tag to a fluorophore to 
create Förster resonance energy transfer (FRET) sensors. The basic principle behind 
this is that, there is no fluorescence until after reaction of DPD with the sensors that 
employ the newly formed quinoxaline as a donor for an appended fluorophore. This 
method will potentially avoid the overlap of emissions of DPD sensors with biological 
molecules present in matrix such as tryptophan. Additionally, this method should be 
very selective as well as sensitive. 
Förster Resonance Energy Transfer (FRET) is a distant dependent molecular 
phenomenon which relies on absorption of energy by a donor moiety followed by 
A) B) 
C) D) 
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transfer of energy from the excited donor molecule to an acceptor moiety by 
spontaneous radiative or nonradiative process.146,147,148 This resonance interaction 
occurs over greater than interatomic distances without conversion to thermal energy 
and without any molecular collision. The transfer of energy leads to a reduction in the 
donor‟s fluorescence intensity and excited state lifetime and an increase in the 
acceptor‟s emission intensity. The donor must have a strong absorption and therefore a 
high extinction. The donor should be a fluorophore, but it does not emit light in FRET; 
the donor just needs to be in the excited state long enough to transfer its energy to the 
acceptor. The acceptor must be able to absorb at the donor emission wavelength, but it 
doesn‟t have to be a strong absorber. A pair of molecules that interacts and also 
responsible for FRET is often referred to as a donor/acceptor pair. Due to its sensitivity 
to distance, FRET has been used to investigate molecular interactions.149,150 This FRET 
technology is commonly used in biomedical research and drug discovery. Due to the 
advantages of this technique, we decided to develop a FRET tag to detect 
DPD.151,152,153,154 
3.10. Synthesis of FRET tag 
 
The synthesis started with the protection of amino ethanethiol using trityl alcohol and 
trifluoroacetic acid to obtain 51 (Scheme 3.10).155 The coupling of bromo propionic acid 
with 51 was carried out in the presence of N-methyl morpholine as a base and ethyl 
chloroformate to obtain 52.156 The conversion from 52 to 53 was achieved by treatment 
with sodium azide.157 The copper-catalyzed click reaction with the terminal alkyne 41 
and azide 53 was performed to yield molecule 54. The reduction of 54 to obtain diamine 
55 was achieved using zinc and acetic acid. Currently, we are working on the 
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deprotection of trityl group of the thiol which will lead to compound 56. This molecule 
can be used for further coupling with the flurophore. Based on the previous 
spectrophotometric experiments, Lucifer yellow is thought to be an appropriate 
fluorophore with absorption frequency of 427 nm and emission frequency of ~525 nm. 
 
Scheme 3.10. Synthesis of the FRET tag 56 
 
Since Lucifer yellow iodoacetamide is not commercially available, we have decided to 
synthesize it. The proposed synthetic pathway is described below in Scheme 3.10.158 
The synthesis starts with sulfonation of molecule 57, which is commercially known as 
brilliant sulfoflavine, followed by treatment with potassium hydroxide as a base and 
hydrochloric acid respectively to obtain 58. The next step will be introduction of nitrogen 
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in the ring, which can be achieved by acid catalyzed reaction with ethylene diamine 59 
to yield 60. The last step will be coupling with iodoacetic acid in the presence of base to 
obtain the target molecule Lucifer yellow iodoacetamide. This coupling should be 
selective for the alkyl amine over the aromatic amine due to presence of electron 
withdrawing groups on the aromatic ring. However, if the coupling does not give the 
desired product then protection of the aromatic amine will be utilized. 
 
Scheme 3.11. Proposed synthesis of Lucifer yellow iodoacetalide 
 
The thiol entity 56 can then be coupled with Lucifer yellow iodoacetamide to obtain the 
desired diamine FRET tag 61. This flurophore Lucifer yellow is reported to react with 
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thiols selectively,159 hence we assume the diamine part of the molecule will not interfere 
in the formation of 61. Molecule 61 can be further reacted with DPD to form the 
corresponding quinoxaline 62, which should be detected by fluorescence (Scheme 
3.12) 
 
Scheme 3.12. Final steps of synthesis of FRET tag and its reaction with DPD 
 
Conclusions 
This chapter describes the current methods of detection DPD along with their 
advantages and drawbacks. The focus of this chapter is the development of optical 
sensors for the efficient detection of DPD. Also, the development of a FRET tag for a 
FRET detection, which will be more sensitive and selective, is in process. 
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3.11. General synthetic methods 
Synthesis of alkyl azides 37a-b 
Alkyl bromide (1 equiv) was dissolved in 2 mL of DMSO, and sodium azide (1.2 equiv) 
was added to it. The reaction mixture was stirred overnight at room temperature. The 
reaction was monitored by thin layer chromatography. At this time, water was added to 
it. The reaction mixture was extracted by 3 X 20 mL of ethyl acetate. All organic layers 
were combined and washed with 2 X 25 mL water. The organic layer was dried with 
MgSO4, filtered, and concentrated in vacuo to obtain clear oil. Heptyl azide 37a and 3-
azidopropanoic acid 37b were characterized by 1H NMR spectroscopy that matched 
reported data.160 
Synthesis of 39, 40, 41 
Preparation of 4-iodo-2-nitroaniline 39, 2-nitro-4-(trimethylsilyl)ethynyl)aniline 40, 4-
ethynyl-2-nitroaniline 41 were carried using reported procedures in US 2011/0224259 
A1. 
Synthesis of 4-ethynylbenzene-1,2-diamine (42) 
The compound 42 (60 mg, 0.45 mmol) was dissolved in 4 mL of ethanol, and 100 mg 
(1.53 mmol) of fine zinc dust was added to it in single portion. Acetic acid (200 μL) was 
added to the reaction mixture as a catalyst. The reaction was stirred for 1 h at room 
temperature. The reaction mixture was decanted to remove zinc and was concentrated 
under vacuo to obtain the crude product. This crude material was dissolved in 
dichloromethane, and the white precipitate was collected on a filter. The filtrate was 
concentrated to obtain the product 42 as a light brown solid. Rf (40% EtOAc/hexanes) 
0.29; IR (KBr, thin film) ‾ν  max (cm
-1) bs 3372, 3274, 3146, 2921, 2953, 2856, 1625, 1501, 
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1454, 1275, 1233, 1163; 1H NMR (300 MHz, CDCl3) 7.39 (m, 2H), 6.69 (d, 6.9 Hz, 1H), 
4.27 (bs, 4H), 2.92 (s, 1H); 13C NMR (126 MHz, CDCl3) δ 136.01, 133.71, 124.88, 
120.20, 115.93, 113.77, 106.15, 91.16; HRMS-ESI (m/z): [M-H]+  calcd for  C8H9N2, 
133.0766; found, 133.0769.   
A general procedure for the click reaction was followed and was reported in US 
2011/0224259 A1. 
4-(1-heptyl-1H-1,2,3-triazol-4-yl)benzene-1,2-diamine (43a)  
A solution of azide 37a (10 mmol) in DMSO (5 mL) was diluted with water (5 mL). 
Sodium ascorbate (1 mmol), alkyne 42 (10 mmol), and copper sulfate (2 mmol) were 
added sequentially and mixture was stirred overnight. The reaction was quenched by 
adding water until a precipitate was formed. The product was isolated and further used 
without purification. The product was obtained as an orange solid in 57% yield, Rf (10% 
MeOH/DCM) 0.1; IR (KBr, thin film) ‾ν  max (cm
-1) bs 3372, 3274, 3146, 2921, 2953, 2856, 
1625, 1593, 1501, 1454, 1349, 1275, 1233, 1163, 1066, 1003, 879; 1H NMR (300 MHZ, 
CD3OD) 8.05 (s, 1H), 7.15 (s, 1H), 7.02 (d, J = 8.7 Hz 1H), 6.72 (d, J = 8.9 Hz 1H), 4.37 
(t, J = 6.2 Hz 2H), 1.93 (m, 2H), 1.29 (m, 8H), 0.88 (m, 2H); 
13
C NMR (126 MHz, CDCl
3
) 
δ 148.08, 134.92, 118.42, 118.37, 117.85, 116.71, 114.17, 50.36, 31.61, 30.39, 28.71, 
26.48, 22.55, 14.05. HRMS-ESI (m/z): [M-H]+  calcd for  C15H24N5, 274.2032; found, 
274.2031.   
3-(4-(3,4-diaminophenyl)-1H-1,2,3-triazol-1-yl)propanoic acid (43b) 
A solution of azide 37b (10 mmol) in DMSO (5 mL) was diluted with water (5 mL). 
Sodium ascorbate (1 mmol), alkyne 42 (10 mmol), and copper sulfate (2 mmol) were 
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added sequentially and mixture was stirred overnight. The reaction was quenched by 
adding water until a precipitate was formed. The product was isolated and further used 
without purification. The product was obtained as a brown solid in 55% yield. Rf (20% 
MeOH/DCM) 0.15; IR (KBr, thin film) ‾ν   max (cm
-1) bs 3436, 3121, 2504, 1559, 1436, 
1409, 1020, 953, 692; 1H NMR (300 MHz, DMSO-d6), 8.11 (s, 1H), 7.04 (s, 1H), 6.83 (d, 
J = 7.94 Hz, 1H), 6.53 (d, J = 7.94 Hz, 1H), 4.49 (t, J = 4.9Hz), 4.1 (bs, 4H), 2.69 (t, J = 
4.9 Hz); 13C NMR (126 MHz, DMSO-d6) δ 177.05, 148, 135.44, 120.62, 119.70, 115.45, 
114.1, 112.02, 49.05, 47.27, 40.85, 36.49. HRMS-ESI (m/z): [M-H]+  calcd for  
C11H14N5O2, 248.1147; found, 248.114.   
4-(1-heptyl-1H-1,2,3-triazol-4-yl)-2-nitroaniline (44a) 
A solution of azide 37a (1.41 g, 10 mmol) in DMSO (5 mL) was diluted with water (5 
mL). Sodium ascorbate (0.198 g, 1 mmol), alkyne 41 (1.62 g, 10 mmol), and copper 
sulfate (0.32 g, 2 mmol) were added sequentially and mixture was stirred overnight. The 
reaction was quenched by adding water until a precipitate was formed. The product was 
orange solid, orange solid, Rf (10% MeOH/DCM) 0.89; IR (KBr, thin film) ‾ν   max (cm
-1) 
3495, 3378, 3495, 1631, 1585, 1551, 1515, 1465, 1414, 1364, 1257, 1199, 1164, 1083, 
926; 1H NMR (300 MHz, CD3OD) 8.58 (s, 1H), 8.28 (s, 1H), 7.79 (d, J = 9.2 Hz, 1H), 
7.06 (d, J = 9.0 Hz, 1H), 4.42 (t, J = 6.4 Hz, 2H), 1.92 (m, 2H), 1.31(m, 8H), 0.89 (bs, 
2H);
 13
C NMR (126 MHz, CDCl3) δ 144.39, 133.30, 131.93, 122.67, 120.33, 119.45, 
119.01, 50.54, 31.53, 30.30, 28.64, 26.44, 22.50, 13.99; HRMS-ESI (m/z): [M-H]+  calcd 
for  C15H22N5O2, 304.1773; found, 304.177. 
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3-(4-(4-amino-3-nitrophenyl)-1H-1,2,3-triazol-1-yl)propionoic acid (44b) 
A solution of azide 37b (1.15 g, 10 mmol) in DMSO (5 mL) was diluted with water (5 
mL). Sodium ascorbate (0.198 g, 1 mmol), alkyne 41 (1.62 g, 10 mmol), and copper 
sulfate (0.32 g, 2 mmol) were added sequentially and mixture was stirred overnight. The 
reaction was quenched by adding water until a precipitate was formed. The product was 
obtained as a orange solid, Rf (10% MeOH/DCM) 0.78; IR (KBr, thin film) ‾ν  max (cm
-1) bs 
3465, 3348, 2361, 1717, 1506, 1348, 1411, 1169, 1105, 1218, 1252, 1284; 1H NMR 
(300 MHz, DMSO-d6) δ 8.53 (s, 1H), 8.43 (s, 1H), 7.86 (dd, J = 8.8, 2.1 Hz, 1H), 7.58 (s, 
2H), 7.10 (d, J = 8.8 Hz, 1H), 4.57 (t, J = 6.6 Hz, 2H), 2.94 (t, J = 6.7 Hz, 2H); 13C NMR 
(126 MHz, CD3OD)  145.76, 132.65, 130.99, 121.86, 120.39, 119.36, 118.59, 39.02; 
HRMS-ESI (m/z): [M-H]+  calcd for  C11H12N5O4, 278.0889; found, 278.089.   
(tritylthio)ethanamine 51 
The protection of 2-aminoethanthiol was carried out using known procedures and the 
product was matched with reported data.155 
3-bromo-N-(tritylthio)ethyl)propanamide (52) 
2-bromopropionic acid (1 equiv) was dissolved in 2 mL of DMF and cooled down to 4 
C. To this cooled solution, ethyl chloroformate (1 equiv) and N-methyl morpholine (1 
equiv) was added and stirred for 30 min at 4 C. Amine 51 (1 equiv) was added at this 
time, and the reaction was stirred for 6-8 h until complete conversion was achieved. The 
reaction was quenched with water, and the mixture was extracted with 3 X 30 mL 
dichloromethane. All organic layers were combined and washed with 2 X 25 mL 
NaHCO3, water, 1M HCl, and water respectively. The organic layer was dried with 
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MgSO4, filtered, and concentrated to obtain a white solid. Rf (40% EtOAc/hexanes) 
0.29; 1H NMR (300 MHz, CDCl3) 7.41 (m, 6H), 7.29 (m, 9H), 5.54 (bs, 1H), 3.58 (t, J = 
6.75, 2H), 3.08 (m, 2H), 2.64 (t, J = 6.75 Hz), 2.43 (m, 2H); 13C NMR (126 MHz, CDCl3) 
δ 169.41, 144.62, 129.55, 129.53, 128.04, 128.02, 126.89, 39.69, 38.30, 31.92, 27.32; 
HRMS-ESI (m/z): [M-H]-  calcd for  C24H23BrNOS, 452.0684; found, 452.07. 
3-azido-N-(tritylthio)ethyl)propanamide (53) 
The synthesis of azide 53 (1 g, 2.42 mmol) followed the procedure mentioned 
previously in general synthetic methods. The product was obtained as a pure white solid 
without further purification. Rf (40% EtOAc/hexanes) 0.28; 
1H NMR (300 MHz, DMSO-
d6) 7.28 (m, 6H), 7.18 (m, 9H), 5.81 (bs, 1H), 3.45 (t, J = 6.5 Hz, 2H), 2.99 (q, J = 6.2 
Hz, 2H), 2.31 (dd, 2H), 2.22 (t, J = 6.2 Hz, 2H); 13C NMR (126 MHz, DMSO-d6) δ 
169.81, 144.88, 129.53, 128.48, 127.19, 47.36, 40.35, 40.19, 40.02, 39.85, 39.69, 
38.05, 34.90, 31.82; HRMS-ESI (m/z): [M-H]-  calcd for  C24H23N4OS, 415.1593; found, 
415.1597. 
3-(4-(4-amino-3-nitrophenyl)-1H-1,2,3-triazol-1-yl)-N-((tritylthio)ethyl)propanamide 
(54) 
A solution of 53 (2.08 g, 1 equiv, 5 mmol) in DMSO (2 mL) was diluted with water (2 
mL). Sodium ascorbate (99 mg, 0.1 equiv, 0.5 mmol) was added as a reducing agent 
followed by addition of the terminal alkyne 41 (0.81 g, 1 equiv, 5 mmol), and then 
copper(II) sulfate (160 mg, 0.2 equiv, 1 mmol). The reaction was allowed to run 
overnight at room temperature. Then water was added until a precipitate was formed. 
The orange solid was filtered and dried. This crude product was purified by column 
chromatography using 10% MeOH:DCM to obtain an orange solid. Rf (10% 
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MeOH/DCM) 0.79; IR (KBr, thin film) ‾ν   max (cm
-1) bs 3461, 3347, 3291, 3155, 3029, 
2916, 2070, 1961, 1648, 1573, 1512, 1439, 1417, 1350, 1281, 1248, 1110, 1024, 952, 
896, 827, 744; 1H NMR (300 MHz, CDCl3) 8.34 (s, 1H), 7.76 (d, J = 8.63 Hz, 1H), 7.68 
(s, 1H), 7.25 (m, 6H), 7.16 (m, 9H), 6.71 (d, J = 9 Hz, 1H), 4.55 (t, J = 5.35, 2H), 5.58 
(bs, 1H), 2.88 (m, 2H), 2.61 (t, J = 5.08 Hz, 2H), 2.27 (t, J = 5.08 Hz, 2H); 13C NMR (126 
MHz, CDCl3) δ 173.72, 149.23, 148.46, 137.00, 133.33, 131.74, 130.60, 126.61, 
124.51, 123.43, 122.87, 70.68, 50.15, 44.06, 42.45, 42.32, 39.86, 35.30; HRMS-ESI 
(m/z): [M-H]-  calcd for  C32H29N6O3S, 577.2022; found, 577.204. 
3-(4-(3,4-diaminophenyl)-1H-1,2,3-triazol-1-yl)-N-((tritylthio)ethyl)propanamide (55) 
The reduction of the nitro group was achieved using protocols described before in the 
general synthetic methods to yield brown solid 55 (25 mg, 0.045 mmol) in 35% yield. 1H 
NMR (300 MHz, CDCl3) 8.42 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.32 (m, 6H), 7.21 (m, 
9H), 6.86 (d, J = 8.47 Hz, 1H), 6.47 (m, 3H), 4.62 (m, 1H), 4.17 (m, 1H), 3.00 (t, J = 6.2 
Hz, 2H), 2.72 (m, 2H), 2.33 (t, J = 6.5 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 177.91, 
169.64, 147.11, 144.55, 134.28, 133.57, 129.47, 127.95, 126.81, 120.90, 120.57, 
118.12, 66.86, 46.31, 40.05, 38.58, 36.14, 21.41; HRMS-ESI (m/z): [M-H]+  calcd for  
C32H33N6OS, 549.2437; found, 549.2432. 
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4. Understanding the mechanism of DPD by 
studying its interaction with metals and NADH 
4.1. Background data 
 
Our lab has been interested in finding out the exact mechanism and role of AI-2 in the 
bacterial kingdom,118,130 and its applications towards prevention or treatment of the 
bacterial infections. The role of AI-2 as an interspecies signaling molecule is widely 
accepted in some species;65 however there is a contradictory hypothesis as well.161 It is 
reported that in some species, disruption of luxS gene did not affect the signaling 
process.162 It is also possible that DPD is just a metabolic byproduct of the activated 
methyl cycle. If DPD is produced for the metabolic reasons, the growth of luxS mutant of 
bacteria with wild type cannot be explained. Our studies of E. coli indicate that it is not 
likely to use AI-2 as a signal, since it does not regulate DPD biosynthesis.130 Generation 
of AI-2 by the LuxS enzyme catalyzed conversion of SRH leads to another hypothesis 
which defines AI-2 as a metabolic by-product of the activated methyl cycle.92 Our former 
graduate student, Jessica Gooding collected data regarding this, and also confirmed 
that E. coli could not use DPD as a carbon source. Also, it was determined that 
metabolism was not affected by the deletion of luxS.162 Lastly, we also considered the 
possibility of AI-2 as a stimulant for the immune system.  
Several studies have been initiated to investigate the association of quorum sensing 
with the host immune response.163 The effect of quorum sensing on cytotoxicity and the 
production of pro-inflammatory mediators was examined using the murine macrophage 
cell-line RAW264.7, and cytotoxicity was determined by measuring lactate 
dehydrogenase release in the culture.164 These results suggest that quorum sensing 
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could be involved in the modulation of TNF- and nitric oxide produced from host cells 
by regulating virulence factors, and that V. vulnificus facilitates its host‟s death and 
bacterial survival by enhancing virulence on host cells.164,165 As we know, the human 
innate immune system represents the first line of defense against microorganisms.166 
Human neutrophils are known to inactivate the agr-derived autoinducing peptide of S. 
aureus. Hence it can be said that, QS significantly impacts the interaction of 
staphylococci with the innate host defense.167 Some bacteria manipulate the immune 
response of the host by inducing apoptosis in host immune cells with quorum sensing 
regulated genes.166 Apoptosis is a regular process by which the body destroys 
unnecessary or diseased cells and activates the immune system to a much lesser 
extent than does host cell lysis induction by a bacterium. This induced apoptosis leads 
to the destruction of the immune system of the host. Recent work on N-acylhomoserine 
lactone-mediated QS has revealed that some soil bacteria exploit host-derived 
substrates to generate an alternative N-substituted homoserine lactone.168,169 The 
detailed mechanism of modulation of host inflammatory signaling pathways by N-(3-
oxo-dodecanoyl)-L-homoserine lactone (Figure 4.1) and the specific ability of it to 
induce apoptosis in certain cells has been explored.170 Data suggest that the quorum-
sensing molecule 3-oxo-C12-HSL is important in the pathogenesis of P. aeruginosa, not 
only in the induction of bacterial virulence factors but also in the modulation of host 
responses.170a  Researchers have concluded that Pseudomonas 3-oxo-C12-HSL 
specifically promotes the induction of apoptosis, which may be associated with 3-oxo-
C12-HSL-induced cytotoxicity in macrophages and neutrophils. Structure-activity 
correlation experiments demonstrated that the fine structure of 3-oxo-C12-HSL, the HSL 
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backbone, and side chain length are required for maximal activity. These literature 
reports motivated us to probe the role of AI-2 in the immune system.171  
 
Figure 4.1. Structure of N-(3-oxo-dodecanoyl)-L-homoserine lactone  
 
Prior work in the lab 
 
Jessica Gooding started working on this, and then I continued the project after her 
graduation. In order to study the effect of DPD in the immune system, mouse 
microphages cell line (RAW264.7) were treated with several concentrations of DPD and 
with or without lipopolysaccharides (LPS), which is an immunostimulant. Supernatant 
solutions were tested for cytokines and RNA using ELISA and microarray experiments 
as depicted in Figure 4.2.  
 
Figure 4.2.  Method of sample collection for cytokine assay 
 
In the microarray data, the decrease in immune response with DPD treatment was 
attributed to the significant change in immune and oxidative stress response genes. We 
expected that a host response to a unique signal of bacterial origin would be through 
Mouse Macrophages
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Stimulate 
18h
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+ 
Microarray
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Collect
Courtesy of Jatin M. Vyes
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the transcription factor NF-κB.163a,172 Responses to immunostimulant lipopolysaccharide 
(LPS) are routed through NF-κB signaling leading to the transcription of cytokines TNF-
α, IL-1β and IL-6.170a,164 The typical immune response to bacteria and viruses are 
different, and often promotion of one response leads to the inhibition of another.163a  In 
order to verify the response by cytokines, the possibility of a viral type response was 
checked by measuring interferon IFN-α. 
The data obtained from the above experiments determined that, DPD lowered TNF-α 
(34%) and IL-6 (77%) production in LPS treated cells (Figure 4.3). Production of IL-1β 
and IFN-α were not observed in the assays, likely due to inadequate LPS 
concentrations.  
 
Figure 4.3. Relative intensity of immune response markers TNF-α, TNF-α + LPS, IL-6 
when RAW264 cells were stimulated for 18 h with DPD  
 
The next step was to determine the biologically relevant DPD concentrations since it is 
not reported. In order to evaluate this, C57/BL6J male mice that were fed either a low 
(10%) or high fat diet were sacrificed, and four segments of the intestinal tract were 
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harvested: stomach, 3 cm of small intestine, cecum and the colon. Contents from these 
segments were derivatized, and the concentration of DPD (20-300 pmol DPD/g) was 
measured (Figure 4.4). However, a couple of problems were encountered with this 
experiment. These include difficult quantification, and the inability to determine the 
importance of local concentration over bulk quantitation. Hence, this experiment was not 
conclusive with respect to the biologically relevant concentration of DPD. 
 
Figure 4.4. [DPD] measured from the contents of several segments the GI tract of male 
C57BL/6J mice fed either a low fat (dark) or high fat (light) diet. Values are the average 
of six mice, and error bars indicate a standard deviation. Chow was measured in 
duplicate and the error bars represent the range 
 
RNA isolation followed by a microarray experiment suggested that, oxidation related 
genes are expressed at a higher level and immune system related genes are 
decreased. Transcriptomic analysis of RAW cells treated with DPD showed the changes 
in several genes related to oxidative stress and immune functions as listed in Table 4.1.
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Table 4.1. Transcriptomic analysis of LuxS mutation for oxidative stress 
Immune response, Oxidative Stress and Redox   
Gene Symbol Gene Name 
DPD-CH 
Fold change 
DPD-CH 
p-value 
AKR1B8 aldo-keto reductase family 1, member B8 3.12 0.0014 
ALDH2 aldehyde dehydrogenase 2, mitochondrial 1.46 0.0488 
BLVRB biliverdin reductase B 4.37 0.000014 
CAT catalase 3.99 0.0011 
CBR3 carbonyl reductase 3 3.66 0.0014 
CYB5 cytochrome b-5 2.63 0.0017 
G6PDX glucose-6-phosphate dehydrogenase X-linked 2.21 0.0078 
GCLM glutamate-cysteine ligase, modifier subunit 7.57 0.000014 
GSS glutathione synthetase 1.53 0.0085 
HMOX1 heme oxygenase (decycling) 1 2.28 0.0493 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 1.81 0.0666 
CCL4 
chemokine (C-C motif) ligand 4 
-1.88 0.115 
CCL7 
chemokine (C-C motif) ligand 7 
- - 
CXCL16 
chemokine (C-X-C motif) ligand 16 
-1.55 0.0976 
IFITM1 
interferon induced transmembrane protein 1 
-1.57 0.0488 
IRF9 
interferon regulatory factor 9 
-1.62 0.0377 
TRAF1 
TNF receptor-associated factor 1 
- - 
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4.2. Literature reports 
 
Previous articles reported that the structural analogue of DPD, methylglyoxal (MG) 
induced a concentration dependent enhancement of IL-8 and IL-6 secretions.173  A co-
incubation with pro-inflammatory cytokines such as tumor necrosis factor-a (TNF-), 
interleukin- 1 (IL-1) or lipopolysaccharides (LPS) and increasing MG concentrations 
further enhanced IL-8 and IL-6 secretion (Figure 4.5).174 Increase in the heme 
oxygenase (HMOX1) was observed after DPD interactions. Oxidative stress is known to 
increase HMOX1 expression, and this enzyme can then cleave heme to release an iron 
cation, biliverdin and carbon monoxide.175  The product generated during the process, 
which is carbon monoxide, may then inhibit the expression of cytokines.173,176  
Insulin-like growth factor is also increased in DPD treated cells, and this protein is 
related with bilirubin levels. It is also a part of an NF-κB controlled anti-inflammtory 
pathway.177,178 The IL-10 anti-inflammatory pathway activates p38 MAPK, a cell stress 
response regulator, in order to modulate HMOX1 levels.  Reactive oxygen species can 
induce this pathway as evident in the study of IL-8 production by methylglyoxal and 
glyoxal by p38 in an intestinal cell line.174,175 
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Figure 4.5. Effect of methylglyoxal in the biological systems 
 
4.3. Cytokine assay 
 
The cytokine assay was repeated using the mouse macrophages (RAW cell line). In this 
experiment, two sets consisting of different concentrations of DPD (94 μM and 188 μM) 
were used with or without LPS. Different radiation treatments were also performed. 
Supernatant solutions were tested by the ELISA test. Relative intensities for the 
samples were calculated. As expected, a decrease in TNF concentrations was 
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observed as the concentration of DPD increased with or without LPS as it can be seen 
in Figure 4.6.  
 
 
Figure 4.6. Relative intensities of TNF- in the supernatant solutions of treated RAW 
cell line A) No LPS B) 10 ng/mL LPS C) 100 ng/mL 
 
Similar results were observed for IL-6, the increase in the DPD concentration decreased 
the relative concentrations of IL-6 (Figure 4.7). This decrease was visible in the last set 
where DPD concentration of DPD was 188 μM. Also, the amount of IFN and IL-β were 
measured, and those were present in insignificant amounts. The significance of this 
change cannot be determined due to lack of knowledge of biologically relevant 
concentration. 
 
Figure 4.7. Relative intensities of IL-6 in the supernatant solutions of treated RAW cell 
line A) No LPS B) 10 ng/mL LPS C) 100 ng/mL 
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These cytokine assays suggested that there is no stimulation of the immune system as 
expected. Interestingly, it demonstrated anti-inflammatory effects in a dose responsive 
manner. Cytokines are signaling proteins that recruit immune system cells to the site of 
an infection.179 A decrease in these signals may prevent immune response to AI-2 
signaling bacteria. This can be one way to detect bacterial infections.  
4.4. Redox potential of DPD in presence of metal 
 
Further experiments were continued to understand the role DPD plays in the immune 
system. Previous literature has mentioned the role of the universal signaling molecule 
autoinducer-2 (AI-2) in biofilm formation by Mycobacterium avium. The addition of AI-2 
to planktonic M. avium cultures resulted in increased biofilm formation. Microarray and 
reverse transcriptase PCR studies revealed an upregulation of the oxidative stress 
response upon addition of AI-2.180 These reports suggested that the response to AI-2 
might be related to oxidative stress in which precursors of AI-2 could act as a reactive 
oxygen species (ROS).175,181 In order to shed light on this aspect, we decided to 
evaluate the possibility of oxidative stress by DPD. “Oxidative stress is an imbalance 
between the systemic manifestation of reactive oxygen species and a biological 
system's ability to readily detoxify the reactive intermediates or to repair the resulting 
damage.”182 This stress can cause toxic effects through the production of free radicals 
that damage proteins, lipids, and DNA.182 In redox signaling, these reactive oxidative 
species act as cellular messengers.183 Hence, oxidative stress can disrupt the normal 
mechanisms of cellular signaling. Several reports described that AI-2 was implicated as 
a signal for a protective increase in oxidative stress response proteins.184,163b Studies of 
the complexation of DPD with iron had been carried out as well.185 We therefore 
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hypothesized that either DPD itself caused the oxidative stress observed in the 
transcriptomics data set, or it bound to the metal centers and disrupts redox activities at 
those sites and caused oxidative stress. To establish the redox potential of DPD, we 
performed cyclic voltammetry experiments. Cyclic voltammetry is one of the most 
commonly used electrochemical techniques186  and is based on a linear potential 
waveform; that is, the potential is changed as a linear function of time.186 The observed 
redox potential for just the DPD solution was -0.9942 V. A freshly polished glassy 
carbon working electrode, was used in conjunction with a platinum auxillary electrode, 
and Ag/AgCl reference electrode to measure the current of each of four solutions from 0 
to -1.4 V.  Samples were prepared with 1 mM solution of iron(II) chloride and 1 mM DPD 
mixture as well as 1 mM of iron(III) chloride and 1 mM DPD solution at room 
temperature. The corresponding controls were also evaluated; the redox potentials for 
acidic iron(II) solution and acidic iron(III) were -1.26 V, -1.19 V respectively. The 
reaction sample containing DPD either with iron(II) or iron(III) displayed the redox 
potential of -1.4 V on the cyclic voltammogram (Figure 4.8 and 4.9). Due to this 
observation, we believed that this experiment was not reliable. 
 
Figure 4.8. Cyclic voltametric analysis of A) 1 mM DPD, B) Acidic Fe(III), C) DPD+ 
Fe(III) 
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Figure 4.9. Cyclic voltametric of A) 1 mM DPD, B) Acidic Fe(II), C) DPD+ Fe(II) 
 
There were several drawbacks to this approach such as requirement for a large sample 
volume at high concentrations. Previous studies on α-diketones showed that the 
relevant redox reaction was irreversible.187 The molecule exists in dynamic equilibrium 
in the water, which may also affect the measured potential. The limit of the redox 
potential measured is limited by the potential of the buffer (water) and dependent on the 
condition of electrode.187 The experiment was attempted in a phosphate-citrate buffer 
with KCl added as a charge carrier. The only redox chemistry observed was that of 
dissolved oxygen. 
4.5. Oxidation of NADH 
 
Further studies to understand the mechanism of AI-2 were based on information about 
the relevant intracellular redox potentials, which are largely based on the potential of the 
electron transport chain components. The electron source in this process is primarily 
NADPH,188 which shares the same redox potential with its less expensive relative, 
nicotinamide adenine dinucleotide (NADH).188 NADH absorbs 340 nm light while its 
oxidized form NAD+ does not.189 Hence it was an ideal candidate to determine if DPD 
has a biologically relevant redox potential, even if cyclic voltammetry (CV) cannot 
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determine the exact potential. As the conversion from NADH to NAD+ takes place, the 
absorbance should decrease (Figure 4.10). The oxidation of NADH can also be 
accelerated by light, so all the samples were stored in the dark and at lower 
temperatures (4 C). 
 
Figure 4.10. Redox reaction of NADH 
 
The first analytical technique used to determine oxidation of NADH was 1H NMR 
spectroscopy. The proton NMR spectra of NADH, NAD+, and the reaction solution of 
NADH and DPD were analyzed. Formation of NAD+ was not observed, not were the 
changes in chemical shifts noticed (Figure 4.11). 
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Figure 4.11. 1H NMR spectrum in water of A) NADH, B) NADH and DPD, C) NAD 
 
In UV-Vis experiments, a decrease in the absorbance was observed over time leading 
to speculation of oxidation of NADH by DPD (Figure 4.12). Samples were prepared of 
DPD solutions with the phosphate buffer (pH= 7.2), and addition of NADH solution in 
water was carried out just before the measurement to avoid NADH oxidation by light. 
NADH 
NAD + DPD 
NAD 
A) 
B) 
C) 
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Figure 4.12. Initial absorbance data at 340 nm for DPD and NADH 
 
The experiment with different concentrations of DPD was carried out to determine 
whether the oxidation of NADH was taking place in a dose dependent fashion. Solutions 
of NADH (0.5 mM) were treated with different concentrations of DPD (0.25 mM, 0.5 mM, 
1 mM, 2 mM) and were monitored by UV-Vis (Figure 4.13). The following graph 
describes the absorbance corresponding to samples with the above mentioned 
concentrations. Based on these graphs, it can be said that NADH is being completely 
oxidized by 4 equivalents of DPD in around 5 min and an equivalent mixture of NADH 
and DPD lead to oxidation. However after thorough analysis it was found that 2 mM 
sample solution was acidic even though solutions were diluted in buffer. Hence the 
oxidation of NADH was attributed to the acidic conditions. 
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Figure 4.13. Absorbance measured to monitor NADH oxidation by DPD 
 
Dependence on the pH of the sample solution was confirmed by testing control 
solutions. A solution of acidic cyclohexanone was prepared and used as a standard 
solution. Additionally, the concentration of test solutions was decreased in order to 
maintain the pH of the solution. The 2 μM NADH solution was then treated with a 10 μM 
DPD solution. As can be seen from the Figure 4.14, there was slight decrease in the 
absorbance over the time due to presence of DPD. The absorbance for just the DPD 
solution was also measured to confirm the lack of absorbance at 340 nm. We could not 
reproduce this result confirming the oxidation of NADH by DPD (B). Also, whether the 
difference between the test solution and the standard (A) is significant or not is 
debatable (Figure 4.13). 
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Figure 4.14. Absorbance measured for the reaction of DPD and NADH over the time 
 
After obtaining less than satisfactory results in the above experiments, we decided to 
monitor the reaction by fluorescence since it is a relatively more sensitive technique.  
The NADH solution was excited at 340 nm, and emission at 460 nm was measured. 
The NAD+ solution does not show fluorescence. As the amount of NADH decreases the 
emission intensity should also decrease. The first experiment was to measure the 
emission of standard (2 μM NADH) as well as test solution (2 μM NADH + 10 μM DPD) 
over the time (Figure 4.15 A). As can be noticed from the graph, there was no 
significant change in the emission intensities. In order to determine the oxidation of 
NADH in the presence of DPD over the time, emission covering the wavelength region 
from 400-550 nm was measured every 10 minutes. Again no change was observed 
(Figure 4.15 B). 
A)
) 
B) 
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Figure 4.15. A) Experiment 1.Emission intensity of NADH and NADH+DPD over 50 min. 
B) Experiment 2. Emission intensity of NADH and NADH+DPD over the wavelength 
after every 10 minutes. 
 
It can be said from these experiments that the oxidation NADH through the sole use of 
DPD is not possible. However it cannot be determined whether DPD interacts with 
metals or free radicals in vivo to cause oxidation of NADPH/NADH. 
4.6. Interaction of DPD with peroxynitrite 
 
The next step was to probe the interaction between DPD and peroxynitrite. This 
experiment was thought to be helpful in determining whether AI-2 generates reactive 
oxidative species (ROS) in vivo. Diacetyl, methylglyoxal, and glyoxal (α-dicarbonyl 
catabolites) are prone to nucleophilic additions of amino groups of proteins and 
nucleobases are known to cause adverse biological responses. Glyoxal is also known 
to react with peroxynitrite, yielding formate as well as molecular oxygen in the singlet 
excited state (1Δg) at rates at least 1 order of magnitude greater than does 
methylglyoxal.190,191,192,193 Peroxynitrite is a reactive species, the product of the coupling 
reaction of two free radicals nitric oxide (●NO) and superoxide (O2
-) via a diffusion-
A)
) 
B) 
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controlled process in vivo. Peroxynitrite is a powerful nucleophile, and it is also able to 
directly and indirectly promote one- and two-electron oxidations through nitrosation.194 
Formation of peroxynitrite in vivo and its contribution to cell and tissue injury is 
associated with several pathologies such as inflammatory conditions, vascular 
diseases, and neurodegeneration.195 The high reactivity of methylglyoxal (MG) and 
other dicarbonyl metabolites to biological nucleophiles is attributed to the presence of 
the electron withdrawing effect of a vicinal carbonyl group, which increases the 
electrophilicity of the adjacent carbonyl moiety, thereby facilitating nucleophilic attack.196 
Likewise, DPD, the AI-2 precursor, can react with peroxynitrite to generate reactive free 
radicals. Peroxynitrite was synthesized in the lab using reported protocols from sodium 
nitrite, hydrochloric acid, and sodium hydroxide as shown in Scheme 4.1. 
Concentrations of H2O2 and peroxynitrite were determined spectrophotometrically at 
240 (ε = 42 M−1 cm−1) and 302 nm (ε = 1670 M−1 cm−1) respectively. 
 
Scheme 4.1. Synthesis of peroxynitrite 
 
If DPD reacts with peroxynitrite, it should generate singlet oxygen in an excited state 
along with free radicals. This singlet oxygen can be easily trapped by the water soluble 
singlet oxygen trap, anthracene-9,10-divinylsulfonate (AVS).197 This compound was 
prepared using methods developed by Alsters et al., described in Scheme 4.2.198 The 
synthesis included a Heck reaction with sodium vinylsulfonate using 1 mol% of 
Herrmann–Beller‟s cyclopalladated phosphine catalyst as described in the following 
Scheme 4.2.  
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Scheme 4.2. Synthesis of singlet oxygen trap AVS. 
 
If DPD reacts with peroxynitrite to generate singlet oxygen, it can be trapped by AVS 
(Scheme 4.3). AVS reacts with 1O2 giving the colorless 9,10-endoperoxide AVSO2.
198  
The trapping of 1O2 by AVS can be readily followed by UV/Vis spectroscopy. After the 
reaction of AVS with singlet oxygen, the bands at 360, 380 and 395 nm, which are 
characteristics of the anthracene core of AVS, disappear and four isobestic points at 
231, 271, 332 and 430 nm appear, indicating the specific formation of AVSO2.
198 An 
absorption band upto 500 nm characterizes this endoperoxide.198 Unfortunately, we did 
not observe any specific bands in this region after reaction of DPD with AVS (Table 
4.2). Hence, either there was no generation of reactive oxygen species or peroxynitrite 
was decomposing before the reaction with DPD. 
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Table 4.2. Absorbance measured to determine the presence of singlet oxygen  
Isobestic points for 
endoperoxides 231 nm 271 nm 332 nm 430 nm 
0.33mM AVS 3.536 3.627 0.370 0.328 
0.33mM AVS+ 0.33mM ONOO 3.566 3.646 0.376 0.344 
3.33mM AVS+ 0.33mM ONOO 
+ Glyoxal 3.357 3.284 0.110 0.039 
0.33mM AVS+0.33mM ONOO+ 
3.33mM DPD 3.549 3.632 0.377 0.340 
 
 
Scheme 4.3. Formation of AVSO2 from AVS 
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4.7. DPD-Iron interactions 
 
Free radicals can be generated by metal catalyzed reactions in vivo.199 The response of 
the immune system in the presence of DPD or the oxidative stress caused by DPD 
might be the result of complexation of DPD with iron, since iron is the part of heme 
oxygenase and is known for its vital role in oxidative processes.200 As iron(III) is 
ubiquitous in most soils and sediments such redox processes could occur,201 e.g. in 
moderately acidic environments, resulting in oxidative degradation of the biomolecules 
involved in cell–cell communication, thus directly affecting the relevant signaling 
pathways.202 Some researchers have reported that microbial alkyl resorcinol 
autoinducers can be abiotically oxidized by soil iron(III) in moderately acidic media. 
However, some of the signaling molecules can easily be oxidized by direct action of 
redox-active metal species.202 The resulting oxidized product is a completely different 
product with completely different properties.202 Thus, an oxidation process can interfere 
with the signaling process by modifying signaling molecules and is more likely to disrupt 
intercellular communication within the microbial consortium.203 Ferric ammonium citrate 
was found to inhibit biofilm formation in a dose-dependent manner.204 In addition, pre-
formed biofilms could be disrupted and completely inhibited by switching to iron-rich 
media in a flow-chamber.204 However in some bacteria, moderate iron concentrations 
allow for biofilm production and are critical for virulence.204 Experiments were carried 
out to determine the interaction of DPD with iron. The DPD was allowed to react with 
Fe(II) as well as Fe(III) in the solution, and the interactions were studied by several 
analytical techniques. The possible complex with DPD is depicted below with +3 as an 
oxidation state. This structure was proposed based on the reported structure of the 
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boron adduct with DPD (Scheme 4.4). 
 
Scheme 4.4. Possible formation of complex of DPD with iron 
 
The isolation or the crystallization of the DPD-iron complex was not successful. Then 
13C NMR spectra were taken for the sample solutions. 13C (CH3) isotope labeled DPD 
was synthesized and was used for these experiments. DPD was deprotected just before 
the experiment, and phosphate buffer (pH=7.2) was used to control the pH of the test 
solution (Figure 4.16 and Figure 4.17). To the 15 mM 13C-DPD, 100 mL of phosphate 
buffer was added followed by addition of 30 mM iron(II) chloride tetrahydrate. 13C NMR 
spectra were taken after every step to confirm the deprotection of DPD, to check the 
effect of the buffer on DPD, and more importantly to evaluate effect of iron on the DPD 
solution. After addition of iron, NMR spectra were taken every 5 min for 30 min, but no 
change was noticed. As the amount of the iron salt was increased, signal intensity 
decreased and broad peaks were observed after adding excess of iron chloride. 
Similarly, DPD was allowed to react with iron(III) choride, and reaction was monitored 
by NMR. No change in the chemical shifts were observed in case of iron(III). However in 
the Fe(II) experiment, the chemical shifts were relatively upfield retaining the difference 
between the chemical shifts of isotopic carbons and non-isotopic carbons. The change 
in the chemical shift was not conclusive since it could be attributed to a change in the 
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concentration as well as to the presence of inorganic salts. 
 
Figure 4.16. Stepwise analysis of 15 mM DPD with iron(II) by 13C NMR A) 15 mM DPD 
in buffer (pH= 7.2), B) 15 mM Fe(II), C) 30 mM Fe(II), D) 45 mM Fe(II), E) Excess Fe(II). 
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Figure 4.17.Stepwise analysis of 15 mM DPD with iron(III) by 13C NMR A) 15 mM DPD 
in buffer (pH= 7.2), B) 15 mM Fe(III), C) 30 mM Fe(III), D) 45 mM Fe(III), E) Excess 
Fe(III). 
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To circumvent this problem, Electron paramagnetic resonance (EPR) or electron spin 
resonance (ESR) spectroscopy was thought be an ideal analytical technique for 
analysis of these iron solutions. This technique is analogous to NMR, but differs in that if 
excitation of electron spins instead of the spins of atomic nuclei to detect single electron 
species.205 The g-factor is equivalent to the chemical shift in the NMR.205 If the unpaired 
electron is in the vicinity of non-zero nuclear spin, splitting is observed which is known 
as hyperfine coupling analogous to J- coupling in NMR.205 Interactions of an unpaired 
electron with its environment influence the shape of an EPR spectral line. The g-factor 
and hyperfine coupling in an atom or molecule may not be the same for all orientations 
of an unpaired electron in an external magnetic field.205  
The DPD solutions were reacted with iron(II) and iron(III) solutions separately in 
phosphate buffer, and their corresponding EPR spectra were recorded. Initial control 
experiments were carried out at different concentrations and temperatures. After 
performing control experiments, optimum reaction parameters were determined. It was 
found that room temperature, 1:1 as a reactant ratio, and the 0.5 mM sample solution 
are appropriate parameters for the experiments.  
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Figure 4.18. EPR spectrum of DPD in presence of Fe(III) at room temperature 
 
A distinct triplet EPR signal was observed when DPD was reacted with Fe (III) chloride 
at room temperature in the beginning, but the signal could not be reproduced. The 
samples with different metal to ligand ratios were also tested, and no significant change 
was observed. This triplet was observed around the magnetic field of 3365 gauss or the 
g-factor of ~1.99 (Figure 4.18). If this signal is real, then it can be said that the triplet 
corresponds to acetyl radical generated after reaction with iron similar to what was 
observed for a hydrated formyl radical generated by glyoxal and peroxynitrite.206,190,207 
Another possibility might be just coordination of iron with DPD to form a complex with 
distorted tetrahedral geometry, which is also supported by the g-factor value observed 
around 2.208 However, these results are not conclusive since the signal could not be 
reproduced. Similar experiments were carried out using different sources of iron, in 
particular hemin as an iron source to create a more relevant biological environment, but 
initial results were not promising. 
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Conclusions 
In summary, it can be said that AI-2 is responsible for suppressing the innate immune 
response by disrupting cytokine signaling, thus implying that this molecule may help 
defend bacteria during host colonization. The transcriptomics data showed that the 
immune cells respond to AI-2 by increasing transcription of oxidative stress response 
proteins, decreasing the production of inflammatory response signals and increasing 
expression of cation transport and scavenging proteins. The actual mechanism of the 
change in the immune system or the exact mechanism which causes this oxidative 
stress is still unknown. 
4.8. Experimental methods 
Determination of cytokine concentrations released from RAW2 Cells.  
 
RAW264.7 cells209 were maintained in RPMI supplemented with 10% BCS and 1% L-
glutamine at 37 ºC and an atmosphere of 5% carbon dioxide. Prior to experiments 
RAW264.7 cells were split 1:3 into fresh media (RPMI 1640, 10% BCS, 1% Gln) and 
allowed to grow to confluence. The cells were then scraped from the surface to suspend 
them in 12 mL media in a flask. This cell suspension was then centrifuged (1000 rpm, 5 
min, 16 ºC). The supernatant was decanted, and the pellet was resuspended in 0.9 mL 
of fresh media. The cells were counted and finally diluted to 5 x105 cells/mL. This cell 
suspension (1 mL) was then added to each well in a 48-well plate and incubated for 6 h. 
During this time, serial dilutions of DPD were made by mixing 500 μL of the 4.7 mM 
DPD stock solution with 500 μL media, mixing thoroughly, and transferring 500 μL of 
this solution to a vial containing another 500 μL media, and repeating once more. In the 
same fashion, a series of serial dilutions were made with a 4.7 mM cyclohexanone 
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solution (pH=1), to control for the other contents of the DPD stock solution. After 6 h, 42 
μL of either media, DPD solution (final concentration of 188, 94, 47, or 23 μM), or 
cyclohexanone solution was added to each well, followed by 10 μL of either media or 
LPS (10 ng/μL). The plates were stimulated over an 18 h period, and then supernatants 
were transferred into a microcentrifuge tube and centrifuged. These supernatants were 
transferred again and stored at -80 ºC until analysis. Cytokines were measured by 
ELISA (IL-1β, IL-6, TNF-α from Biolegend (San Diego, CA) and IFN-α kits from Pierce 
Protein Research (Thermo Fisher Scientific, Rockford, IL), and NO was measured by 
the Griess assay (Promega, Madison, WI) according to the manufacturer‟s instructions.  
Determination of gene expression Levels in RAW2 Cells.  
RNA was isolated from the cell pellets for the cytokine experiments using an RNeasy kit 
(Qiagen, Germantown, MD) according to the manufacturer‟s instructions. The RNA was 
tested for quality, then shipped to McGill University and Genome Quebec Innovation 
Centre for microarray experiments. Statistical analysis was completed on the resulting 
data, and trends in those probes that were significantly different in gene expression 
level were analyzed using the DAVID gene ontology program.210  
Determination of [DPD] in Murine GI Segments.  
The University of Tennessee Institutional Animal Care and Use Committee approved all 
animal studies. A 47 mM DPD stock solution of 13C-DPD was diluted 10 uL into 460 uL 
of H2O followed by another dilution of 20 uL into 180 uL, to make a 10 μM working stock 
solution 13C-DPD internal standard. Six C57BL/6J male mice211 fed continuously on a 
low fat diet (10%) were euthanized by carbon dioxide asphyxiation. The stomach, ~ 3 
cm of small intestine starting from the distal sphincter of the stomach, cecum, and the 
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descending colon were harvested. The contents of each were removed and collected 
into each of four preweighed eppendorf tubes containing derivatizing solution (5 mg/mL 
in 300 μL H2O). As soon as possible, 3 μL of the working stock solution of 
13C-DPD was 
added to the suspended solution of tag and contents and mixed thoroughly. Solutions 
sat at r.t. for at least 1 h, and during this time samples collected from mice were 
weighed to determine the mass of the contents added. The tubes were then centrifuged 
(13,200 rpm, 16,100 rcf, 5 min), chilled at 4 ºC for at least 30 min to facilitate any 
precipitation, and centrifuged again. The supernatants were stored at 4 ºC until mass 
spectrometric analysis.  
Cyclic voltammetry 
A freshly polished glassy carbon working electrode was used in conjunction with a 
platinum auxillary electrode and an Ag/AgCl reference electrode to measure the current 
of each of four solutions from 0 to -1.4 V. Solutions were made in a McIlvaine buffer of 
sodium phosphate (0.174 M), citric acid (0.013 M), and potassium chloride (40.4 g/L). 
This buffer was diluted 2x with either water, 2 mM 2,3-butanedione, 2 mM acidic 
cyclohexanone, 2 mM DPD, and/or 2 mM iron salt solutions to make each solution 
tested  
Microtiter plate assays 
The microplate assays were analyzed using a PerSeptive Biosystems Cytofluor 4000 
microtiter plate reader (Framingham, MA). For the NADH autofluorescence assay, 
NADH and DPD solutions were diluted with the phosphate buffer to obtain the desired 
pH. The absorbance was measured at 340 nm. The NADH fluorescence was measured 
by excitation at 340 nm and emission detection at 460 nm. 
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5. Conclusions 
 
This dissertation describes the development of synthetic strategies to generate 
biologically important natural products and their analogues and to probe their 
significance. In particular, Chapter 1 demonstrated the acid-catalyzed reaction of 
hydroxyarenes and dehydroascorbic acid (DHAA) to prepare natural products such as 
phloroascorbinol and the core structure for the tea ployphenol 8-C-ascorbyl 
epigallocatechin, which is a lipase inhibitor and a potent anti-obesity drug (Figure 6.1). 
In addition, this chapter also described the bioassay of all synthesized molecules in 
different biological systems. 
 
Figure 5.1. Reactions of DHAA with phenolic compounds 
 
The syntheses of DPD, which is a precursor of autoinducer-2 (AI-2), along with its 
analogues were described in the Chapter 2 of the dissertation. It also includes 
investigations of the role of AI-2 in biofilm formation in complex biological systems like 
dental plaques. AI-2 moderates interactions between pioneer colonizers in biofilms that 
are grown under environmental conditions representative of the healthy oral cavity: at 
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37 oC in flowing human saliva. Biofilms containing S. gordonii DL1 may be more 
susceptible to the integration of periodontal pathogens than those of S. oralis 34. This 
information is valuable from the perspective of future approaches to control periodontal 
disease, which could therefore incorporate AI-2 analogs or inhibitors to manipulate early 
dental plaque communities to favor species that do not support the 
coaggregation/integration of pathogens. This chapter also described the synthesis of 
some analogues of DPD, and their effect in biological systems. Interestingly, It was 
observed that the enantiomer of DPD interferes in the DPD importation of E. coli, 
although it is 100 fold less active than DPD in V. harveyi. Some other structural 
analogues, e.g. C1-CH2-ODPD were also less potent than DPD in V. harveyi. 
Chapter 3 depicted the problems in the detection and quantification of DPD and 
discussed strategies to overcome these issues. This chapter reported a partial 
synthesis of optical sensors, specifically fluorescence sensors (Figure 6.2). It also 
described the efforts taken towards the synthesis of sensors for the FRET detection of 
DPD in biological matrices (Figure 6.2). Currently, efforts are ongoing on the synthesis 
of the thiol selective flurophore, Lucifer yellow iodoacetamide.  
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Figure 5.2. Development of optical sensors for the detection of DPD 
 
In the future, we plan to attach these FRET tags to a solid support to facilitate the 
convenient synthesis. Attaching these FRET tags on solid support is also expected to 
result in selective and efficient detection of DPD from the biological samples (Figure 
6.3). 
 
Figure 5.3. Solid supported FRET tags 
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The last chapter consists of several approaches to evaluate role of DPD in bacterial 
communities and to determine its effect on macrophages (Figure 6.4). AI-2 is reported 
to modulate immune responses through cytokines secretion, particularly TNF  and 
IL-6.163a It is also known to play a critical role in oxidative stress. In order to determine 
the exact mechanism, the redox potential was measured by CV. The generation of 
reactive oxidative species was also checked by reaction with peroxynitrite. In the 
future, highly controlled reaction conditions can be carried out to confirm the results. It 
was found that there was no oxidation of NADH by just DPD. However the possibility 
of DPD being an important part of oxidative process by coordinating with metals or 
other enzymes in vivo cannot be discluded.  The interaction of AI-2 with DPD was also 
probed; however, the results were not conclusive due to inadequate analytical data. 
This part of the project can be studied further to evaluate interaction with iron using 
Mossbauer spectroscopy and/or iron NMR. 
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Figure 5.4. Investigations into the activity of DPD 
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                        Appendix A – Representative NMRs from Chapter 1 
 
1H and 13C NMR spectra of 7d in acetone-d6
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1H and 13C NMR spectra of 7b in acetone-d6 
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1H NMR spectrum of 11c in acetone-d6 
 
13C NMR spectra of 11c in CD3OD 
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1H-1H NMR COSY spectrum of Chromane diol 
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1H-13C NMR HSQC spectrum Chromane diol 
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1H and 13C NMR spectra of 11b in DMSO-d6
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1H and 13C NMR spectra of 1a in D2O 
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1H-1H NMR COSY spectrum of 1a 
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1H-13C NMR HSQC spectrum of 1a 
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1H and 13C NMR spectra of 1b in D2O 
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1H-1H NMR COSY spectrum of 1b 
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1H-13C NMR HSQC spectrum of 1b 
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1H NMR spectrum of 1a in DMSO-d6 
 
 
1H NMR spectrum of 1b in DMSO-d6 
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1H and 13C NMR spectra of 3 in CDCl3 
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1H and 13C NMR spectra of 12c in D2O 
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1H-1H NMR COSY spectrum of 12c 
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1H-13C NMR HSQC spectrum of 12c 
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1H-13C NMR HMBC spectrum of 12c 
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13C HSQC – 13C HMBC spectra of 12c 
 
 
 
 
 
 
 
 
  
205 
 
1H and 13C NMR spectra of 13c in D2O 
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1H-1H NMR COSY spectrum of 13c 
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1H-13C NMR HSQC spectrum of 13c 
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1H-13C NMR HMBC spectrum of 13c 
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13C HSQC – 13C HMBC spectra of 13c 
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Appendix B – Representative NMRs from Chapter 2 
1H and 13C NMR spectra of 24 in CDCl3
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1H and 13C NMR spectra of 25 in CDCl3 
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1H-1H NMR COSY spectrum of 25 
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1H and 13C NMR spectra of 26 in D2O 
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1H and 13C NMR spectra of 27 in CDCl3
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1H and 13C NMR spectra of 28 in CDCl3 
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1H and 13C NMR spectra of 29 in CDCl3 
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1H-1H NMR COSY spectrum of 29 
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1H and 13C NMR spectra of 30 in D2O 
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1H and 13C NMR spectra of 32 in CDCl3
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1H-1H NMR COSY spectrum of 32 
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1H and 13C NMR spectra of 33 in CDCl3 
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1H-1H NMR COSY spectrum of 33 
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Appendix C – Representative NMRs from Chapter 3 
1H and 13C NMR spectra of 42 in CDCl3 
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1H and 13C NMR spectra of 43a in CDCl3
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1H NMR spectrum of 43b in D2O 
 
13C NMR spectrum of 43b in CD3OD 
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1H-1H NMR COSY of 43b 
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1H and 13C NMR spectra of 44a DMSO-d6 
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1H and 13C NMR spectra of 44b DMSO-d6 
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1H-1H NMR COSY of 44b 
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1H and 13C NMR spectra of 46 in CD3OD
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1H and 13C NMR spectra of 52 in CDCl3 
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1H and 13C NMR spectra of 53 in DMSO-d6 
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1H NMR spectrum of 54 in CDCl3 
 
13C NMR spectrum of 54 in CDCl3 and CD3OD
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1H and 13C NMR spectra of 55 in CDCl3 
 
 
 
 
Acetic acid 
Acetic acid 
Acetic acid 
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1H-1H NMR COSY of 55 
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Appendix D – Representative Tables from Chapter 1 
Table A1. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for 1b.  U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor 
 
 
 
 
 
 
 x y z U(eq) 
C(5) 2706(3) 7943(1) 8739(1) 27(1) 
C(3) 2808(3) 7593(1) 10337(1) 29(1) 
C(2) 2904(3) 6614(1) 10129(1) 29(1) 
C(6) 2965(3) 6970(1) 8570(1) 27(1) 
C(4) 2695(3) 8267(1) 9645(1) 27(1) 
C(1) 3038(3) 6271(1) 9240(1) 29(1) 
C(8) 2775(4) 4996(1) 10756(1) 45(1) 
C(7) 2826(4) 9606(1) 10671(1) 41(1) 
O(1) 3141(2) 6771(1) 7653(1) 30(1) 
C(10) 2328(3) 8442(1) 7849(1) 29(1) 
C(9) 3216(3) 7689(1) 7182(1) 28(1) 
C(12) 5358(3) 8074(1) 7071(1) 30(1) 
C(11) 3551(3) 9334(1) 7672(1) 37(1) 
C(13) 6300(3) 7979(1) 6123(1) 32(1) 
C(14) 6946(3) 6965(1) 5929(1) 39(1) 
O(4) 2563(2) 9237(1) 9764(1) 37(1) 
O(5) 2900(2) 6023(1) 10883(1) 35(1) 
O(3) 3127(3) 10159(1) 7815(1) 57(1) 
O(2) 5251(2) 9093(1) 7272(1) 42(1) 
O(7) 2302(2) 7597(1) 6355(1) 33(1) 
O(6) 320(2) 8618(1) 7658(1) 43(1) 
O(9) 8630(2) 6741(1) 6476(1) 51(1) 
O(8) 7901(2) 8633(1) 6023(1) 41(1) 
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Table A2. Bond lengths [Å] for 1b 
 
Bond number Bond length [Å] 
C(5)-C(4)  1.399(2) 
C(5)-C(10)  1.495(2) 
C(3)-C(4)  1.377(3) 
C(3)-C(2)  1.389(3) 
C(2)-O(5)  1.372(2) 
C(2)-C(1)  1.387(2) 
C(6)-O(1)  1.375(2) 
C(6)-C(1)  1.377(2) 
C(4)-O(4)  1.355(2) 
C(8)-O(5)  1.434(2) 
C(7)-O(4)  1.433(2) 
O(1)-C(9)  1.445(2) 
C(10)-O(6)  1.404(2) 
C(10)-C(11)  1.507(3) 
C(10)-C(9)  1.547(2) 
C(9)-O(7)  1.364(2) 
C(9)-C(12)  1.548(3) 
C(12)-O(2)  1.442(2) 
C(12)-C(13)  1.531(3) 
C(11)-O(3)  1.194(2) 
C(11)-O(2)  1.329(3) 
C(13)-O(8)  1.416(2) 
C(13)-C(14)  1.496(3) 
C(14)-O(9)  1.423(3) 
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Table A3. Bond angles [°] for 1b 
 
Bond angles  
C(6)-C(5)-C(4) 118.88(15) 
C(6)-C(5)-C(10) 108.40(14) 
C(4)-C(5)-C(10) 132.54(16) 
C(4)-C(3)-C(2) 120.17(15) 
O(5)-C(2)-C(1) 123.33(16) 
O(5)-C(2)-C(3) 113.91(15) 
C(1)-C(2)-C(3) 122.74(15) 
O(1)-C(6)-C(1) 123.39(15) 
O(1)-C(6)-C(5) 112.41(14) 
C(1)-C(6)-C(5) 124.20(15) 
O(4)-C(4)-C(3) 125.46(15) 
O(4)-C(4)-C(5) 116.00(14) 
C(3)-C(4)-C(5) 118.54(16) 
C(6)-C(1)-C(2) 115.11(16) 
C(6)-O(1)-C(9) 106.97(12) 
O(6)-C(10)-C(5) 114.71(15) 
O(6)-C(10)-C(11) 110.56(15) 
C(5)-C(10)-C(11) 115.75(15) 
O(6)-C(10)-C(9) 111.40(15) 
C(5)-C(10)-C(9) 99.94(13) 
C(11)-C(10)-C(9) 103.32(15) 
O(7)-C(9)-O(1) 108.98(13) 
O(7)-C(9)-C(10) 116.55(15) 
O(1)-C(9)-C(10) 106.11(13) 
O(7)-C(9)-C(12) 111.10(14) 
O(1)-C(9)-C(12) 112.64(14) 
C(10)-C(9)-C(12) 101.32(14) 
O(2)-C(12)-C(13) 106.84(14) 
O(2)-C(12)-C(9) 105.54(14) 
C(13)-C(12)-C(9) 116.95(15) 
O(3)-C(11)-O(2) 121.59(19) 
O(3)-C(11)-C(10) 128.3(2) 
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Bond angles  
  
O(2)-C(11)-C(10) 110.01(16) 
O(8)-C(13)-C(14) 110.94(16) 
O(8)-C(13)-C(12) 110.78(15) 
C(14)-C(13)-C(12) 111.89(15) 
O(9)-C(14)-C(13) 109.28(16) 
C(4)-O(4)-C(7) 117.56(13) 
C(2)-O(5)-C(8) 119.07(14) 
C(11)-O(2)-C(12) 112.24(15) 
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Table A4. Anisotropic displacement parameters (Å2x 103) for 1b.  The anisotropic 
displacement factor exponent takes the form: - 2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
 
 U11 U22 U33 U23 U13 U12 
C(5) 28(1)  31(1) 23(1)  1(1) 0(1)  2(1) 
C(3) 28(1)  39(1) 20(1)  -2(1) -1(1)  1(1) 
C(2) 26(1)  35(1) 25(1)  5(1) -2(1)  -3(1) 
C(6) 26(1)  34(1) 22(1)  -3(1) 2(1)  0(1) 
C(4) 25(1)  32(1) 25(1)  -3(1) 0(1)  2(1) 
C(1) 30(1)  30(1) 28(1)  0(1) 0(1)  1(1) 
C(8) 62(1)  33(1) 40(1)  9(1) -5(1)  -8(1) 
C(7) 50(1)  41(1) 31(1)  -14(1) 1(1)  1(1) 
O(1) 41(1)  29(1) 22(1)  -2(1) 3(1)  2(1) 
C(10) 31(1)  32(1) 23(1)  -2(1) 1(1)  7(1) 
C(9) 32(1)  30(1) 20(1)  0(1) 2(1)  3(1) 
C(12) 33(1)  34(1) 23(1)  1(1) -2(1)  2(1) 
C(11) 54(1)  37(1) 19(1)  -1(1) 1(1)  3(1) 
C(13) 30(1)  39(1) 26(1)  6(1) 1(1)  -1(1) 
C(14) 37(1)  44(1) 36(1)  -2(1) 6(1)  -2(1) 
O(4) 55(1)  31(1) 25(1)  -5(1) 0(1)  6(1) 
O(5) 45(1)  36(1) 26(1)  6(1) -5(1)  -5(1) 
O(3) 97(1)  31(1) 45(1)  -2(1) 13(1)  8(1) 
O(2) 49(1)  34(1) 42(1)  -6(1) 7(1)  -8(1) 
O(7) 31(1)  46(1) 21(1)  -3(1) -2(1)  -2(1) 
O(6) 36(1)  68(1) 24(1)  -2(1) -2(1)  19(1) 
O(9) 35(1)  41(1) 76(1)  16(1) 1(1)  2(1) 
O(8) 41(1)  45(1) 38(1)  14(1) 0(1)  -8(1) 
 
 
 
 
 
 
241 
 
 
 
Table A5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 
103) for 1b. 
 
 x  y  z  U(eq) 
H(3) 2820 7793 10943 35 
H(1) 3168 5616 9106 35 
H(8A) 1663 4848 10371 67 
H(8B) 2607 4687 11338 67 
H(8C) 3971 4767 10474 67 
H(7A) 1749 9394 11051 61 
H(7B) 2848 10300 10654 61 
H(7C) 4056 9372 10917 61 
H(12) 6215 7759 7522 36 
H(13) 5291 8152 5669 38 
H(14A) 5876 6519 6067 46 
H(14B) 7279 6898 5287 46 
H(7) 1197 7362 6427 49 
H(6) -272 8734 8136 64 
H(9) 8459 6219 6730 76 
H(8) 8625 8598 6473 62 
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